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Biliary excretion is one of the main elimination pathways for drugs and/or their 
metabolites. Therefore, an insight into the structural profile of cholephilic 
compounds through accurate modelling of the biliary excretion is important for the 
estimation of clinical pharmacokinetics in early stages of drug discovery. The aim 
of this project was to develop Quantitative Structure-Activity Relationships 
(QSAR) as computational tools for the estimation of biliary excretion. In addition, 
the structural requirements for biliary excretion were investigated in relation to the 
structural requirements for binding to uptake and efflux transporter proteins that are 
involved in hepatobiliary elimination.  
The study used three datasets; 1. percentage of dose excreted intact into bile in rat 
for 217 compounds, 2. P-gp inhibition constants for 219 compound, 3. percentage 
inhibition of OATP transporters, OATP1B1, OATP1B3 and OATP2B1. Statistical 
techniques were stepwise regression analysis, Classification and Regression Trees 
(C&RT), Chi-square Automatic Interaction Detector (CHAID), Boosted trees (BT), 
Random Forest (RF) and Multivariate Adaptive Regression Splines (MARS) 
models.  
The study resulted in QSARs for the prediction of biliary excretion, P-gp binding 
constants and percentage inhibition of OATPs, along with QSARs incorporating 
predicted P-gp and OATP inhibition values for the prediction of biliary excretion. 
Simple regression tree models were of similar accuracy to the boosted trees model 
in the estimation of the percentage of bile excretion of compounds. Molecular 
descriptors selected by these models indicated a higher biliary excretion for 
relatively hydrophilic compounds especially if they have acid/base dissociation, and 
a large molecular size above 348 Da. 
The major role of OATPs in biliary excretion was indicated using interactive 
decision tree models with OATP1B1 binding being the most successful predictor of 
biliary excretion amongst the three OATP subfamilies. In contrast, predicted P-gp 
binding parameters were not successful in the prediction of biliary excretion. This 
may be due to problems in extrapolating the in vitro P-gp binding data to the in vivo 
situation, or due to the difference in the chemical spaces of the P-gp and biliary 
excretion datasets which may lead to the compounds in biliary excretion dataset to 






1.1. Drug Discovery and Development 
Discovery and development of a drug is a very expensive process (Djulbegovic et 
al., 2014). Toxicity, poor efficacy and poor bioavailability are the main reasons for 
failure during discovery, development and registration of drug candidates (Gad, 
2005). Early identification of poor candidates is very essential for reducing the cost 
and the resources spent on drug discovery and development. For most drugs, 
discovery and development could be a remarkably long process. For example, from 
initial stage to approval of Food and Drug Administration (FDA) for taxol which is 
a chemotherapeutic drug, was nearly 30 years (Rowinsky et al., 1990). There has 
been a steady decline in the number of drugs approved for marketing by regulatory 
agencies since the 1960s, despite the advancements in drug discovery technology, 
and the increasing investments of the pharmaceutical companies. The trend can be 
seen from 70-100 drugs introduced in the 1960s, and 60-70 drugs in the 1970s, to 
about 50 in the 1980s, and less than 40 in the 1990s and after (Hillisch and 
Hilgenfeld, 2003) (Figure 1.1). 
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Figure 1.1. Graph showing the number of new drugs introduced from the 1960s to 
1990s (Adapted from Hillisch and Hilgenfeld, 2003) 
Some of the factors that are considered to be responsible for this decline are the 
stricter control of the process by regulatory agencies such as the FDA to ensure the 
safety of compounds before approval. This leads to high attrition rates and a 
prolonged duration of the drug development process (Hillisch and Hilgenfeld, 
2003). The major cause for decline of new molecular entities (NMEs) or failures 
recorded in drug development was attributed to poor pharmacokinetics (39%) and 
animal toxicity (11%) (Waterbeemd and Gifford, 2003; Rang, 2006).  
Drug candidates normally undergo prior investigation with selection of those 
compounds with optimal properties including physicochemical parameters 
(Lipinski et al., 1997). According to Kerns and Di (2008) important properties in 
drug discovery can be classified in four groups: (1) Structural properties, e.g. 
hydrogen bonding, lipophilicity, molecular weight (MW), pKa, polar surface area, 
shape and reactivity, (2) Physicochemical properties such as solubility, 
permeability and chemical stability, (3) Biochemical properties, such as metabolism 
and transport, (4) Pharmacokinetics and toxicity, e.g. clearance, half-life, 
bioavailability and LD50.  
18 
 
Initial identification of drug candidates is based mainly on the ability of compounds 
to have a desired activity and selectivity against a target (e.g. inhibitory effect). 
Investigation of other properties is traditionally postponed to later stages of the 
development process, due in part to the success of pharmaceutics research in 
achieving adequate absorption or bioavailability of drug molecules (Bleicher et al., 
2003). Recently, with the advent of modern technologies in drug discovery 
including in silico methods, to address the problem of high attrition rate, screening 
of potential drug candidates for their pharmacokinetic and physicochemical 
properties is being introduced by the pharmaceutical industry much earlier during 
drug development (Rang, 2006). A much better approach which helps facilitate the 
success and approval of a drug molecule is the use of predictive tools in the design 
phase of the synthesis of compound libraries (Waterbeemd and Gifford, 2003). 
Nowadays, in vitro methods and statistical modeling are used extensively in the 
development of drugs. These methods allow the reduction in more expensive in 
vivo experiments. Model development in drug development is usually empirical or 
exploratory in nature. Models are developed using experimental data and then 
refined until a reasonable balance is obtained between overfitting and underfitting 
(Bonate, 2006). Computational modeling may be helpful in assay systems resulting 
in faster discovery of new potential drugs (Bronchud et al., 2008). 
 
The prediction ability of ADME properties as well as the knowledge of the 
binding/modulating properties of drug molecules on membrane transporter proteins 
are important as they inherently contribute to the pharmacokinetic properties. 
Transporters such as P-glycoproteins belong to the ATP-binding cassette 
superfamily of membrane transporters (Poongavanam et al., 2012). The FDA has 
urged that every new molecular entity should be routinely checked for a possible 
interaction with P-glycoproteins (FDA Guidelines, 2014). Thus, in lead 
optimisation process, early identification of membrane transport protein ligands, 
being substrates or inhibitors, is of utmost importance to improve the ADME 





Absorption, distribution, metabolism and excretion (ADME) are the main processes 
in biological disposition of a drug. Following drug administration, depending on the 
site of administration, drug concentration will increase in the blood, plasma and 
consequently in tissues due to the absorption process. This is followed by a decline 
in plasma concentration due to drug distribution into tissues and elimination. 
Pharmacokinetics (PK) is the study of the time course of drug concentration in the 
body. In addition to dosage regimen decisions, other applications of 
pharmacokinetics studies include bioavailability measurements, effect of 
physiological and pathological conditions on drug distribution, elimination and 
absorption, dosage adjustment of drugs in disease states when necessary, 
correlation of pharmacological responses with administered doses, evaluation of 
drug interactions and finally clinical prediction using pharmacokinetic parameters 
to individualize the drug dosing regimen (Jambhekar and Breen, 2009). In general, 
PK parameters of a drug result from its physicochemical and biochemical 
properties. These properties are determined by the structure of the drug (Kerns and 
Di, 2008).  
Absorption phase is the first pharmacokinetic process before the distribution and 
elimination. After a standard dosage of oral administration enters the gastric fluid, 
the drug is gradually released from the formulation and the absorption process starts 
(Rosenbaum, 2011). In this phase, the dissolved drug has the chance to pass 
through the GI membrane into the blood. Passive absorption is thought to be the 
main mechanism of absorption for most drugs. However, uptake transporters 
(carrier proteins) in intestinal epithelial membrane may be facilitating the 
absorption process. Besides, in the enterocyte membrane, drug absorption may be 
reduced if efflux transporters take the drug back into the lumen (Rosenbaum, 2011). 
Absorption of proteins and macromolecular drugs from the GI tract is hard due to 
their large size and, therefore, parenteral administration is the predominant route of 
drug delivery for these drugs (Pandit, 2007). Other routes of administration include 
the transdermal route, when drug is applied to the skin for systemic absorption 
through the skin, the respiratory route, in which drug is inhaled into the lungs and 
the main absorption happens in the alveoli, and the nasal route, where the nasal 
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mucosa with a good blood supply can absorb the drugs quickly depending on the 
duration of drug contact with the nasal mucosa (Pandit, 2007). 
Distribution is the next important phase in pharmacokinetics that controls drug 
concentrations in the tissues and the observed pharmacological response. Drug 
distribution to peripheral tissues is dependent on four main factors: (1) the drug 
concentration; (2) the drug physicochemical properties; (3) the blood flow to the 
tissue; and (4) the affinity of drug for the tissue vs. the drug affinity to plasma 
proteins. Amongst these factors, physicochemical properties of drugs such as acid 
dissociation constant and molecular weight (MW) are some of the most influential 
factors in tissue distribution (Riviere, 2011). Apart from the above mentioned 
parameters, the rate of drug metabolism plays a key role in distribution, since 
readily metabolised compounds are less available for tissue distribution (Riviere, 
2011). Metabolism plays an essential function in the drug elimination. The rate of 
metabolism for drugs that are very rapidly or very slowly cleared can present 
problems in accurate control of the plasma levels, and, with persistent compounds 
of very long half-lives , the risk of toxicity can be considerable (Coleman, 2005). 
First-pass metabolism is a situation when a drug is metabolized prior to reaching 
systemic circulations. First-pass metabolism may happen in both the liver and the 
gut (Chesnokova et al., 2007). In general, the liver is the most important and 
sometimes the only site of metabolism. Extensive metabolism in one or more other 
tissues, such as the kidney, lung and gastrointestinal membrane is rarely observed 
(Tozer and Rowland, 2006). 
In addition to the metabolism, drug excretion by the kidneys and liver are the main 
routes of drug elimination. The Kidney is the main organ of excretion, while 
several compounds are excreted in bile. The renal excretion is mainly by 
glomerular filtration (Rosenbaum, 2011). Drugs that are secreted into the bile 
finally pass into the intestine. In the intestine they may be re-absorbed; this process 
is known as the enterohepatic circulation. The route and the rate of a drug’s 
elimination has major consequences in terms of the pharmacokinetics, drug-drug 
interactions, and the pharmacotherapy in general. The elimination process has been 




1.3. Elimination of Drugs 
Drugs can be eliminated by metabolism or excretion. Excretion is the process that 
removes a drug from tissues and circulation (DiPiro et al., 2010). Therefore, 
excretion in theory could include discharge into the urine, feces (via bile from the 
liver), exhaled air (via the lungs), or sweat (via the skin). However, for most drugs, 
the primary route of excretion is the renal excretion into the urine via the kidneys 
and/or the biliary excretion into the bile via the liver (Taft, 2009). Renal excretion 
is more common for the water-soluble molecules; hence, many polar drugs with 
low log P values are excreted unchanged directly into the urine. Lipophilic drugs 
may experience the process of tubular reabsorption and move from the urine (tubule 
of the nephron) into the peritubular capillaries, and consequently cannot be 
eliminated by renal excretion. For these drugs, hepatic clearance may be the main 
route of elimination. The primary purpose of hepatic metabolism is to create more 
hydrophilic molecules that will not be reabsorbed and, thus, can be excreted from 
the body in the urine or bile. Most drugs are lipophilic in nature and are eliminated 
by metabolism or biotransformation (Rosenbaum, 2011). Drug molecules that are 
larger (high molecular weight), and glucuronide and glutathione conjugates are 
more likely to be excreted via the liver into the bile. Compounds that are excreted 
into the bile end up in the intestines, where they may be eliminated by the feces or 
reabsorbed (Taft, 2009).  
Clearance is a parameter that indicates the rate at which a drug is cleared from the 
body. It is defined as the volume of plasma from which all drug is removed in a 
given time presented in volume per time units (Stringer, 2006). This powerful 
parameter is used in pharmacokinetics for the evaluation of the elimination, and for 
clinical applications. Clearance may be viewed as a factor of drug elimination rate 
(eq. 1.1): 
Rate of elimination = Cl . C                                                                     Eq. 1.1 
Where C is the blood concentration (Tozer and Rowland, 2006). As we can see in 
Eq.1.1, clearance relates the rate of drug elimination to the concentration. Total 
clearance (Cl) or total body clearance which is referred to as systemic clearance, is 
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sum of all the component clearances by different body organs (Rosenbaum, 2011) 
given by eq. 1.2. 
 Cl = ClR + ClH + Clother                                                                           Eq. 1.2 
In eq. 1.2, Cl is the total body clearance, ClR is the renal clearance, ClH is the 
hepatic clearance, and Clother indicates any other form of clearance. 
The compartmental models below show how we can calculate elimination in the 
body (Patric, 2006): 
  
  
                                                                                                       Eq. 1.3 
Where X is the amount of drug in the body and t is the time after administration of 
dose and kel shows the elimination rate constant. 
Integration from the above equation presents the next expression: 
X = X0 . e
-kel.t 
         then,           log X = logX0 -  
         
     
                          Eq. 1.4 
Where X0 represents the initial amount of drug in the body. 
Alternatively, kel, can be calculated with the help of other pharmacokinetic 
parameters (eq. 1.5): 
  
kel = ClT / Vd                                                                                              Eq. 1.5 
Where Vd represents the apparent volume of distribution. 








                 and                    Vd =  
 
 
                                       Eq. 1.6  
Here, C stands for the drug concentration in plasma. 
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1.3.1. Renal Excretion 
Renal excretion is a very vital process by which the products of metabolism and 
waste metabolites are cleared from the organism (DiPiro et al., 2010). Although 
kidneys have several functions, maintaining the homeostasis by regulating fluid and 
electrolyte balance is the main function of the kidney. The kidneys are responsible 
for the reabsorption of water, glucose, and amino acids (Pandit, 2007). Renal 
elimination of drugs consists of three stages of glomerular filtration, proximal 
tubular secretion and distal tubular reabsorption (Stringer, 2006). As it was stated 
before, the water-soluble materials are excreted better from the kidney (Haschek et 
al., 2010). Acidic or basic states of a drug and pH of the urine are important 
parameters in the fate of a drug in renal excretion (Haschek et al., 2010). Active 
tubular secretion and glomerular filtration are the main pathways in renal 
elimination (Haschek et al., 2010).  
A glomerulus is a big knot consisting of capillaries and surrounded by Bowman’s 
capsule; 120 to 150 ml of blood is filtered at the glomerular capillaries per minute. 
The glomerular capillaries are fenestrated and freely permeable to water, 
electrolytes and most plasma ingredients. The pore size in these capillaries can 
permit most agents and drugs with the molecular weight smaller than 67 kDa to 
pass through and return to plasma (Smith, 2006). 
If a drug does not binds to a plasma protein (such as albumin) and it is small 
enough to be filtered in the glomerulus, then, its clearance by glomerular filtration 
is equal to the glomerular filtration rate (GFR). 
ClGF = GFR                                                                                                 Eq. 1.7 
In Eq. 1.7, ClGF is the clearance by glomerular filtration. However, many drugs 
bind to the plasma proteins, and bound drug will not be filtered. Here, fu is the 
unbound fraction of drug.  
As a result the glomerular clearance can be calculated by Eq. 1.8 below (Janku, 
1993). 




Some of the chemicals that are filtered at the glomerulus are reabsorbed by active 
transport system found primarily in the proximal tubules. In proximal renal tubules, 
there are two systems primarily responsible for the active tubular secretion of 
drugs, one for organic anions and another for organic cations. The anionic system 
(OATs transporters) transports organic acids such as penicilins, indomethacin and 
glucuronides. The cationic system (OCTs transporters) transports organic bases 
such as morphine, procaine and quaternary ammonium compounds. Both active and 
passive transports are involved in tubular secretion process (Burckhardt and Wolff, 
2000). It is worth mentioning that P-glycoprotein is present in the brush border of 
the renal proximal tubules, and can play a role in the active tubular secretion of 
exogenous substances. This pump is involved in tubular secretion of, for example 
digoxin, and can be inhibited by quinidine or verapamil, leading to an increase in 
digoxin serum concentrations (Giacomini et al., 2010). Some drugs can inhibit the 
secretory function of tubules and renal clearance would reduce consequently. 
Probenecid which is also used in treating gout and hyperuricemia, is a good 
example of a drug that can inhibit tubular secretion of several agents such as 
verapamil (Piscitelli et al., 2005). 
Volume of plasma that is cleared from a compound in kidneys in unit time shows 
renal clearance (ClR) and can be calculate by equation 1.9 (Rosenbaum, 2011). 
ClR = (Cur . QR) / C                                                                                         Eq. 1.9 
Where, ClR is the renal clearance of a compound, Cur stands for drug concentration 
in the urine, C shows plasma concentration and QR is the urine flow rate (ml/min). 
 
1.3.2. Elimination by the Liver 
Liver is a major elimination organ which eliminates drugs by metabolism and 
biliary excretion. One of the most important functions of the liver is the formation 




Bile is a composition of bile acids and other components such as phospholipids, 
bilirubin and cholesterol that is formed in the canaliculus between adjacent 
hepatocytes and is actively discharged across the canalicular membrane. Many 
drugs are also excreted through this system in significant quantities (Taft, 2009). 
The resulting bile is stored in the gallbladder and released into the intestine. Once 
bile is released into the intestine, some metabolites and unchanged drugs continue 
their way of elimination through the feces. Others, mostly lipid-soluble drugs, are 
reabsorbed from the intestine and move to the systemic circulation (Luscombe and 
Nicholis, 1998). This process is known as enterohepatic circulation and it affects 
pharmacokinetics by keeping the plasma concentration high (Plusquellec et al., 
1998). Despite the possibility of reabsorption, bile plays an important role in the 
excretion of xenobiotics, including drugs and their metabolites, which is in addition 
to its physiologic role in the intestinal digestion of lipids and lipid-soluble vitamins. 
This includes a diverse array of compounds, both polar and lipophilic, including 
anions, cations, and neutral molecular (Taft, 2009). Elimination of some drugs, e.g. 
oestrogens, is very slow while water-soluble drugs are excreted in faeces through 
the intestine quickly (Smith, 2006). Enterohepatic cycling and biliary elimination 
can continue until the compound is ultimately eliminated from the body by faecal 
or renal excretion or metabolism. 
   
Hepatic clearance (ClH) (by metabolism and/or biliary excretion) is defined as the 
volume of blood from which drug is removed completely by the liver per unit time. 
Hepatic clearance is a function of hepatic blood flow (QH) and the extraction 
efficiency of the liver for the drug (EH) (Tozer and Rowland, 2006). 
ClH = QH . EH                                                                                             Eq. 1.10 
Hepatic elimination can range from 0 (when the liver is incapable of removing the 
drug) to 100% (when the liver extracts the entire drug presented in a given pass). 
Moreover, ClH is equal to systemic clearance only when the drug is cleared 
completely by the liver after intravenous administration (Burton et al., 2006). 
The amount of circulating drug presented to the liver enzymes and cleared from the 
blood depends on the rate of hepatic blood flow (QH), binding to the circulating 
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proteins, and the metabolic activity and bile excretion involved in the hepatic 
elimination of the compound (Nassar et al., 2009). The hepatic intrinsic clearance 
of unbound drug in the liver (Clu.int) indicates the maximal ability of hepatocyte to 
remove drug from the liver. In most cases Clu.int will exceed the hepatic clearance 
of the total drug (see equation below). The hepatic intrinsic clearance of unbound 
drugs is frequently related to metabolic activity, which often is assumed to be the 
rate-limiting step in hepatic elimination: 
Clu.int ∑    
    
     
                                                            Eq. 1.11 
Where Vmax is the maximum rate of the reaction for enzyme involved in the 
metabolism of the substrate, Km is the concentration at which the metabolic rate 
will be half in the enzyme reaction and Cu is the concentration of unbound drug at 
the enzyme site in the liver (Burton et al., 2006). 
 
1.3.3. Elimination by the Other Sites 
Beside the major routes of excretion (bile and kidney), excretion can also take place 
through other excretion routes such as lungs, saliva, sweat, feces, mother’s milk and 
hair. Lungs have the main role in pulmonary excretion of some xenobiotics which 
exist in gaseous phase in the blood (Haschek et al., 2010).  
In breastfeeding mothers, unchanged drugs, drug metabolites and toxicants can be 
excreted into the milk as an excretion route. As milk’s pH is slightly acidic at about 
6.5, basic compounds are more excreted into the milk than acidic compounds.  
In case of extensive sweating, study of elimination through sweat could be 
essential. Iron, cadmium, zinc and some other metals could be excreted in sweat 
(Hale et al., 2002). 
Feces can be the main route of elimination for any drug which is not absorbed in 




1.4. Function of the Liver and its Role in Drug Elimination 
Liver is the largest internal organ in the body; it is relatively larger in infancy, 
comprising one-eighteenth of the birth weight (Sherlock and dooley, 2008). The 
liver is divided into the right and left lobes but most of the liver’s mass is found in 
the right lobe. Anatomically this exocrine and endocrine organ is situated in a very 
strategical place, between pancreas, gastrointestinal tract and spleen (Figure 1.2). 
The entire surface of the liver is covered by a capsule that contains nerves which 
can sense pain (Sherlock and dooley, 2008). The gallbladder is located under the 
liver (Figure 1.2). The liver has a double blood supply; portal vein brings venous 
blood from the intestine and spleen, and the hepatic artery, coming from the celiac 
axis, supplies the liver with arterial blood. The liver receives approximately 1100 
ml/minute of blood from the portal vein and 350 ml/minute of blood from hepatic 
artery (Taft, 2009).  
Liver acts as a detoxifier to protect the general blood circulation from toxins that 
are absorbed through gastrointestinal tract. This is done through metabolism and 
excretion through bile. Moreover, liver is responsible for maintaining adequate 
blood sugar concentrations. Blood from pancreas, which is rich in glucagon and 
hormones, and the blood from spleen, which contains the metabolites from the red 
blood cell breakdown, pass through the liver via the portal vein for detoxification. 
Apart from the production of bile and metabolism, hepatocytes play other important 
functions such as destroying bacteria by the use of peroxisomes and lysosomes. A 
hepatocyte can contain 800-1000 mitochondria per cell. Besides, hepatocytes have 
many rough and smooth endoplasmic reticulums. Smooth endoplasmic reticulum 
produces lipids, and catabolise estrogen, progesterone and testosterone. Rough 
endoplasmic reticulum may synthesise plasma proteins such as albumin from amino 
acids and then return them back to the space of disse (You and Morris, 2007). Other 
functions of hepatocytes are synthesise of the alpha and beta globulin, plasma 
proteins, coagulation factor, very low density lipoprotein (VLDL), low density 
lipoprotein (LDL) and high density lipoprotein (HDL). Activation of vitamin D is 




                                     
Figure 1.2. Bile release into the duodenum: 1. Hepatic lobule, 2. Left hepatic duct, 
3. Right hepatic duct, 4. Common hepatic duct, 5. Cystic duct, 6. Gall bladder, 7. 
Stomach, 8. Pancreatic duct, 9. Pancreas (adapted from Guyton and Hall, 2006). 
 
1.4.1. Biliary Excretion of Drugs 
Functional unit of the liver is known as lobule. Figure 1.3 shows the structure of the 
liver‘s lobule. A lobule is defined at the histological scale and involves branches of 
the portal vein and hepatic artery, and a central vein in terms of the blood flow. The 
blood from branches of the portal vein and hepatic artery vessels eventually mix at 
sinusoid. In the sinusoids the mixed blood will keep moving from periphery to the 
centre of the lobule. The plasma near hepatocytes leaks in the area close to 
hepatocyte cells, which is called space of disse. All the plasma is well exposed to 
hepatocyte and therefore hepatocyte can efficiently exchange chemicals with 
plasma in the space of disse. For example, the toxin in the plasma can be detoxified 
or the extra glucose can be converted to glycogen by the hepatocyte and then 
returned to the space of disse. Central vein is situated in the centre of each lobule; 
the blood from portal vein and hepatic artery passes to the central vein through the 
sinusoid (Guyton and Hall, 2006).  
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Hepatocyte’s one face is to the blood (via space of disse) and the other face is to the 
other hepatocytes. This means that, hepatocytes are laid back to back and the bile is 
secreted by the hepatocytes in the space between them, bile canaliculus, and then 
the bile duct. Excreted bile, unlike the blood flow, moves away from the centre of 
the lobule to the periphery (Figure 1.3). The resulting bile drains into branches of 
intrahepatic bile ductules that converge to the common hepatic bile duct 
(Matsumoto and Nakamura, 1992). Finally, the secreted bile from the left hepatic 
duct together with the right hepatic duct join together to make common hepatic 
duct. The common hepatic duct joins to the gallbladder through the cystic duct. In 
the healthy man, gallbladder stores about 50 ml of bile and during storage bile 
becomes more concentrated which increases its potency and intensifies its effect on 
fats (Guyton and Hall, 2006). Uptake from sinusoidal blood and then secretion of 
bile salts across the canalicular hepatocyte membrane are the major factors 
controlling the rate of bile secretion. 
                                 
Figure 1.3. Schematic representation of bile duct and blood flow in lobule organisation. 
Lobule is the basic functional unit of the liver. The liver lobule is constructed around a 
central vein, which empties into the hepatic vein; 1. Branch of hepatic artery, 2. Branch of 
portal vein, 3. Space of disse, 4. Hepatocyte, 5. Bile canaliculas 6. Central vein, 7. Sinusoid 





Figure. 1.4. The cartoon depicts substrate transport processes in the hepatocyte 
including sinusoidal and canalicular proteins efflux (E) and uptake (U) transport of 
drugs/drug-likes and their metabolites. 1. Sinusoidal membrane, 2. Ito cell, 3. space 
of Disse, 4. hepatocyte, 5. mitochondria, 6. nucleus, 7. endoplasmic reticulum, 8. 
lysosomes, 9. Peroxisome (Sharifi and Ghafourian, 2014) 
 
Liver plays a very key role in drug elimination via bile. Liver is able to secrete up 
to 1 litre bile per day, which accumulates in gallbladder and can be emptied in 
duodenum for digestion of food (Pandit, 2007). The most important components of 
the bile are conjugated bilirubin, phospholipids and lecithin, IgA antibodies, 
cholesterol and bile salts such as cholic acid and chenodeoxycholic acid. Bile acids 
are some of the most important substances in bile that are vital for efficient 
digestion and emulsification of lipids. Most bile acids originate from the 
recirculation pool (Dawson et al., 2009). Bile acids are also synthesized by the liver 
from cholesterol.  
Canalicular bile secretion is an osmotic process in which active excretion of organic 
solutes into the bile canaliculus is the main driving force for the passive inflow of 
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water, electrolytes, and nonelectrolytes from hepatocytes (Trauner and Boyer, 
2003). Several different types of transporter proteins are involved in the uptake of 
compounds from the blood into hepatocytes, and others are responsible for efflux of 
the compounds from hepatocyte into the canaliculus through canalicular membrane. 
These proteins are located in the basolateral and canalicular membranes of the 
hepatocytes and the substrate compounds include chemically diverse metabolites 
and unchanged drugs. Figure 1.4 shows the main transport proteins in hepatocytes 
that are responsible for the uptake of compounds from plasma and excretion to 
outside the cells. While products of the multidrug resistance gene family (MDR), 
namely bile salt export pumps, Bsep (rat) and BSEP (human), transport monovalent 
bile salts (Rollins and Klaassen, 1979), excretion of non-bile salt organic anions 
and divalent sulphate or glucuronide bile salts is carried mainly by the multidrug 
resistance protein 2 (MRP2) and P-glycoprotein. Bile salt export pump has a 
limited role in drug excretion (Morgan et al., 2010). The transporter proteins 
responsible for biliary excretion have been explained in section 1.5. 
Chemical structure, polarity and molecular size as well as characteristics of the 
liver such as specific active transport sites within the liver cell membranes are the 
main factors which determine elimination via the biliary tract (Rollins and 
Klaassen, 1979). Apart from physico-chemical factors, species, strain, gender 
differences and diet also can play a role in hepatic elimination. For instance, sex-
dependant expression and activity of hepatic BCRP in males is higher in both mice 
and humans (Merino et al., 2005a). Another interesting fact is that hepatic MRP2 
expression in rats is nearly 10 fold higher than in humans (Li et al., 2008) 
moreover, species differences in substrate specificities in transporters are not 
negligible (Takekuma et al., 2007). 
 
1.4.2. Metabolism of Drugs 
The liver is the important site of metabolism for various compounds including 
drugs. Metabolism, or biotransformation, is a major route of elimination for many 
drugs. Drug metabolism often converts lipophilic compounds into more polar 
products. Carbohydrates, fats, and proteins are all broken down by hepatic 
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enzymes. A healthy liver detoxifies much of the harmful substances (Gibson and 
Skett, 2001), but liver diseases can affect drug metabolism and the biliary clearance 
(e.g., Cirrhosis, Cholestasis and Carcinoma) (Paintaud et al., 1996). Studies in 
biliary excretion of some extensively metabolised drugs show that many patients 
with liver dysfunction can metabolise and excrete drugs normally, while other 
patients have a decreased metabolism and biliary excretion rates (Hvidberg et al., 
1974; Adjepon-Yamoah et al., 1974).  
A thorough understanding of the metabolic pathway of a drug is important in 
characterizing its pharmacokinetic profile (Kwon, 2001). Figure 1.5 shows the 
biotransformation of drugs as an elimination pathway. Metabolism is usually 
catalysed by enzymes that can be found in most organs especially in the liver. If 
metabolism of a compound by one enzyme is blocked due to substrate saturation or 
by structural modifications, the compound can be metabolized by other types of 
enzymes (Kerns and Di, 2008). Drug metabolism or biotransformation is 
traditionally divided into two categories: Phase I and phase II reactions (Williams, 
1959). Phase I metabolism results in the introduction of functional groups into 
molecules and hence it is also known as functionalization reaction. Phase II 
reactions are conjugation reactions with various endogenous compounds. 
Cytochrome P450 monooxygenase, and nitro and azo reductase are some of the 
main phase I enzymes, while important phase II enzymes include D-glucuronic 
acid, glutathione and sulfate transferase (Tsaioun and Kates, 2011). Phase I and II 






Figure. 1.5. Drug biotransformation (Katzung et al., 2004). 
 
  
1.5. Elimination by Membrane Transporters 
Influx and efflux transporters are proteins expressed in cell membrane that have 
been shown to have a significant effect in the absorption, distribution and drug 
elimination. In the past ten years, there has been an enormous increase in the 
literature regarding the role of membrane transporters governing drug 
pharmacokinetics and response. An evaluation of the contribution of transporters to 
total tissue uptake and excretion is necessary to understand the drug disposition 
route (Giacomini et al., 2010). Membrane transporters are classified according to 
their mode of transport, energy coupling mechanism, molecular phylogeny, and 
substrate specificity. Transporter categories include channels (e.g. Escherichia coli 
GlpF glycerol channel), primary active transporters (e.g. Lactococcus lactis LmrP 
multi drug efflux pump), ABC transporters (e.g. P-gp in humans and 
microorganisms), secondary transporters (e.g. E.coli LacY lactose permease) and 
group translocators (e.g. E.coli MtlA mannitol transporters) (Ren and Paulsen, 
2005). Terada and co-workers have classified drug transporters into five main 
groups based mainly on their functions. There are: 1. Peptide transporters (PEPT), 
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2. Organic anion-transporting polypeptides (OATP), 3. Organic ion transporters 
(OAT, OCTN and OCT), 4. H
+
/ organic cation antiporters (MATE) and 5. ATP-
binding cassette (ABC) transporters (mainly P-gp, MRP1 and BCRP). The 
structures of these transporters, distribution in tissues and their roles are different. 
In vivo and in vitro techniques can be used to assess the character of transporters 
(Terada et al., 2006). 
Various transporters have been implicated in the clearance of several compounds 
and metabolites. Transporters are known to be partially responsible for drug 
concentration ratios in plasma and tissues, thus efficacy and toxicity. A big part of 
intact drug molecules and their metabolites are excreted into the bile by efflux 
transporters and passive diffusion into the bile channel (canaliculus) (Niemi et al., 
2011). Transporters can be found in all tissues but the four major locations that 
transporters operate significantly are intestinal epithelia, hepatocytes, kidney 
proximal tubules and blood-brain barrier (Giacomini et al., 2010). Figure 1.6 
illustrates a schematic representation of the important transporters and their 
positions in the membrane domain of different organs such as sinusoidal 
membranes of hepatocytes. As seen in this Figure, several uptake and efflux 
membrane transporters including apical ATP-dependant efflux pump (including P-
gp, MRPs and BCRP), organic anion transporting polypeptide family (OATPs), 
ileal sodium-dependent bile acid transporter (ASBT), organic cation transporters 
(OCTs) family, peptide transporters (PEPTs), organic cation/carnitine transporters 
(OCTN), multidrug and toxin extrusion protein (MATE) and urate transporter 





Figure. 1.6. The cartoon illustrates selected human transport proteins in plasma 
membrane domains of intestinal epithelia (a), hepatocytes (b), kidney proximal 
tubules (c) and brain capillary endothelial cells (d) (Adapted from Giacomini et al., 
2010)   
 
1.5.1. Peptide Transporters (PEPT) 
The currently known peptide transporters include peptide transporters 1 and 2 
(Pept1 and Pept2) and peptide/histidine transporters 1 and 2 (PHT1 and PHT2). 
Studies showed that Pept1 is a low-affinity and high-capacity transport system for 
di and tripeptides (Leibach and Ganapathy, 1996). Conversely, Pept2 is a high 
affinity and low capacity transporter for di and tripeptides. The PHT1 and PHT2 
transport di- and tri-peptides as well as histidine. These transporters are 




Pept1 was first cloned in rabbit intestinal epithelium membrane (Fei et al., 1994). 
Pept2 for the first time was cloned from human kidney (Liu et al., 1995). Pept1 and 
Pept2 can transport many peptides with different volumes and charges, but not long 
peptides with more than four peptide bonds (Daniel, 2004). These transporters are 
found mostly in the small intestine and kidney’s proximal tubules and they mediate 
absorption of certain drugs e.g. cephalosporins and other beta-lactam antibiotics. 
There is no evidence of existence of these peptide transporters in blood brain 
barrier (BBB) (Han et al., 1998). However, the expression of Pept1 was found with 
low levels in the liver, in addition to the major sites, small intestine and kidney 
(Liang et al., 1995). Recently, the H
+
-peptide cotransport has been established in 
the human bile duct epithelium cell line SK-ChA-1 (Knutter et al., 2002). 
Human PHT1 and PHT2 were found to be expressed at low levels in 
gastrointestinal tract and different tissues with mRNA expression throughout the 
gasterointestinal tract. In addition, the mRNA expression was also demonstrated in 
the liver, brain, colon, heart, kidney, lung, ovary, pancreas, placenta, prostate, 
spleen and testis (Herrera-Ruiz et al., 2001). 
In the past decade, amino acid modifications have been used in the design of 
prodrugs to allow for PEPT1 and PEPT2 intestinal absorption of weakly absorbed 
drugs such as antiviral agents levovirin and azidothimidine, and anticancer drugs 
gemcitabine and floxuridine (Sugawara et al., 2000; Li et al., 2006).  
 
1.5.2. Organic Anion-Transporting Polypeptides (OATP) 
OATP is a family of membrane transporters that mediate the cellular uptake of 
endogenous substrates and drugs. The importance of OATPs in excretion has been 
shown by different studies (Cvetkovic et al., 1999; Mikkaichi et al., 2004; Kim, 
2003). The human OATP family consists of 11 members: OATP1A2, 1B1, 1B3, 
1C1, 2A1, 2B1, 3A1, 4A1, 4C1, 5A1 and 6A1 (Hagenbuch and Meier, 2003). As 
seen in Figure 1.6, members of this family can be found in sinusoidal (basolateral) 
membrane of hepatocytes, basolateral membrane of proximal tubules, and apical 
(luminal) side of the blood-brain barrier and intestinal epithelia. Certain OATP 
isoforms are selectively involved in hepatic uptake of hydrophobic anions from the 
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plasma (Taft, 2009). Although the role of OATPs in renal (Sekine et al., 2006) and 
hepatic excretion (Nozawa et al., 2005) as well as uptake across the blood-brain 
barrier  (Gao et al., 2000) and gastrointestinal tract (Sai et al., 2006) has been 
demonstrated, their importance in pharmacokinetics is still not fully understood 
(Glaeser and Kim, 2006). 
Despite the title, OATP substrates are not limited to organic anions, but also 
include cations as well as neutral and zwitterionic compounds (Niemi et al., 2011). 
The OATP family members mediate the sodium ion co-transport of various organic 
agents including organic dyes, bile salts, steroid conjugates and thyroid hormones. 
In rat, the organic anion transporting polypeptides Oatp1, Oatp2 and Oatp4 have 
been indicated as the main sodium independent uptake proteins (Kullak-Ublick et 
al., 2000). 
OATP structure is a protein with twelve transmembrane domains (Hagenbuch and 
Gui, 2008). The first of the organic anion-transporting polypeptides OATP1A2 
(OATP1) was originally cloned from a human kidney cDNA library (Lu et al., 
1996). Later, OATP1A2 was cloned from rat liver and since then, several different 
forms of OATPs in human and rodents have been discovered (Jacquemin et al., 
1994). For instance, OATP1B1 was cloned independently by different laboratories 
(Tirona et al., 2001; Hsiang et, 1999; Konig et al., 2000a; Abe et al., 1999). 
OATP1B3 was also cloned from human liver (Abe et al., 2001; Konig et al., 
2000b). OATP1B3 is mainly expressed in the basolateral membrane of hepatocytes 
(Abe et al., 2001), but it has also been detected in certain cancer cell lines and 
tissues (Abe et al., 2001). Over the last two decades the impact on drug 
pharmacokinetics of the organic anion transporting polypeptides (OATPs: OATP-
1B1, 1B3 and 2B1), expressed on the sinusoidal membrane of the hepatocyte, has 
been increasingly recognized.  
Human OATP1B1 (also known as OATP2) is a liver specific transporter that is 
expressed on the sinusoidal membrane of human hepatocytes and mediates the 
hepatic uptake of many endogenous compounds. The substrate specificity of 
OATP1B1 is closely comparable to OATP1A2 and both can transport drugs such as 
eicosanoids, benzylpenicillin, methotrexate, rifampin, pravastatin, rosuvastatin and 
cerivastatin (Glaeser and Kim, 2006). Apart from hepatocytes, OATP1A2 is 
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expressed in various tissues including brain and kidneys. Moreover, OATP1A2 can 
facilitate the entry of its substrates through the duodenal wall into circulation 
(Glaeser et al., 2007). Regarding the acidic, basic and neural character of 
substrates, OATP1A2 possesses perhaps the broadest spectrum among the members 
of the superfamily (You and Morris 2007). 
OATP1B3 has a significant substrate overlap with OATP1B1 (Karlgren et al., 
2012a). However, OATP1B3 is also able to transport oligopeptide hormones such 
as cholecystokinin 8 (Ismair et al., 2001) and digoxin (Kullak-Ublick et al., 2001), 
although the latter has been disputed (Taub et al., 2011). Unlike OATP1B1, 
OATP1B3 has been implied in the transport of angiotensin II receptor antagonist, 
telmisartan, and its glucuronide conjugate (Abe et al., 1999) as well as mediating 
the cellular uptake of opioid peptide II, digoxin and ouabain (Kullak-Ublick et al., 
2001). The importance of OATP1B1 and OATP1B3 in hepatic transport has been 
explained by recent studies by Fenner and co-workers indicating that OATP1B-
mediated transport can be the rate-determining step of hepatobiliary drug clearance 
(Fenner et al., 2012).  
In addition to drug clearance role, recent studies have suggested that overexpression 
of OATP1A2, OATP1B1 and OATP1B3 in pancreatic cancer tissues (Kounnis et 
al., 2011) as well as in ovarian cancer cells (Svoboda et al., 2011) may be exploited 
in the design of novel targeted cancer therapy (Sainis et al., 2010). This is 
particularly important in light of the increasing global burden of cancer. 
GLOBALCAN 2008 (Ferlay et al., 2010) reported over 12.7 million cancer cases 
and 7.6 million cancer deaths are estimated to have occurred in 2008 and deaths 
from cancer worldwide are projected to continue rising with an estimated 13.1 
million deaths in 2030 (Jemal et al., 2011). 
 
1.5.3. Organic Ion Transporters (OAT, OCTN and OCT) 
Organic anion and cation transporters (OATs and OCTs) and organic 
cation/carnitine transporter (OCTN) superfamily are members of the solute carrier 
family, subfamily 22 (SLC22). These transmembrane proteins are largely expressed 
in excretory organs such as kidney and liver, as a major component of the human 
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xenobiotic excretion machinery. In the liver, these uptake transporters play 
important role in the initial sinusoidal influx of drugs into hepatocytes (van 
Montfoort et al., 2003) (see Figure 1.6). These transporters have wide substrate 
specificities for a range of exogenous and endogenous substrates including many 
commonly used drugs, antibiotics, anti-hypertensives, and anti-inflammatories, 
among others (Leabman et al., 2003). 
In kidneys, organic cation transporters mediate the transport of small organic cation 
such as tetraethylammonium. OCT1 was the first discovered OCT from rat kidneys 
in 1994 (Grundemann et al., 1994). In humans, OCT1 is expressed at extremely 
low levels in the kidney and is mainly found in the liver (Motohashi et al., 2002). 
As seen in Figures 1.4 and 1.6, OCT1 can be found abundantly in hepatocytes and 
may be seen as the most important transporter for distribution of cationic 
compounds into the liver from sinusoidal membrane (Nies et al., 2009). OCT2 was 
isolated from the rat kidney using cDNA cloning of the OCT1 sequence (Okuda et 
al., 1996). OCT2 is generally considered to be a kidney transporter, though mRNA 
is expressed at low levels in other tissues such as spleen, placenta, small intestine 
and brain (Gorboulev et al., 1997). OCT3 has the widest tissue distribution of the 
OCTs and its protein expression has been confirmed on the basolateral membrane 
of hepatocytes (Nies et al., 2009), the basal membranes of trophoblasts (Sata et al., 
2005), the apical membrane of enterocytes (Muller et al., 2005) and the luminal 
membrane of lung epithelial cells (Lips et al., 2005). Substrates for OCT1-3 include 
a wide range of structurally unrelated organic cations, including many drugs. An 
extensive list of OCT1-3 substrates and inhibitors has been provided in a recent 
review on the importance of organic cation transporters in drug therapy (Nies et al., 
2011). Among these substrates are catecholamines, monoamine neurotransmitters 
and several antiviral drugs. 
OATs are fairy well-studied organic anion transporters and are mainly expressed in 
excretory organs, especially kidney for the uptake of organic anions from the blood 
to renal tubule cells (see Figure 1.6). OATs are membrane proteins with 12 putative 
membrane-spanning domains and function as sodium-independent exchangers or 
facilitators. OATs mediate the influx of a wide range of organic anions including 




), endogenous (e.g. cyclic nucleotides, 
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prostaglandins, urate, dicarboxylates) and exogenous anions (various anionic drugs 
and environmental substances) (Sekine et al., 2000). In comparison with OATPs, 
substrates of OAT have been suggested to be generally lower molecular weight 
(Roth et al., 2012). The transport mechanism of OAT1 and OAT3 is known to be 
indirectly sodium-dependent and involves a ‘tertiary active transport’ mechanism to 
move organic anions across the basolateral membrane into the proximal tubule 




-ATPase located on the basolateral membrane 
pumps Na
+
 from intracellular to extracellular space to maintain a Na
+
 gradient 
(Glaeser and Kim, 2006). This is used by the secondary active Na
+
-dicarboxylate 
cotransporter to maintain a high intracellular concentration of α-ketoglutarate, 
which is used to drive uptake of other organic anions by OAT1 and OAT3. Several 
studies have revealed that rat Oat1 transports a broad spectrum of substrates 
(Glaeser and Kim, 2006). Endogenous organic anions such as prostaglandins, cyclic 
nucleotides, folates (Sekine et al., 1997) and some xenobiotics such as beta-lactam 
antibiotics (Jariyawat et al., 1999; Leabman et al., 2003), NSAIDs (Apiwattanakul 
et al., 1999) as well as many antiviral drugs (Cihlar et al., 1999; Wada et al., 2000) 
are examples of compounds transports by rat Oat1. Human OAT1 also transports 
adefovir, cidofovir, zidovudine (AZT), acylclovir and ganciclovir (Cihlar et al., 
1999; Ho et al., 2000). 
OAT2 mRNA has the highest expression levels in the liver with lower levels also 
seen in kidney (Sekine et al., 1998; Sun et al., 2001; Hilgendorf et al., 2007). 
Human OAT3 is exclusively expressed in the basolateral membrane of the proximal 
tubule cells of kidneys (Cha et al., 2001; Sun et al., 2001) while in rat, Oat3 is most 
abundantly expressed in liver and to lesser extent in kidney and brain (Kusuhara et 
al., 1999). OAT4 mRNA is expressed in kidney and placenta (Bleasby et al., 2006). 
OAT5 expression in human is not well studied, although Northern blot analysis 
demonstrates mRNA expression in the liver (Sun et al., 2001). OAT7 has been 
shown to be exclusively expressed in the liver, where its expression has been 
localized to the basolateral membrane of hepatocytes (Shin et al., 2007). OAT10 
mRNA has the highest expression levels in the kidney followed by brain, heart, 
small intestine and colon (Bahn et al., 2008). URAT1 is expressed in kidney and it 
is the only member of the OAT family for which mutations have been linked to a 
disease (Enomoto et al., 2002). 
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Carnitine is an essential zwitterion cofactor that plays an important role in the 
metabolism of lipids and subsequently in the production of energy. Carnitine 
absorption is via small intestine with the help of Organic Cation/Carnitine 
transporter 2 (OCTN2), which is located on the brush border membrane (Elimrani 
et al., 2003). OCTN2 transports organic cations without involving Na
+
, but it 
transports carnitine only in the presence of Na
+
. Wu and colleges found that rat 
OCTN1 is expressed in a wide variety of rat tissues and organs such as intestine, 
liver, kidney, heart and brain (Wu et al., 2000). OCTN2 is also expressed in the 
heart, kidney, placenta and brain (Wu et al., 1999). There is no evidence of 
presence of OCTN2 in human liver while it is strongly expressed in rat liver (Tamai 




/ Organic Cation Antiporter (MATE) 
Multidrug and toxin extrusion transporters (MATE) mediate cellular efflux of a 
variety of organic cations, including many drugs (Lickteig et al., 2008).  MATE1, 
which functions as drug/sodium antiporter, is the first example of Na
+
-coupled 
multidrug efflux transporter (Morita et al., 2000). The MATE are protein 
transporters which are primarily expressed in the kidney and liver, localized at the 
apical membranes of the renal tubules and bile canaliculi (Motohashi and Inui, 
2013; Motohashi et al., 2013). MATE1 has been isolated as an H
+
/organic cation 
antiporter located at the renal brush-border membranes (Asaka et al., 2007). 
MATE1 can transport zwitterionic drugs such as fexofenadine and levofloxacin, as 
well as organic cation drugs such as metformin and cimetidine (Terada et al., 2006; 
Masuda et al., 2006).  
In rat, apart from kidney, MATE1 also expressed abundantly in the placenta, 
slightly in the spleen, but not expressed in the liver (Terada et al., 2006). Rat 
multidrug and toxin extrusion (MATE1) transporter is expressed in kidney, but not 
in the liver (Ohta et al., 2006; Masuda et al., 2006). In humans, MATE1 mRNA 
levels are highest in the liver, and are localized to the canalicular membrane of 
hepatocytes. MATE1 mRNA expression is also high in the kidneys, where it is 
localized to the apical membrane of the renal tubule. Similarly, MATE2 mRNA 
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levels are by far at their highest in the kidneys, while relatively low in most other 
tissues (Lickteig et al., 2008). 
 
1.5.5. ABC Transporters 
ATP-binding cassette (ABC) transporters are transmembrane proteins that utilize 
the energy of adenosine triphosphate (ATP) binding and hydrolysis to carry out 
certain biological processes including translocation of various substrates across 
membranes. These are mainly efflux transporters that help export compounds out of 
the cells (Massey et al., 2014). Amongst the largest transporter superfamilies, these 
transporters may be found in all known organisms and around 1100 various 
transporters belong to this group (You and Morris, 2007). Figure 1.6 illustrates 
several members of ABC transporters in brain, kidney, intestine and liver. In the 
liver, the ABC transporters MRP2, BCRP, P-gp and BSEP (ABCB11 and also 
known as sPgp (sister of P-glycoprotein)) are found in the canalicular membrane of 
hepatocytes exporting the substrates into the bile. Other members of ABC 
transporter family, including MRP3, MRP4 and MRP6, are distributed in sinusoidal 
membrane and they export the substrates from hepatocytes back into the blood. 
ABC transporters can be found in many normal tissues with an important role in 
drug elimination or other biological processes.  
Genetic defects in some of the ABC transporters may result in a disease; mutations 
in up to 14 mammalian ABC transporters (out of 48 ABC genes) have been 
associated with disease states (Borst and Elferink, 2002). For example, dysfunction 
of ABCB2 transporter results in immune deficiency problems and dysfunction of 
ABCC2 results in Dublin-Johnson syndrome (Gottesman and Ambudkar, 2001).  
These transporters are further categorised into seven distinct subfamilies of proteins 
using phylogenetic analysis. The subfamilies include: ABCA (12 members), ABCB 
(11 members), ABCC (12 members) ABCD (4 members), ABCE, ABCF (3 
members) and ABCG (1 member) (Hennessy and Spiers, 2007). The best-studied 
proteins of this family include P-gp (ABCB1) also known as MDR1 due to its 
ability to produce multiple drug resistance in cancer cells, and the sulphonylurea 
receptor (SUR) subfamily encoded by members of ABCC genes that is involved in 
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regulating insulin secretion in β-cells of the pancreas (Dassa and Bouige, 2001).  
Others include the ABCC subfamily which encodes the cystic fibrosis 
transmembrane conductance regulator (CFTR) protein that plays a part in exocrine 
secretions of chloride (Dean, 2002; Dassa and Bouige, 2001). A number of these 
proteins including MRP1, BCRP and P-gp are reported to be overexpressed in 
malignant cells thus causing these cells to be resistant to drug therapy, hence the 
multidrug resistance (MDR) terminology. 
In eukaryotic cells, ABC transporters usually direct molecules from the cytoplasm 
to the outside of the cell (Dean, 2002) with the main function of transporting 
xenobiotic compounds out of the cell for transport to other areas of the body or for 
excretion. On the other hand, ABC transporters in prokaryotic cells can be either an 
importer or exporter of compounds. Bacterial importers are important for the cell 
survival and typically important substrates such as iron, inorganic ions as well as 
peptides and amino acids. Substances requiring removal from prokaryotic cells 
include cell wall components such as liposaccharides and toxins involved in 
pathogens e.g. haemolysin (Davidson et al., 2008). 
Structurally, ABC transporters consist of two distinct domains, the nucleotide 
binding domain (NBD) and the transmembrane domain (TMD). A typical ABC 
transporter may have two TMD domains and two NBD domains (Higgins, 2001). 
The TMD of various ABC transporters is diverse and could contain 6–11 
membrane-spanning α-helices and provides the specificity for the substrate in order 
to function as the route for molecules to cross the membrane. The NBDs of the 
protein, also known as the ATP-binding domain, can be found in the cytoplasm and 
are consequently hydrophilic in nature (Dean, 2002). These domains help transfer 
the energy needed to transport the substrate across the membrane (Dean, 2002; 
Ambudkar et al., 2003). NBD consists of two subdomains: 1. ‘the catalytic core 
domain’ that includes walker motif A and walker motif B with a dodecapeptide part 
that connects the two walker motifs, and 2. a smaller, structurally diverse α-helical 
subdomain that contains the ABC signature motif. ABC transporter proteins bind 
ATP through their NBDs and use the energy derived from this to transfer molecules 
across cell membranes. A glutamine residue residing in a flexible loop called Q 
loop that connects the TMD and NBD is presumed to be involved in the interaction 
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of the NBD and TMD, particularly in the coupling of nucleotide hydrolysis to the 
conformational changes of the TMD during substrate translocation. The H motif or 
switch region contains a highly conserved histidine residue that is also important in 
the interaction of the NBD domain with ATP. 
 
1.5.5.1. ABC Transporters in Multidrug Resistance 
During cancer treatment, tumour cells can become resistant to chemotherapy due to 
increased excretion of drugs out of tumour cells or target proteins (Dean, 2002). 
Pathways such as these can lead to multidrug resistance (MDR) thus contributing to 
the failure of chemotherapy in malignant diseases. Multidrug resistance is the term 
given to describe tumours developing resistance to two or more chemotherapeutic 
drugs. This is the net result of the overexpression of membrane transporters that 
actively remove toxic chemotherapeutic agents out of tumour cells (Sarkadi et al., 
2006). ABC transporters have been widely associated with resistance and the ABC 
genes ABCB1 (encoding P-gp), ABCC1 (encoding MRP1) and ABCG2 (encoding 
BCRP) are the main genes that can be upregulated in cancerous cells. MRP1 is 
expressed in epithelial cells and in non-malignant cells it plays a role in protecting 
kidney tissues, bone marrow and the intestinal mucosa from xenobiotics as well as 
contributing to the removal of drugs from the cerebrospinal fluid (Schinkel and 
Jonker, 2003). Moreover, MRP1 confers drug resistance to a range of cancer drugs 
and transports conjugates of hydrophobic drugs as well as organic anions (Schinkel 
and Jonker, 2003). P-glycoprotein (P-gp) was one of the first ABC transporters to 
be associated with resistance (Leslie et al., 2009) and led to the discovery of other 
genes in the ABC transporter family involved in multidrug resistance. P-gp is 
highly expressed in cancerous tissues and it is reported to be involved in cancers of 
the liver, colon and kidney tissues (Schinkel and Jonker, 2003).  Breast Cancer 
Resistance Protein (BCRP) was discovered after analysis of mitoxantrone-resistant 
cell lines that did not over-express P-gp or MRP1 by Doyle et al (1998). It was first 
cloned from a multidrug-resistant breast cancer cell line, hence the name. 
In addition to chemotherapeutic agents P-gp, BCRP and MRP1 also actively 
transport non-cytotoxic drugs and xenobiotics (Matsson et al., 2009; Sharom, 2008; 
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Mao and Unadkat, 2005), thereby affecting the pharmacokinetics and tissue 
distribution of these drugs. Table 1.1 gives a summery description of these 
transporters. 
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Apart from their role in MDR, transporter proteins encoded by ABCB1, ABCC 
family (mainly MRP2) and ABCG2 have major functions in the pharmacokinetics 
and tissue distribution of different drugs. As can be seen in Figure 1.6, P-gp, BCRP 
and MRP2 are located in the apical membrane of intestinal epithelia and export the 
substrate compounds from epithelial cells back into the lumen, while MRP3 is 
located in the basolateral membrane and transports its substrates from cytoplasm 
into the blood. The main ABC transporters in the kidney are P-gp, MRP2 and 
MRP4, with an efflux role for active secretion of their substrates. P-gp, BCRP and 
MRP2 are also involved in bile secretion through efflux of their substrates in the 
canalicular membrane. P-gp, BCRP, MRP4 and MRP5 are the main ABC 
transporters responsible for the efflux of compounds from the brain. Below is a 
description of these ABC transporters in terms of their structure, binding and efflux 
mechanisms, substrates, inhibitors and polymorphisms. 
 
1.5.5.1.1. P-glycoprotein (ABCB1 Subfamily, MDR) 
The schematic diagram of P-gp can be seen in Figure 1.7. This protein consists of 
1280 amino acids forming 12 transmembrane segments. P-gp has an exceptionally 
wide range of substrate specificity for cationic and lipophilic drugs. Apart from 
drugs, P-gp as a strong efflux pump is able to export a number of structurally 
diverse compounds including anthracyclines, epipodophyllotoxins and vinca 




Figure 1.7. Schematic diagram showing the structure of human P-gp with 1280 
amino acids and 12 transmembrane segments. Each loop in this topological view 
represents an amino acid residue (Adapted from Gottesman and Pastan, 1988). 
P-gp is expressed at many physiological barriers such as the intestinal epithelium, 
hepatocytes, renal proximal tubular cells, pancreatic and bile ductules, adrenal 
gland and the endothelial capillaries of the brain comprising the blood brain barrier  
(Kim et al., 1998; Thiebaut et al., 1987; Croop et al., 1989). This transport protein 
plays a significant role in different steps of absorption, distribution, metabolism and 
elimination of many compounds including anticancer drugs (Schinkel et al., 1995; 
Leveque and Jehl, 1995; Relling, 1996).  In the membrane of hepatocytes, where P-
gp is mostly expressed, P-gp is involved in the efflux of xenobiotics into the bile 
(Yu et al., 2010). In the gastrointestinal tract, P-gp pumps out the substrates into the 
gastric lumen; in such a case, the agents cannot access the portal vein to reach the 
systemic circulation (Schinkel et al., 1997). Therefore, P-gp can reduce the 
absorption and oral bioavailability of the substrate drugs. Moreover, it can be found 
in testis barrier (Melaine et al., 2002), blood brain barrier cells (Beaulieu et al., 
1997), blood mammary tissue barrier (Edwards et al., 2005), blood-inner ear barrier 
(Saito et al., 1997), placenta (Gil et al., 2005) and endometrium of pregnant women 
(Arceci et al., 1988). A natural function of P-gp is that it prevents harmful 
chemicals or foreign compounds (xenobiotics) including drug molecules from 
getting into the brain and the placenta (Lin and Yamazaki, 2003). 
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P-gp is highly overexpressed in tumour cells and is able to bind and transport many 
chemically and structurally unrelated drug molecules thus explaining its MDR 
ability in cancer chemotherapy (Gottesman and Ambudkar, 2001). As a 
consequence of P-gp blockage, e.g. in the presence of inhibitors, the intracellular 
accumulation of the substrate drugs (chemotherapeutic agents) will increase which 
may result in excessive toxicity of these drugs. However, the reduction of 
chemotherapeutic dose is not a solution as it will reduce the overall efficacy 
(Wacher et al., 1995; McDevitt and Callaaghan, 2007; Wandel et al., 1999). An 
example of this situation is when a drug molecule such as digoxin, which is a P-gp 
substrate, is accumulated in the liver and kidney as a result of P-gp inhibitors 
preventing the biliary and renal elimination of digoxin by active secretion with the 
aid of P-gp efflux system (Hennessy and Spiers, 2007). 
P-gp has a promiscuous binding site that can accept a wide range of substrates of 
varying chemically unrelated chemical structures. The weight range of P-gp 
substrates can be very broad and vary from a MW of 250 to 1850 Da. Besides, the 
substrate molecules can be acidic, zwitterionic, uncharged or positively charged 
(Schinkel et al., 1997). Moreover, substrates can be amphipathic or hydrophobic 
(Kerns and Di, 2008). In terms of the modulators of this multispecific transporter, 
not only pharmaceutical drugs but also herbal products and some food components 
can affect the function of P-gp as a transporter. It is therefore advisable that in drug 
discovery, when a drug candidate is found to be a P-gp substrate, structure 
modifications are applied to reduce the P-gp activity, leading to a better therapeutic 
effect with less complications such as drug-drug interactions in drug discovery 
projects (Kerns and Di, 2008). 
The structure of human P-gp was first elucidated by electron microscopy 
(Rosenberg et al., 1997) and image analysis. P-gp was reported as having a central 
core with an opening to the extracellular side of the membrane but is closed 
towards the cytoplasm. Recently, Aller et al reported a medium resolution (3.8-4.4 
Å) X-ray structure of P-gp that supported previous claims about the structure of P-
gp and revealed tentative binding sites for drug compounds (Aller et al., 2009). The 
study proposed a detailedstructure for mouse P-gp which has 87% sequence 
identity to human P-gp. In addition to the structure of apo P-gp at 3.8 angstroms, 
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two structures of P-gp co-crystallised with cyclic peptide inhibitors cyclic-tris-(R)-
valineselenazole (QZ59-RRR) and cyclic-tris-(S)-valineselenazole (QZ59-SSS) 
were also determined. The structures showed distinct drug-binding sites in the 
internal cavity capable of stereoselectivity that is based on hydrophobic and 
aromatic interactions. The structure of apo P-gp reveals a large internal cavity that 
is approximately 6000 angstroms cubed, and a big gap of 30 angstrom between the 
two nucleotide-binding domains (Figure 1.8). In agreement with previous theories 
(Rosenberg et al., 1997, Higgins and Gottesman, 1992), the apo and drug-bound P-
gp structures in Aller’s work indicate portals open to the cytoplasm and the inner 
leaflet of the lipid bilayer for drug entry. The inward-facing conformation 
represents an initial stage of the transport cycle that is competent for drug binding 
(Figure 1.8). 
 
Figure 1.8. (a) P-gp structure and efflux activity; substrates are in red while ATP is 
in magenta. (b) Ligand-binding site on the transmembrane domain of P-gp (adapted 
from Chen et al., 2012). 
 
The X-ray crystal structures proposed by Aller gave some useful information 
regarding the amino acid residues involved in substrate binding to P-gp. The crystal 
structure PDB Code (3G60) showed one molecule of QZ59-RRR bound to the 
middle site in the binding pocket and two molecules of QZ59-SSS bound at upper 
and lower sites which are overlapping the middle site. This showed that P-gp can 
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bind to two drug molecules at the same time and confirmed the diverse and 
polyspecific nature of P-gp (Aller et al., 2009).  
According to Aller and co-workers, the binding pocket of P-gp includes the 
transmembrane helices 1, 6, 7 and 12 which mainly consist of hydrophobic and 
aromatic residues. These included phenylalanine (Phe) and tyrosine (Tyr) residues 
in addition to the aromatic and aliphatic residues serine, Threonine and Glutamine 
(Ser, Thr, Gln). Despite these key attributes being made available, questions have 
been raised about the absence of ATP in the structure and the fact that the structures 
do not appear to undergo conformational changes upon drug binding (Gottesman et 
al., 2009).  
Substrates of P-gp mainly interact with the protein by hydrophobic interactions, π-π 
stacking and van der Waals forces. The P-gp X-ray crystal structure also shows this 
as the cyclic peptide inhibitors bind to P-gp through hydrophobic aromatic side 
residues (Aller et al., 2009). Studies have also demonstrated that P-gp is a flexible 
molecule that can alter its conformation in order for substrate entry. These findings 
led to a proposed induced-fit mechanism for drug binding to P-gp, in which the 
substrate enters the large binding pocket and both drug and protein modify their 
shape to generate more favourable contacts unique to that substrate (Alonso et al., 
2006). This mechanism is supported by the X-ray structure of P-gp, where each of 
the ligands bound to P-gp interact with the protein at different or the same 
overlapping amino acid residues. Recent site-directed mutagenesis studies have 
provided evidence that each substrate can bind to more than one site and all sites 
are capable of transport function (Chufan et al., 2013). 
 
1.5.5.1.2. Multidrug Resistance-Associated Protein (MRP, ABCC Subfamily) 
Multidrug resistance-associated protein consists of ABCC1, ABCC2, ABCC3, 
ABCC4, ABCC5, ABCC6, ABCC10, ABCC11 and ABCC12 (You and Morris, 
2007). All of these MRPs act as efflux pump. 
Many compounds including glutathione conjugates were identified as MRPs 
substrates including LTD4, S-glutathionyl 2,4-dinitrobenzene (DNP-SG), 17β-
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glucuronosyl estradiol, lithocholyltaurine 3-sulfate, oxidized glutathione and 
bilirubin glucuronosides (Jedlitschky et al., 1996). Furthermore, numerous 
unconjugated amphiphilic anions are transported by ABCC1. Examples are folate 
and its antimetabolite methotrexate (Hooijberg et al., 1999). Its function as a pump 
for cytostatic agents, confers resistance a broad range of anti-cancer drugs. MRP1 is 
mostly found in the lung, testis, kidney, and macrophages. MRP1 shares a similar 
distribution pattern with MRP2, which holds the role of excretion and 
detoxification of endogenous and xenobiotic anions in the bile (Nies et al., 2007). 
However, localization of MRP1 makes its role more to protect the cells from toxic 
effects of endogenous and xenobiotic anions rather than excretion (Bakos and 
Homolya, 2007). 
ABCC2 (MRP2) is an efflux transporter which transports sulphate conjugates, 
glucuronide and glutathione of many compounds and xenobiotics (Jansen et al., 
1985). This transporter abundantly exists in canalicular membrane of liver and 
plays crucial role in the biliary transport of anionic conjugates. Studies in mutant 
rats indicated that the lack of functional MRP2 leads to deficiency in the secretion 
of anionic conjugates into bile (Hosokawa et al., 1992). MRP2 has a crucial role in 
the biliary secretion of many endogenous and exogenous compounds (Morikawa, et 
al., 2000) and down-regulation of MRP2 expression leads to impaired biliary 
excretion of amphiphilic anionic conjugates in the rat models of cholestasis 
(Trauner et al., 1997). 
ABCC3 (MRP3) can transport a wide range of endogenous and exogenous 
substrates (mainly conjugated organic anions) to blood circulation. As shown in 
Figures 1.4 and 1.6, unlike MRP2, this transporter is mostly expressed at the 
basolateral membranes of liver and intestine (Ehrhardt and Kim, 2008). Studies in 
mutant rats with chronic conjugated hyperbilirubinemia, which are unable to 
secrete bilirubin glucuronosides into bile shows that hepatic MRP3 expression is 
inducible but appears to be constitutive in other organ (Hirohashi et al., 1998; 
Fernández-Barrena et al., 2012). MRP3 may function as a “backup” transporter for 
amphipathic conjugates in cholestatic conditions. It may have a role in 




ABCC4 (MRP4) is characterized as an ATP-dependent organic anion transporter. 
Nucleoside monophosphate analogues were the first substrates that were discovered 
for MRP4 (Schuetz et al., 1999). In addition, transport of the prostaglandins PGE1 
and PGE2 is mediated by MRP4 (Reid et al., 2003). MRP4 is acquired in 
basolateral as well as in apical membrane localizations. MRP4 was found in apical 
membrane of proximal tubule epithelial of human cells (van Aubel et al., 2002) and 
rat kidney (Denk et al., 2004). MRP4 was demonstrated in the basolateral 
membrane in human, rat and mouse hepatocytes (Denk et al., 2004 and Rius et al., 
2003) (See Figures 1.4 and 1.6). 
ABCC5 (MRP5), similar to MRP4 may be found either in basolateral or apical 
membrane. In intact human cells, MRP5 was able to mediate efflux of the anionic 
dye fluorescein diacetate with ATP consumption (McAleer et al., 1999). The 
ABCC6 (MRP6) protein is detectable in liver and kidney, in the basolateral 
membrane of rat (Madon et al., 2000) and in hepatocytes in human (Keppler et al., 
2001). ABCC10, ABCC11, and ABCC12 are recently identified members of the 
MRP family that are at relatively early stages of investigation. ABCC10 and 
ABCC11 are lipophilic anion pumps that are able to confer resistance to 
chemotherapeutic agents. ABCC11 is an efflux pump that is able to transport cyclic 
nucleotides (Guo et al., 2003). It is also able to transport leukotriene C4 (LTC4 ), 
2,4-dinitrophenyl glutathione (DNP-SG), estradiol 17-β-D-glucuronide (E217βG), 
monoanionic bile salts cholyglycine and cholyltaurine, folate and antimetabolite 
methotrexate, steroid sulphates E13S and DHEAS (Chen et al., 2005). In human, 
ABCC11 is localized in the cerebral cortex of neurons. A recent study on 
localization of ABCC proteins has shown the expression of ABCC11 in Sertoli (rat 
testis cells) (Klein et al., 2014). The human genes and transmembrane helices of 
ABCC12 orientation show a high similarity to those of ABCC4 and ABCC5 
(Toyoda et al., 2008; Yabuuchi et al., 2001). No functional characterization has 





1.5.5.1.3. Breast Cancer Resistance Protein (BCRP, ABCG2 Subfamily) 
ABCG2 subfamily is another ATP-binding cassette transmembrane transporter 
which transports a range of several drugs. It was first identified in MCF-7 human 
breast carcinoma cells, hence the name BCRP (Doyle et al., 1998). Ross et al 
(1999) postulated that BCRP may be the main transporter that causes resistance to 
mitoxantrone in cancer cells (Ross et al, 1999). Exposure to mitoxantrone, 
topotecan, or doxorubicin results in over-expression of the ABCG gene in mice 
lacking P-gp and MRP hence the transporter is one of the three major transporters 
involved in multidrug resistance (Allen et al., 1999; Doyle and Ross, 2003). BCRP 
also effluxes non-chemotherapeutic drugs and xenobiotics such as prazosin, 
glyburide, and 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (Ni et al., 2010; 
Saito et al., 2010). BCRP also mediates the intestinal efflux of antibiotics. For 
example nitrofurantoin which is an antibiotic used in treating urinary tract infection 
has a very high biliary excretion predominantly mediated by BCRP (Merino et al., 
2005b). Human BCRP and mouse bcrp1 can transport a range of organic substrates, 
including hydrophobic compounds, organic anions, weak bases, and conjugates of 
glucuronide, sulfate, glutamylate and glutathione of many endogenous and 
exogenous molecules. There is overlapping substrate specificity between BCRP and 
P-gp however the transport efficacies for these substrates differ (Ni et al., 2010; van 
Herwaarden and Schinkel, 2006). 
Tissue distribution of BCRP is similar to that of P-gp; BCRP is located in the apical 
membrane of epithelial cells of the intestines where it mediates direct intestinal 
excretion of its substrates and in the bile canalicular membrane of hepatocytes it 
stimulates hepatobiliary excretion (Allen et al., 1999). Besides, BCRP has been 
shown to have protective role in blocking the absorption of drugs into CNS via the 
blood-brain barrier (Loscher and Potschka, 2005). 
 
1.6. Assessment of drug-transporter Interactions 
Transporters impact on both safety and efficacy in humans. Effect of transporter 
interactions on the therapeutic and other biological effects of drugs is complicated 
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due to the distribution pattern of these transporters in tissues and membrane 
localisations and varying, often complicated, roles in different tissue compositions. 
As a result, interaction of drugs with different transporters can impact their ADME 
properties and may lead to potential drug-drug interactions. In drug discovery, it is 
important to identify the possible drug-drug interactions for a drug candidate and 
evaluate the risk of occurrence in patient populations that are likely to receive a 
concomitant medication (Koenen et al., 2011; Li, 2008).  
Drug transporter interactions may be assessed using in vitro methods and they may 
be estimated using in silico techniques during drug discovery (Li, 2008). Ex vivo 
animal tissues have been traditionally used to measure drug permeability and 
transporter mechanisms, but since emergence of human overexpressing cell lines, 
these models have limited use in the industry (Obach et al., 2012). The value of 
these assessments in drug development is to enable the prediction of drug-drug 
interaction risk in clinical settings (Li, 2008).  
The experimental study of transporters requires the transporter expressed in a 
correct location of a plasma membrane (apical/basolateral) in correct orientation. 
During the experiment, the disappearance of drug substance from one compartment 
and/or appearance of the drug in the other compartment is/are measured. In order to 
measure the inhibition of a transporter by a drug, a validated specific substrate of 
that transporter is required to test the inhibitory activity against the transport of the 
substrate (Keogh, 2012). For example, hepatocytes can be grown in collagen 
sandwich cultures allowing them to establish the bile canaliculi necessary for 
directional flux to explore the impact of inhibitors on bile acid transporters (Kotani 
et al., 2011, Maeda et al., 2010, Marion et al., 2011; Nakanishi et al., 2011). In 
addition to primary hepatocytes, renal proximal tubule cells (Brown et al., 2008) 
and brain microvessel endothelial cells (Lippmann et al., 2012) are also used to 
mimic tissue barriers. 
The experimental methods can generate quantitative or semi-quantitative measures 
such as binary data (substrate or non-substrate), IC50, Ki, Km, Vmax, efflux ratio 
and intrinsic permeability. Michaelis-Menten model of enzyme kinetics are 
generally used to describe the interactions with transporters (Agnani et al., 2011; 
Kolhatkar and Polli, 2010). Dissociation or association constant from the inhibitor-
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enzyme complex and the concentration of the inhibitor to cause 50% inhibition at 
one chosen substrate concentration (IC50) are some of the most common ways to 
present enzyme inhibition data (Li, 2008).  
IC50 is defined as the required concentration of an inhibitor to inhibit the enzyme 
population by half (Copeland, 2005). IC50 can also be calculated from inhibitor 
concentrations and percentage of control activity using some non-linear regression 
methods (Chiba et al., 2001). Typically, enzymes and IC50 determinations for the 
enzymes and transporters occur in early stage of preclinical development in order to 
generate preliminary inhibition data on a large set of compounds across a broad set 
of enzymes (Yan and Caldwell, 2001; Crespi and Stresser, 2000).  However it must 
be noted that IC50 values can vary depending on the substrate used, the 
concentration of the labelled ligand (substrate) and different experimental variables 
and conditions (Böhm and Schneider, 2003). An advantage of IC50 determination is 
that it is independent of the inhibition mechanism and needs fewer samples to 
produce a meaningful result (Krishna, 2004). Nevertheless, the IC50 determination 
is dependent on the experimental and incubation conditions under which they are 
measured (Madan et al., 2002). Thus, IC50 value is only meaningful at the substrate 
concentration for which the IC50 was determined for all forms of inhibition. 
Depending on the concentration of substrate used in the preliminary IC50 
experiment, there can be a correlation between the IC50 and the inhibition constant 
(Ki) which can be used as an early approximation of Ki (Krishna, 2004). 
Inhibition constant (Ki) plays an important role in predicting the clinical 
significance of inhibitions in in vitro methods. The Ki is a measure of enzyme-
inhibitor potency and indicates how potent an inhibitor is. It is the concentration 
required to produce half maximum inhibition. In contract to the IC50 value, Ki is 
more reproducible because they are less dependent on experimental conditions as 
they are measured based on a range of substrate-inhibitor concentration (Krishna, 
2004). IC50 value can be is converted to an absolute inhibition constant Ki by the 
Cheng-Prusoff equation. For enzymatic reactions, this equation is: 
Ki = 
    
   
   
  
                                                                 Eq. 1.12 
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Where Ki presents dissociation constant of the inhibitor, [S] is fixed substrate 
concentration and Km is the concentration of substrate at which enzyme activity is 
at half maximal (Cheng and Prusoff, 1973). In theory, a larger Ki value is an 
indication of low affinity and vice versa. For example in P-gp inhibition, the small 
Ki value means that substrate strongly blocked the P-gp and also means that 
enzyme-substrate complex (E-S) is more stable.  
Although lab-to-lab variability is a well-established phenomenon for many 
experimental measurements, this may well be more pronounced for transporter 
assays using live cells, as many variables will impact on assay outputs including 
expression levels of the transporter, potentially endogenous transporters, passage 
number, assay formats (Keogh, 2012). A recent cross-pharma comparison of 
quantitative in vitro P-gp inhibition assays using a common substrate digoxin, with 
Caco-2, MDCK-MDR1 or P-gp vesicles, several assay end points, and data 
calculation methods showed limited agreement between assay outputs (Lee, 2011). 
The sources of variability are multi-factorial including cell-type, assay format and 
data manipulation (Bentz et al., 2013). 
For robust and reproducible in vitro transporter inhibition investigation, there is a 
need for characterised probe substrate(s) and inhibitors to determine the transport 
kinetic parameters such as initial rates, Km, Vmax, IC50 or Ki. In binary (yes or no) 
assays, there is a need for a single probe substrate concentration at or below Km, 
with and without inhibitors at concentrations sufficient to cause complete 
inhibition.  
Although animals provide important in vivo mechanistic insights for transporters, 
their utility is limited, due to low throughput, the expense, and more importantly, 
the interspecies differences in transporter tissue distribution, expression levels and 
metabolism which limits the direct translation from preclinical species to humans 




1.7. In silico Methods in Drug Discovery 
Traditionally, drugs are usually discovered in biological assays and in time-
consuming in vivo and in vitro testing. However, the use of computer modelling in 
drug discovery has rapidly been developed creating techniques and software that 
are able to analyse and predict information about biological, chemical and medical 
data. The term ‘in silico’ refers to the computational approach of drug discovery 
which is complementary to in vivo and in vitro experiments (Ekins et al., 2007). In 
a widely expanding field, in silico techniques have been used to create virtual 
models that enable scientists to make predictions about biological activity and 
provide advances in medicine. Computational methods are used widely in drug 
discovery for the design of virtual compound libraries, identification of lead 
compounds (virtual screening), development of 3-D homology models for the 
biological targets, computing the interaction energies and geometries (protein-
ligands docking), protein-protein interactions and estimations of biological activity 
of choice (Ekins et al., 2002a). For example, quantitative structure-activity 
relationship (QSAR) has been applied for the analysis of growing collections of 
ADME data and the resulting models are used for the prediction of properties of 
new bioactive compounds (Golbraikh et al., 2014).  
In drug discovery, the use of computational methods to facilitate the discovery 
process is well established and plays an important role in modern drug discovery 
(Krogsgaard-Larsen et al., 2010). Other commonly used in silico methods involve 
pharmacophore modelling that uses 3D structure representations to describe how 
candidate ligands may bind to a target (Ekins et al., 2007). In addition, there are 
target based methods that include docking compounds to a target site and the use of 
scoring functions to score the binding affinity of the ligand to the target. It has 
gained popularity in recent times and has been involved in the discovery of 




1.7.1. Quantitative structure-activity Relationships (QSAR)  
Since the 1960s when it was introduced by Corwin Hansch, QSAR has been used to 
describe the mathematical relationship between the structure of a molecule and 
biological activity (Van de Waterbeemd and Rose, 2003). QSAR models are 
empirical models in which a quantitative description of a chemical structure is 
related to the biological activity through an algorithm to guide future drug design 
(Cumming et al., 2013). The predictive ability of QSAR models is directly 
influenced by dataset characteristics such as size and chemical diversity as well as 
employing different molecular modelling techniques, molecular descriptors, and 
statistical model development methods (Golbraikh et al., 2014) and a thorough 
validation of the model for future predictions (Gramatica, 2013).  
QSAR and other computer based methods can significantly reduce the time and the 
cost in drug design and discovery processes. Regression models in QSAR relate a 
set of predictor variables to the numerical potency of the response variable, while a 
classification algorithm relates the predictor variables to a categorical value of the 
response variable. The predictors consist of physicochemical and molecular 
properties of compounds and the QSAR response could be a biological activity of 
the compounds (Nantasenamat et al., 2010).  
The ability to predict a pharmacological activity is important. Predictive models are 
based on the given data, the technique to develop the model and the quality of 
information of the dataset. An ideal QSAR model should be simply understandable, 
interpretable and mechanistically relevant (Cronin et al., 2010). A simple model 
should have a very small number of descriptors to form the relationship with the 
dependant. In QSAR, information and particular effect from molecular structure in 
a biological system can help us understand the relationship of molecular structure in 
a biological system (Cronin et al., 2010). 
 
1.7.1.1. Molecular Descriptors 
The manipulation and analysis of chemical structural information is made possible 
through the use molecular descriptors (Leach and Gillet, 2003). According to Hong 
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et al. 2008, “Molecular descriptors are used to extract the structural information in 
the form of numerical or digital representation that is suitable for model 
development, serving as the bridge between the molecular structures and 
physicochemical properties or biological activities of chemicals”. Molecular 
descriptors on a more mathematical based has been described by Todeschini and 
Consonni: “The molecular descriptor is the final result of a logic and mathematical 
procedure which transforms chemical information encoded within a symbolic 
representation of a molecule into a useful number or the result of some standardized 
experiment” (Todeschini and Consonni, 2008). 
Molecular descriptors play an essential role in chemistry and pharmaceutical 
sciences. Molecular descriptors are commonly used in QSAR for the identification 
and unique representation of molecules and fragments which are likely to become 
drug candidates (Malik et al., 2006). Descriptors encode or map the structure of 
molecules into a set of numerical or binary values representing various molecular 
properties which explains activity (Dudek et al., 2006). 
Molecular descriptors are classified based on the compounds physiochemical 
property, topology, kappa shape indices, molecular finger prints, and 
pharmacophore keys (Dudek et al. 2006). The information contained in a molecular 
descriptor about a compound depends on the format in which the chemical is 
represented. This could either be a one-, two-, or three dimensional representations. 
One-dimensional (1D) descriptors represent mainly the molecular formula of the 
compound and describe only the bulk properties of the compound such as its 
molecular weight and number of specific atoms. Descriptors based on two-
dimensional (2D) representations are able to provide information regarding atom 
types, connectivity patterns and topology such as number of aromatic group, 
number of hydrogen bond donors and acceptors, molecular refractivity, number of 
rotatable single bonds, bond distance and branching. 3D descriptors are more 
complex and provide information on conformation, geometry, potential energy such 
as dipole moment, ionisation potential, solvent accessible area, bond energy and 




1.7.1.1.1. 2D Molecular Descriptors 
2D molecular descriptors are defined as numerical properties that can be calculated 
from the connectivity matrix, i.e. connection table representation, of a molecule but 
not from atomic coordinates. Therefore, the 2D descriptors are not dependent on the 
molecular conformation. As a result of this, they can be calculated quickly without 
the need for the optimisation of the three dimensional structures and are most 
suitable for large database studies. They can include physical properties such as 
sum of formal charges, bond counts, molecular connectivity and shape indexes 
(Hall and Kier, 2007), adjacency and distance matrix descriptors (Mihalic et al., 
1992), pharmacophore feature descriptors and partial charge descriptors. 
Examples of 2D molecular descriptors provided by MOE software (Chemical 
Computing Group Inc. Montreal, Canada) include the van der Waals surface area 
calculated using a connection table approximation from 2D structure (vdw_area), 
octanol/water partition coefficient (log P), molecular mass density (density), sum of 
formal charges (Fcharge) and sum of the atomic polarisabilities (apol). The number 
of rings (rings), Lipinski’s drug like test (Lipinski et al., 2001) (lip_druglike), and 
number of aromatic bonds (b_ar) are examples of simple count descriptors, which 
are considered as 2D descriptors as they require 2D atomic connection map.  
The Kier and Hall connectivity (chi, χ) and shape (kappa, κ) indexes are topological 
descriptors calculated from the hydrogen suppressed molecular graph (Hall and 
Kier, 1977; 2007). In addition, based on the same graph theory, the atom type 
electrotopological state indexes were suggested. These are atom level indexes that 
combine the electronic character of the atoms and the topological environment for 
each skeletal atom in a molecule (Kier and Hall, 1999). 
Some 2D descriptors are calculated from adjacency or distance matrixes. The 
elements of an adjacency matrix for a molecule take the value of one if the two 
atoms are bonded and zero otherwise. The elements of a distance matrix of a 
chemical structure are the length of the shortest path between the two atoms. An 
example of descriptors calculated from adjacency matrix is BCUT descriptors 
(Pearlman and Smith, 1997). The BCUT descriptors are calculated from the 
eigenvalues of a modified adjacency matrix and are extensions of parameters 
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originally developed by Burden (1989). These parameters are based on a 
combination of the atomic feature for each atom and a description of the nominal 
bond-type for adjacent and nonadjacent atoms (Stanton, 1999).  
Atomic partial charges can be combined by a variety of methods to calculate 
molecule level properties (descriptors). For example, total of all the negative atomic 
charges, or the sum of absolute charges can be calculated for a molecule to 
represent polarity of the molecule. In addition, van der Waals surface area of atoms 
with specific atomic charge ranges can be summed. An example of this is fractional 
positive van der Waals surface area (PEOE_VSA_FPOS) that can be calculated by 
MOE software (MOE Help file, 2012). 
 
1.7.1.1.2. 3D Molecular Descriptors 
3D descriptors are also known as shape-based descriptors as they depend on 
internal coordinates, conformation and three dimensional structure of the molecule. 
Such descriptors can be as simple as inter-atomic distances or torsion angles or as 
complex as the distribution of electrostatic potential around a molecule. Also 
similarity descriptors, allow comparison of the similarity of a molecule with a set of 
standard active molecules, on the bases of either electrostatic potential or steric 
parameters (Dearden and Cronin, 2005). An example of such molecular descriptors 
is dipole moment, which is controlled by the atomic charges, connection of atoms, 
and the three dimensional shape (internal coordinates) of the molecule. These 
computed 3D descriptors correlate well with the well-known experimentally 
observed physicochemical properties such as solubility (Kombo et al., 2013). 
Due the importance of the 3D shape, molecular structures need to be optimized 
(energy minimization) before the calculation of these descriptors (Akamatsu, 2002). 
Molecular orbital descriptors calculated by MOPAC are examples of these 
descriptors (Karelson et al., 1996). Surface area, molar volume and shape 
descriptors and conformation dependent charge descriptors are other molecular 




Volsurf descriptors (known as the vsurf descriptors within the MOE program) were 
developed by Cruciani and co-workers (Cruciani et al., 2000a) and noted as an 
important class of descriptors for the prediction of pharmacokinetic properties 
(Cruciani et al., 2000b). These descriptors are calculated from 3D molecular fields 
of interaction energies also known as GRID (Goodford, 1985) molecular fields. In 
mathematical terms, these are 3D matrixes where the elements of the matrix are the 
attractive and repulsive forces between an interacting partner and a target. To 
calculate the Volsurf (and other molecular field) parameters, software first 
computes the fields by placing each molecule into a rectangular 3D grid (Leach and 
Gillet, 2003). Then a probe group is placed at each grid vertex and interaction 
energy between the probe and the molecule at points around the molecule is 
calculated (Goodford, 1985). For instance, MOE software calculates a parameter 
called vsurf_HB, which is calculated using a probe called O (carbonylic oxygen) to 
generate 3D H-bond donor fields (Fortuna et al., 2008). The H-bond donor regions 
may be defined as the molecular envelope generating attractive H-bond donor 
interactions. H-bond donor descriptors can be calculated at different energy levels.  
Other 3D molecular descriptors include electrostatic (E_ele) and van der Waals 
(E_vdw) components of the potential energy which can be calculated by 
semiempirical methods such as those implemented in the MOPAC engine in MOE 
software. The dipole moment (AM1_dipole), and the energy of the Highest 
occupied and the Lowest Unoccupied Molecular Orbitals (AM1_HOMO and 
AM1_LUMO respectively) are the examples of MOPAC descriptors that are 
calculated by AM1 semiempirical method (Stewart, 1993). 
 
1.7.1.2. QSAR Model Development and Validation 
QSAR models are statistically significant relationships between a biological 
property and molecular parameters of a set of compounds. The theoretical basis of 
classical QSAR is that the molecular structure is responsible for all the properties 
and biological activities of compounds and similar compounds should have similar 
biological and physicochemical properties (Katritzky et al., 2001). Building a 
model that fits the available data is not adequate as the aim of any modelling 
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procedure is to be able to use the models for making future predictions. According 
to Gramatica (2011) ‘an ideal QSAR  should: 1) consider an adequate number of 
molecules for sufficient statistical representation, 2) have a wide range of quantified 
end-point potency (i.e. several orders of magnitude) for regression models or 
adequate distribution of molecules in each class (i.e. active and inactive) for 
classification models, 3) be applicable for reliable predictions of new chemicals 
(validation and applicability domain) and 4) allow to obtain mechanistic 
information on the modelled end-point.’  
 
1.7.1.2.1. Statistical Modeling Techniques  
A wide range of statistical techniques have been applied to the QSAR field. These 
can be classified based on the type of the data being modelled. Categorical data, 
such as the binary data types substrate/non-substrate or active/inactive, can be 
modelled using classification techniques that utilise the molecular descriptors in 
order to divide the data into the respective classes (Han and Kamber, 2006). 
Continuous data such as IC50 values can be subjected to prediction methods. 
Prediction methods, also known as regression-based methods, are used to predict 
missing or unavailable numerical data values rather than class labels (Han and 
Kamber, 2006). Among the regression-based approaches, the methods of multiple 
linear regression (MLR) and partial least squares (PLS) regression are prime 
examples in the QSAR field, while examples of classification methods involve, 
discriminant analysis and classification decision trees and support vector machines 
(Eriksson et al., 2003). 
Classification and prediction may need to be preceded by ‘relevance analysis’, 
which attempts to identify attributes that do not contribute to the classification or 
prediction process. These attributes can then be excluded. The commonly used 
terminology for this analysis in QSAR field is feature selection (Newby et al., 
2013a) or variable selection (Ghafourian and Cronin, 2006), or data reduction 
(Livingston, 2004). Due to the large numbers of molecular descriptors that are 
available through many commercially available software packages, variable 
selection has become a necessity in QSAR model development. This practice is 
essential to avoid overfitting to the training set data and the risk of chance 
64 
 
correlation (Ghafourian and Cronin, 2006). In addition, fewer molecular descriptors 
increase interpretability and understanding of resulting models (Weaver, 2004) and 
it can provide improved model performance for the prediction of new compounds 
(Norinder, 2003). Recently, ‘descriptor pharmacophore’ was introduced as a new 
concept in QSAR on the basis of variable selection. The descriptor pharmacophore 
is defined as a subset of molecular descriptors that lead to the most statistically 
significant QSAR models. It has been demonstrated that chemical similarity 
searches using descriptor pharmacophores as opposed to using all descriptors is 
more effective in successful mining of chemical databases or virtual libraries for 
identification of compounds with desired biological activity (Tropsha et al., 1999; 
Tropsha and Zheng, 2001). Feature selection can be split into two broad categories: 
data pre-processing or embedded methods. Data pre-processing feature selection 
involves reduction of the number of molecular descriptors prior to incorporating 
them in the model development exercise. On the other hand, embedded methods 
incorporate the feature selection into the training of the model (Saeys et al., 2007).  
There are some unsupervised feature selection methods that do not use the 
dependent variable in the process of data reduction. An example of these methods, 
which can be used at pre-processing stage, is clustering of the variables.  Cluster 
analysis is a useful tool for the visualisation of the clusters of variables as well as 
clusters of compounds (Livingstone, 2004). Another unsupervised method is 
Principle Component Analysis (PCA). This is multivariate technique in which a 
new set of variables called Principle Components (PCs) are created from linear 
combinations of original variables. PCs are orthogonal to each other and the first 
PC has the maximum information (variance) of the original data. Subsequent PCs 
describe the maximum of the remaining variance (Livingston, 2004). In this way, 
only the first few new variables (PCs) will be sufficient to explain the data and the 
remaining variables can be discarded, hence data reduction. 
Other pre-processing techniques can be further split into filter and wrapper 
techniques. Filter techniques usually involve calculating a relative score of the 
molecular descriptors and ranking them in order of best score, and the descriptors 
that are at the top of the list are then used as input for classification. Wrapper 
techniques consider a number of subsets of molecular descriptors, evaluate each of 
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these based on the predictive performance of a classification model built from that 
descriptor subset, and eventually select the descriptor subset with the best 
predictive performance (Kohavi and John, 1997). 
It’s worth mentioning that any resulting QSAR model is only as statistically valid 
as the data that led to its development. In brief, an ideal QSAR model should 
consider enough number of training molecules, have a wide range of quantified 
endpoint potency for regression models and be applicable for prediction of new 
untested compounds (Gramatica, 2013).  
To have a successful QSAR model, depends on accuracy of the input data and 
selection of appropriate descriptors should be considered (Chirico and Gramatica, 
2012; Roy, 2007).  
 
1.7.1.2.2. Validation of QSAR Models 
The best fit models may not be the best ones for prediction. Only a stable and 
predictive model can be usefully interpreted for its mechanistic meaning, even 
though this is not always easy or feasible (Gramatica, 2011). The use of these 
statistical techniques in this context leads to ‘statistical learning’ from data that can 
be used for predictions. So far, much effort has been placed into performing some 
form of validation on QSAR models. Usually, this has been in terms of a model’s 
statistical fit and more recently the focus has turned to using an external test set 
(Cronin, 2010).  
Various strategies can be used for validation of QSAR models. According to Wold 
and Eriksson (1995) the most important validation strategies are: 1. internal 
validation set or a standard cross-validation method, 2. external validation by 
splitting the dataset into training set for model development and to evaluate the 
predictive ability of the model, 3. blind external validation (by using the model on a 
new external set), 4. data randomisation or Y-scrambling for verifying the absence 
of chance correlation between the dependent variable and descriptors (Wold and 
Eriksson, 1995).  
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The general idea of V-fold cross-validation is to divide the overall sample into a 
number of subgroups (V-folds). Subgroups are removed from the training set one at 
a time to serve as the internal test set and the model is developed successively for 
the remaining compounds (V – 1 folds). For each modelling run, some index of 
predictive validity is computed for the subgroup that is left out and the results of the 
v replications are averaged to yield a single measure of the stability of the 
respective model. The V-fold cross-validation technique is used in various 
analytical procedures to avoid overfitting of the data (Burden, 1989). V-fold cross 
validation is especially useful when the data is not large enough to allow for 
external validation of the model. The leave-one-out (LOO) method can be 
considered as a special case of V-fold cross validation. The outcome of this 




), which is may regarded as a criterion of both 
robustness and predictive ability of the model. The robustness of LOO procedure 
has been debated recently (Kubinyi et al., 1998; Golbraikh et al., 2003). 
Y-randomization is a widely used approach in validation of QSARs which is often 
used along with the cross-validation (Golbraikh et al., 2003). It consists of 
repeating the model calculation procedure with randomized activities and 
subsequent probability assessment of the resultant statistics (Golbraikh et al., 
2003). 
A more robust way for validation is to use external validation by splitting the 
dataset into training set, for model development, and validation set, to evaluate the 
predictive ability of the model. This is done before building the models so the 
validation set is kept external and not involved at any stage of model development. 
There are different methods for splitting the data into training and validation sets. It 
has been suggested that splitting data should be performed in a way that all 
representative compounds of the validation set are close to the training set 
compounds in the multidimensional descriptor space, and the representative points 
of the training set must be distributed within the whole area occupied by the entire 
dataset (Golbraikh and Tropsha, 2002.). The rational division of a dataset into 
training and test sets can be done by randomly allocating a fixed proportion of a 
homogeneous dataset to the validation set. In order for the training and validation 
sets covering similar activity ranges, the data could be ranked according to the 
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magnitude of the biological response, and every third or fourth chemical could be 
removed for validation set (Sharifi and Ghafourian, 2014). Other selection methods 
include selection on the basis of relevant physicochemical descriptors for example 
through multivariate design; this results in a test series of compounds in which all 
major structural and chemical properties are systematically varied at the same time 
(Eriksson et al., 2003). An example of the other methods that can ensure similar 
distribution of training and validation set data is K-means-cluster based division of 
training and prediction sets (Leonard and Roy, 2008). 
 
1.7.1.2.2.1. Applicability Domain  
It is usually noted that QSAR is applicable only to compounds that are similar to 
the training set compounds (Katritzky et al., 2001). Structurally limited training 
sets, when the dataset is small or when the chemical diversity is low, are a 
limitation of QSAR models in terms of their application for future predictions 
(Dimitrov et al., 2005). A good model performance on the training set does not 
guarantee that a model will be predictive for validation set or external compounds 
(Stouch et al., 2003). In other words, QSAR models sometimes are not applicable 
to the new compounds. As a result of this, there needs to be conditions set for the 
applicability of QSAR models (Eriksson et al., 2003). This is very important in 
light of the increasing number of commonly termed global QSAR models which 
can be built on small datasets of low diversity (Weaver and Gleeson, 2008), or with 
poorly homogeneous training sets that contain partially overlapping clusters of 
compounds e.g. several classes of chemical compounds or chemotypes (Eriksson et 
al., 2003). Defining a model’s applicability domain is essential in order to 
determine the space of chemical structures that could be predicted reliably. 
According to Weaver and Gleeson (2008) the domain of applicability is an 
important concept in quantitative structure-activity relationships (QSAR) that 
allows one to estimate the uncertainty in the prediction of a particular molecule 
based on how similar it is to the compounds used to build the model. In practice, 
there are various methods available for determining the range of applicability of 
QSAR models. For example, Dimitrov et al (2005) utilized a stepwise approach for 
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determining the applicability domain of QSAR models based on physicochemical 
properties in the training set of toxicity and skin sensitization datasets. This method 
involved four stages to account for the diversity and complexity of the QSAR 
models. First, the range of variation of the physicochemical properties of the 
training set compounds was specified. Then the structural similarities between 
chemicals that are correctly predicted by the model were assessed. At the third 
stage, the domain was defined based on a mechanistic understanding of the 
modelled phenomenon. Finally, the reliability of simulated metabolism was 
considered in assessing the reliability of predictions, if metabolic activation of 
chemicals is a part of the (Q)SAR model (Dimitrov et al., 2005).  
Sahigara et al (2012) has reviewed the applicability domain methods (Sahigara et 
al., 2012). Accordingly, they have classified all the methods into: 1. range-based 
and geometric methods; 2. distance-based methods; 3. probability density 
distribution-based methods; 4. other approaches that may include decision trees and 
decision forests approach and stepwise approaches, such as the method suggested 
by Dimitrov et al (2005). Range based methods are the simplest approaches which 
may use a ‘bounding box’ defined on the basis of maximum and minimum values 
of each descriptor used to build the model or principle components of PCA 
(Netzeva et al., 2005). In distance based methods, first the distance between an 
individual molecule will be computed from a defined point within the descriptor 
space of the training data using common distance measures e.g. Euclidean distance. 
Then, a threshold is applied to separate the compounds that are outside the domain 
of applicability. The threshold is a user defined parameter (Xu and Gao, 2003). As 
a distance based method, k nearest neighbour method can be used to measure the 
similarity by calculating the distance between the compound and the nearest 
neighbour compound in the training set (Xu and Gao, 2003). Probability density 
distribution-based methods are some of the most advanced approaches for defining 
applicability domain, as they are able to identify the internal empty regions within 




1.7.2. Enzyme-ligand Docking 
Availability of a detailed 3D structure for biological drug targets (mainly receptors 
or enzymes) opens the possibility of a number of computer-based techniques in 
drug discovery arena. Structure-based drug design is one such technique that can 
use the information regarding shape and properties of the binding site of target 
molecules to design compounds which possess corresponding properties for fitting 
into and interacting with the binding site. Therefore, we require methods for 
determination of 3D structure of the biological targets (Krogsgaard-Larsen et al., 
2010). Other target based methods involve docking compounds to a target site and 
the use of scoring functions to score the binding affinity of the ligand to the target. 
It has gained popularity in recent times and has been involved in the discovery of 
inhibitors of HIV-1 integrase (Hayouka et al., 2010) and aldose reductase inhibitors 
(Iwata et al., 2001). Enzyme-ligand docking may guide a target’s structural 
requirements for ligand (e.g. substrate/inhibitor) interaction by correlating the 
molecular features of validated ligands with their biological activity (Matsson et al., 
2007; Nicolle et al., 2009; Ahlin et al., 2008; Gombar et al., 2004). The 3D 
structure of a protein can be obtained by prevalent methods such as X-ray 
crystallography and NMR spectroscopy, or predicted by homology modeling 
methods. The quality of an X-ray structure or a homology model is an important 
factor that should be taken into consideration before using the protein (Krogsgaard-
Larsen et al., 2010). 
 
1.7.2.1. Conceptual Frame and Methodology of Molecular Docking 
Computational approaches establish enzyme-ligand binding affinities by using 
structural information of the ligand and target enzyme, thus reducing the time and 
materials associated with experiments (Guvench and Mackerell, 2008). After X-ray 
crystallography or multidimensional NMR studies, the solved 3D structures of 
proteins are deposited into the Protein Data Bank (PDB) (RCSB Protein Data Bank, 
2014). These structures can be analysed to discover the essential interactions and 
principles of molecular recognition (Raffa, 2001). The forces of interaction that 
bind a substrate to the enzyme active site consist of ionic bonds, hydrogen bonds, 
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van der Waals, hydrophobic, dipole-dipole and ion-dipole interactions. Once the 
interactions involved in substrate binding have been established, it is possible to 
look at the structure of a substrate and hypothesize the probable interaction that it 
will have with its active site (Schmidt et al., 2013). The docking process involves 
the prediction of ligand conformation and orientation (or posing) within a targeted 
binding site. In general, there are two aims of docking studies: accurate structural 
modelling and correct prediction of activity (Kitchen et al., 2004). Docking studies 
can be used to identify the fit between active site of the enzyme and the potential 
ligand. Also, docking can be used as a component of virtual screening, where a 
database of ligands is screened against a target protein (Kitchen et al., 2004). 
The docking process consists of two elements, the first is searches to find suitable 
conformation and the second is the measurement of the affinity of various 
conformations (Dror et al., 2004). The process begins with the application of 
docking algorithms that positions small molecules in the active site. However, even 
relatively simple organic molecules can contain several conformational degrees of 
freedom. Conformational analysis is carried out to recognise conformational 
characteristic of ligand 3D structure created by energy minimization (Secundo, 
2013). Energy minimization reduces the potential energy of a given conformation 
to make it suitable, but the obtained structure might not be essentially the most 
stable one as energy minimization stops when it reaches the first stable structure 
(the local minimum). To achieve the minimum with the lowest energy, structural 
variations will need to be carried out which helps in reaching the most stable 
conformation. In protein ligand docking, the docking program aims to find the 
preferred conformation of the ligand at a binding site of the target (Sousa et al., 
2006). Sampling of different conformations must be performed with sufficient 
accuracy to identify the conformation that best matches the receptor structure, and 
must be fast enough to permit the evaluation of thousands of compounds in a given 
docking run. The binding energy is then calculated for each conformation and is 
ranked and scored to give an estimation of the binding affinity between a 
compound and the target. Scoring functions are designed to predict the biological 
activity through the evaluation of interactions between compounds and potential 
targets (Kitchen et al., 2004). 
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At present, there is a wide range of docking software available in the market with 
different scoring functions. The program AUTODOCK is one of the most cited 
docking programs and uses the Lamarckian genetic algorithm as well as a 
traditional genetic algorithm (Sousa et al., 2006). GOLD is another program that is 
popular in the field and enables flexibility of the protein hydrogen bonds as well as 
the ligand being tested. Unlike AUTODOCK, docking scores in GOLD are ranked 
using a force field scoring function that includes the contributions of hydrophobic 
interactions, van der Waals forces and number of hydrogen bonds (Cummings et 
al., 2005). FlexX is another software package that permits protein flexibility and 
scores the final position of molecules using the empirical Böhm’s scoring function 
(Sousa et al., 2006). In addition to these aforementioned programs, the Molecular 
Operating Environment (MOE) is a suite of applications that can be used for 
medicinal chemistry purposes. It includes a docking tool that searches for 
complimentary binding poses between a ligand and a rigid receptor which can be 
used to determine interactions between candidate ligands and targets. 
 
1.7.2.2. Scoring Functions 
Scoring functions are used to calculate the binding energy of poses generated after 
docking placements. A very accurate scoring function is desired to be able to 
successfully predict binding affinity, however due to the complexity and high 
computational cost involved, scoring functions make assumptions about molecular 
interactions based on experimental data from independent reactions (Lipkowitz and 
Boyd, 2002). In all scoring functions, a lower score indicates a more favourable 
pose while higher scores suggest that binding is less likely. Scoring functions are 
based on different calculation methods and can be divided into three categories: 
knowledge-based, force field and empirical based methods. 
 Knowledge-based functions use data from statistical analysis of structural 
complexes in the protein data bank, to estimate interatomic reactions occurring 
frequently between a ligand and the protein in specified intervals (Schulz-Gasch 
and Stahl, 2004).  
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GoldScore, Assisted Model Building and Energy Refinement (AMBER) and the 
Optimised Potentials for Liquid Simulations function (OPLS), are examples of 
force-field scoring functions. Force-field scores are calculated by measuring 
electrostatic and van der Waals interactions (Schulz-Gasch and Stahl, 2004) but are 
limited by the exclusion of solvation and entropic properties (Sousa et al., 2006).  
In contrast to these two scoring functions, empirical scores estimate free binding 
energy based on a sum of localised independent reactions (Lipkowitz and Boyd, 
2002). In most cases, the constants in empirical formulas are derived from binding 
energies calculated in experiments of receptor-ligand complexes (Sousa et al., 
2006).  An example of an empirical scoring function is the London dG scoring 
utilised in MOE (Equation 1.13).  
 
 
Equation 1.13. London dG Scoring Function (Corbeil et al., 2012) 
The formula above calculates binding energy, where Eflex represents the energy due 
to loss of flexibility of the ligand, ƒhb and Сhb are measurements of hydrogen bonds, 
while СM and ƒM measure energies related to metal ligation.  
Early scoring functions evaluated compound fits. Relatively simple scoring 
functions, on the basis of approximate shape and electrostatic complementarities, 
are heavily used during the early stages of docking simulations and in virtual 
screening of compounds. The selected conformers can then be further evaluated 
using more complex scoring schemes with more detailed treatment of electrostatic 
and van der Waals interactions, and inclusion of at least some solvation or entropic 




2. Aims and Objectives 
 
Biliary excretion is one of the main elimination routes of compounds and/or their 
metabolites with consequent effects on drug half-life and possible implications on 
gastro-hepatic cycle. The prediction of biliary excretion is a key target in the drug 
design and it helps with the selection of candidates for the development stage. The 
broad aim of the project involved not only the use of Quantitative Structure-
Activity Relationships (QSAR) and data mining tools for estimation of biliary 
excretion, but also investigating the role of several transporter proteins in this 
elimination route. QSAR techniques employ molecular structural information of the 
compounds (molecular descriptors) and various statistical/ data mining techniques 
for the prediction of biological properties of new compounds. In this investigation 
QSAR methods were used to achieve both aims of the project.  
Excretion of compounds through bile depends on the structural factors and 
physicochemical properties of the compounds. For example it has been suggested 
that compounds with molecular weights above 500 Da are highly excreted through 
bile (You and Morris, 2007) and this threshold value may be different in different 
animal species (Yang et al., 2010). Therefore, it should be possible to link the 
biliary excretion fractions to molecular properties of drugs and obtain predictive 
tools using state-of-the-art data mining tools. At the first phase of the project, 
biliary excretion data measured as the percentage of intact compounds excreted 
through bile were collated from the literature. Several statistical analysis methods 
were used to develop and validate QSAR models to rationalize the effect of 
molecular structure of the compounds on the excretion of chemicals through bile. 
This is of a particular value during earlier stages of drug discovery where low-cost 
estimation procedures are required. Validation of each model would allow us to 
identify the most accurate models that could be used for the estimation of biliary 
excretion.  
However, due to complexity of this disposition mechanism, that involves many 
transporter proteins for the active uptake of compounds from the blood into the 
hepatocytes and then active excretion of compounds from hepatocytes into the 
74 
 
canaliculus, previous QSAR models have encountered problems regarding the 
prediction accuracy when applied to new compounds (Gandhi and Morris, 2012). 
As a result, at the second phase of the project the binding of compounds to some of 
the important transporters with high expression levels in hepatocytes were used as 
an input parameter for the estimation of biliary excretion. The transporters that 
were considered at this stage included the efflux transporter P-gp and the uptake 
transporters OATP1B1, OATP1B3, and OATP2B1, which are known to have 
significant roles in biliary excretion of compounds (Pfeifer et al., 2014; Kusuhara 
and Sugiyama, 2002).  
To investigate the effect of binding to the above mentioned transporters on biliary 
excretion of compounds, it was necessary to investigate the structural requirements 
for binding. As a result, the objectives of this phase of the project included: 1. 
development of QSAR models for the binding of compounds to P-gp, OATP1B1, 
OATP1B3 and OATP2B1; 2. using the most accurate QSARs for each transporter 
to predict the binding activity of compounds in the biliary excretion dataset; and 3. 
incorporation of predicted transporter binding values in the QSAR models for the 
prediction of percentage excretion of compounds through bile. This workflow has 
been summarised in Figure 2.1.  
 
 
Figure 2.1. A diagram representing the phase II of this project 
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The application of computational modelling algorithms to obtain insight into 
transporter-substrate interactions has met with increasing success by the availability 
of high-quality datasets and atomic resolution structures of some transporters 
(Giacomini et al., 2010). A further objective of this project was to investigate 
ligand-transporter docking as a prediction tool for the estimation of binding of 
compounds to the transporters. The 3D structure of mouse P-gp was available 
through Protein Data Bank (PDB) website and the substrate binding site has been 
proposed recently by (Aller et al., 2009). The score of docking experiment was 
used as a molecular descriptor for the prediction of compounds binding to P-gp. 
There are a number of linear and non-linear prediction (regression-based) methods 
and classification methods that are available for the statistical model development 
in QSAR studies. Each method may offer a number of advantages and 
disadvantages. In this investigation, the aim was to use a combination of various 
available methods in order to achieve the best predictive models. The methods 
included stepwise regression analysis, Classification and Regression Trees 
(C&RT), Chi-square Automatic Interaction Detector (CHAID), Boosted trees (BT), 
Random Forest (RF) and Multivariate Adaptive Regression Splines (MARS) 
models. 
QSAR models developed in this study for the prediction of biliary excretion can be 
very useful in explanation and understanding of the clearance system as well as 
selecting the candidate drugs in selection processes in drug discovery. Moreover, 
the models resulted in some insight into major factors that can affect biliary 






The major methods employed in this work consisted of various QSAR and 
molecular docking techniques that were used for the estimation of biliary excretion 
and binding of compounds to the transporters, P-gp, OATP1B1, OATP1B3 and 
OATP2B1.  
3.1. Datasets 
The datasets for each investigation have been explained in the relevant chapters 
(Chapters 4-6). Table 3.1 gives a summary of the datasets. 
Table 3.1.  Summary of the datasets used. 
Dataset N Data type 
Biliary Excretion 217 Percentage of intact dose excreted through bile in 
rats (log BE%) 
P-gp binding 219 Inhibition constant (log Ki) measured in vitro 
OATP binding 225 Percentage inhibition measured in vitro 
 
3.2. Calculation of Molecular Descriptors 
3.2.1. ACD Labs/LogD Suite 12.0. 
Simplified Molecular Input Line Entry System (SMILES) notations for all 
compounds were obtained by search in systematic names in ACD/dictionary (ACD 
Labs/LogD suite version 12.0., Advanced Chemistry Development Inc., Ontario, 
Canada). If compounds were not available in the ACD/dictionary, then ChemFinder 
gateway version 3.0 (CambridgeSoft, USA) was utilized to obtain the molecular 
structure. Moreover, SMIELS codes were double-checked in the online database 
ChemSpider (approved by the community of Royal Society of Chemistry - RSC) 
(ChemSpider, 2001). The SMILES notation of each compound was generated either 
by entering the systematic name of the compound in the ACD/Dictionary to acquire 
their molecular structures and SMIELS codes or by drawing the structure in the 
software and then obtaining the SMILES for the drawn structure. 
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Compound names and SMILES codes from Excel were copied into a Notepad file, 
and saved in txt format. Notepad file was imported into ACD history view and 
different physicochemical properties were calculated for all compounds. The 
properties included logarithm of the octanol/water partition coefficient (LogP), 
logarithm of apparent partition coefficient (LogD) at different pH values 2, 5.5, 6.5, 
7.4 and 10, dissociation constant (pKa) for acidic and basic compounds, molar 
volume, index of refraction, polarisability, polar surface area and others.  
Fraction of compounds ionised at pH 7.4 were calculated from dissociation 
constants (pKa). The fractions of compounds that is ionised at pH 7.4 as acid (FiA), 
as base (FiB), or (for zwitterionic compounds) as acid and base (FiAB), and the 
fraction unionised (Fu) were calculated from the lowest acidic and the highest basic 





                   
                                                 (Eq. 3.1) 
FiB 
 
                   
                                                 (Eq. 3.2) 
   
FiAB = FiA x FiB                                                                               (Eq. 3.3) 
    (1-FiA) x (1-FiB)                                                                       (Eq. 3.4) 
  
In Equations 3.1 and 3.2, pKa is the most acidic and the most basic pKa, 
respectively, which were obtained from ACD Labs pKa database and, in case the 
experimental pKa was not available, it was calculated by the software. 
The ACD/LogD calculations were performed for all compounds and the results 
were transferred to Microsoft Excel worksheet. 
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3.2.2. TSAR 3D  
Using TSAR 3D software (Version 3.3., Accelrys Ltd.) additional molecular 
descriptors were calculated. The SD file created by ACD software was imported 
into TSAR 3D. In this software, each row stored information about one compound 
and each column stored a molecular descriptor. Initially, the partial atomic charges 
were calculated for the molecules and COSMIC optimize 3D was applied to 
minimize the molecular potential energies. This was essential since the generation 
of 3D descriptors needs to be based on an accurate 3D molecular structure and 
geometry. However, due to errors in some of the imported structures, COSMIC 
energy minimisation did not automatically work for some of the compounds. Hence 
the 3D structures of these compounds were modified manually by using the 3D 
visualise tab in TSAR 3D to correct the errors and then run the COSMIC 
minimisation. In most cases the structural errors were due to the valence state of 
atoms which varied between ACD generated SD files and those in TSAR 3D. For 
some of the compounds the SD molecular file format could not be used and the 
SMILES codes were imported to TSAR instead. The SMILES codes and the 
compound names were copied and pasted in MS-Word as ‘text’. Using the “Find” 
icon, the document was edited by finding “Tab” and replacing with “space”. The 
edited document was then copied into WordPad and saved as text with .smi file 
extension. The codes were then imported into TSAR 3D and eventually cosmic 
minimisation was successfully executed. In few cases, calculations by TSAR 3D 
were not possible. For example, the presence of heavy metal Platinum (Pt) in the 
structure of a compound would lead to such an error. 
A series of descriptors consisting of electronic, steric and hydrophobic parameters 
as well as topological indexes were calculated using TSAR 3D for each compound. 
The quantum mechanical properties were calculated using VAMP electrostatic 
routine in TSAR 3D. The method used in VAMP was the semi-empirical approach, 
AMI Hamiltonian. The calculated quantum mechanical properties include 
electronic energy, total energy, accessible surface area, mean polarisability, dipole 
moment, energy of the highest occupied molecular orbital (HOMO), and energy of 
the lowest unoccupied molecular orbital (LUMO). VAMP calculations were not 
possible for compounds with more than 50 heavy atoms in their molecular 
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structures. The minimized molecular structures were saved as a SD file and the 
molecular descriptors were exported to Excel. 
 
3.2.3. Molecular Operating Environment (MOE) 
The saved SMILES codes and names from ACD Labs/LogD were imported into 
MOE software (Version 2012.10, Chemical Computing Group Inc. Montreal, 
Canada). Using the wash tab, any unwanted fragments including salts and water 
molecules were removed from the molecular structures. This process also 
neutralized the protonated state of any charged structure. 
Following the wash procedure, energy minimization was carried in order to 
calculate atomic coordinates corresponding to the local minima. Within the energy 
minimization function, the “preserve existing chirality” was also selected. 
Thereafter, self-consistent field (SCF) calculations were performed. The SCF 
energy minimization technique constructs an initial guess density matrix, in terms 
of the atomic orbitals and then iteratively refines them by correcting the kinetic 
energy, nuclear energy and electron – electron repulsion. This allows the density 
matrix to be self-consistent. The parameters calculated by SCF for the minimized 
structures were SCF energy, HOMO-LUMO energy gap, heat of formation and 
dipole moment.  
Finally, after SCF energy minimization, all molecular descriptors were calculated 
for each of the compounds and all data were saved as SD format and exported to 
Excel.   
 
3.2.4. Symyx QSAR version 2.2 
Symyx QSAR software (previously known as MDL-QSAR) was used to obtain 
additional molecular descriptors for the compounds in the datasets. Symyx QSAR 
can calculate many new molecular descriptors such as atom type electrotopological 
indexes. The SD file from MOE was imported and electrotopological state indexes 
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for different atom types along with other topological indexes were calculated. The 
molecular descriptors were then exported into an Excel file.  
 
3.3. Development and Validation of QSAR Models 
In this work, various data analytical techniques were used for the development of 
QSAR models. Datasets of compounds were first divided into training and external 
validation sets. In order for the training and test sets to have a similar range of 
biological activities, compounds in each dataset were ordered according to the 
relevant response variable and, depending on the size of the dataset, from each 
group of five or four compounds one was allocated into the external validation set. 
Models were developed using the training set compounds. These models were used 
for the estimation of the response variable for the external validation set. The 
details of these processes for individual datasets have been explained in the relevant 
chapters.  
Goodness-of-fit in prediction (regression based) models 
Discrepancy between observed and predicted values shows the error, and is used to 
assess the accuracy of QSAR models. The mean absolute error (MAE), root mean 
squared error (RMSE) and mean fold error (MFE) were utilised to assess the 
accuracy of predictions by QSAR models. 
MAE 
∑                         
 
                                                         (Eq. 3.5) 
 
RMSE = √
∑                         
 
 
                                                   (Eq. 3.6) 
 
Mean Fold Error = antilog (
∑                 –             
 




Calculation of error in classification models 
There are extensive numbers of performance measures used to validate the 
predictive power of classification models. The performance of each algorithm was 
measured using three performance measures, sensitivity (SE), specificity (SP) and 
overall accuracy.  
Sensitivity is proportion of compounds correctly predicted to be positive relative to 
all the compounds experimentally determined to be positive:  
Sensitivity = TP/ (TP + FN)                                                (Eq. 3.8) 
Where TP is number of true positives, TN is number of true negatives, FP is 
number of false positives, and FN is number of false negatives. 
Specificity is proportion of compounds correctly predicted to be negative relative to 
all the compounds experimentally determined to be negative: 
Specificity = TN/ (TN + FP)                                                            (Eq. 3.9) 
Overall accuracy in this study is defined as: 
Overall Accuracy = SP × SE                                                            (Eq. 3.10) 
 
3.3.1. Stepwise Regression Analysis 
Minitab Statistical Software Version 16 was used for the development of multiple 
linear regression (MLR) models. In stepwise regression analysis, independent 
variables were normally all the molecular descriptors and the dependent (response) 
variable was the activity under investigation. For example logarithm of the 
percentage dose excreted via bile (log BE%) was the dependent variable in Chapter 
4. In all regression analyses, a P value of less than 0.05 was considered to be 
statistically significant for the variables. Values for “alpha to enter” and “alpha to 




3.3.2. Classification and Regression Trees (C&RT) 
Introduced by Breiman in 1984, C&RT are decision tree algorithms that produce 
classification or regression trees depending on whether the dependent variable is 
categorical or numerical. The analysis uses the Gini coefficient as an identifier of 
suitable splitting criteria (Breiman et al., 1984). Based on recursive partitioning, 
C&RTs are constructed by successively splitting a dataset into increasingly 
homogeneous subsets until it is infeasible to continue, based on a set of stopping 
rules (StatSoft, 2009). The analysis has an embedded feature selection method 
which picks the most significant molecular descriptors for splitting the data into the 
two most homogeneous groups (called branches or nodes).The process works by 
monitoring the error on the test data during growth and choosing the one with 
minimal error (Breiman et al., 1984). This algorithm starts off with the complete 
training set, evaluates all available attributes (e.g. molecular descriptors), choosing 
the one which best separates it. It then recursively proceeds to split the resulting 
subsets until no improvement can be made by continuing to split; this happens 
when the tree reaches a certain complexity based on the pre-set stopping criteria or 
until all the data in the nodes have the same value. 
STATISTICA software has Classification and Regression Trees (C&RT) routine, 
which can develop classification tree (CT) or regression tree (RT) by selecting the 
most significant molecular descriptors out of the descriptor pool at every step of 
partitioning. C&RTs can also be built interactively, using the manually selected 
descriptors.  
Stopping rules are the criteria used to find the right-sized tree. The size of a tree in 
C&RT analysis is an important issue, since an unreasonably big tree can lead to 
overfitting and make the interpretation of results more difficult. Stopping 
parameters could be a combination of the minimum number of cases, the maximum 
number of levels, the maximum number of nodes, and minimum fraction of objects 
for splitting. The parameters have mainly to do with which nodes should be split 
and which should be terminal nodes. STATISTICA offers two choices for stopping 
nodes: 1. Prune variance, and, 2. FACT direct stopping. When using deviance, the 
minimum number of cases and maximum number of nodes are used for stopping. 
For example with minimum number of cases equal 100, a node with less than 100 
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cases will be a terminal node and no further split will be made. The maximum 
number of nodes controls the overall tree complexity. The default stopping 
parameters in STATISTICA software depend on the number of data points (number 
of compounds). For the FACT style stopping method, fraction parameters, rather 
than number of compounds, will determine if a node should be split.  
The advantage of C&RTs is their simplicity at interpretation of results summarized 
in a tree. The final results of using tree methods for classification or regression can 
be summarized in a series of logical if-then conditions (tree nodes). Therefore, there 
is no implicit assumption that the underlying relationships between the predictor 
variables and the dependent variable are linear. 
 
3.3.3. Interactive Tree (I-tree) Using C&RT 
Interactive tree is a C&RT-style tree, which allows for the molecular descriptors to 
be selected manually by the operator. This tool is useful when investigating the 
effect of certain variables/ molecular descriptors on the property under 
investigation. In I-tree, apart from the usual V-fold cross-validation procedure, 
another cross-validation option, “Cross-validate tree sequence” was also applied. 
This validation method is applied to the entire tree sequence, instead of just the 
final tree in V-fold cross-validation (Hill and Lewicki, 2006).  
 
3.3.4. Chi-square Automatic Interaction Detector (CHAID) 
The Chi-square Automatic Interaction Detector (CHAID) is one of the oldest 
decision tree methods initially suggested by Kass in 1980 (Kass, 1980). This tool 
performs multi-level splits where C&RT uses binary splits. CHAID is well suited 
for large datasets. Cross validation either V-fold or train and test samples can be 
used to safeguard against overfitting the CHAID tree. The Stopping criteria 
includes minimum number of cases for splitting, maximum number of nodes, 
probability for splitting and probability for merging. To test the statistical 
significance of splits, CHAID computes a Bonferroni adjusted P-value for the 
84 
 
respective descriptor (Hill and Lewicki, 2006). Bonferroni adjustment is an option 
in CHAID, used to control the type one error rate (familywise error rate) when 
testing multiple hypotheses. It usually is accomplished by dividing the alpha level 
by the number of tests being performed (usually 0.05 / n). In this work, we 
employed Bonferroni adjustment as our preliminary results showed lower cross 
validation error when this adjustment was used. 
 
3.3.5. Boosted Trees (BT) 
Boosted trees analysis generates a series of very simple boosting regression trees 
(BT) where each successive tree is built for the prediction of residuals of the 
preceding tree. Each of these trees has a weak predictive accuracy, but using the 
weak predictors together can create a strong predictor (Lewicki and Hill, 2006). 
The user defined parameters in this analysis includes the learning rate, the number 
of additive terms (number of trees), random test data proportion (fraction of data 
points in testing pool) and subsample proportion The seed for random number 
generation that controls which cases are selected in sampling was set to one. The 
maximum number of nodes was set to three, which means that each tree will have 
just one binary split. 
 
3.3.6. Random Forest Trees Model (RF) 
A random forest (RF) model is an ensemble of tree predictors such that each tree 
depends on the values of a random vector (a random selection of molecular 
descriptors and training set compounds) sampled independently. The method builds 
a series of simple trees where the predictions are taken to be the average of the 
predictions of all the trees (Breiman, 2001). The analysis removes a user defined 
portion of the data and keeps it as the internal test data. The remaining training set 
data is sampled consecutively and models are developed for each subsample. 
Various subsample proportions along with different numbers of trees may be 
selected.  The number of predictors (to be randomly considered at each node) was 
set to nine throughout the thesis. The default settings were used for stopping 
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conditions including minimum number of cases, maximum number of levels, 
minimum number in child node and the maximum number of nodes which is 
different depending on the size of the dataset. The best model was selected based 
on the estimation error for the internal test data. 
 
3.3.7. Multivariate Adaptive Regression Splines (MARS) Model 
MARS is a non-parametric regression procedure that constructs a relation between 
the dependent and independent variables from a set of coefficients and basic 
functions that are entirely driven from the regression data (Friedman, 1991). It is a 
very flexible technique that automatically models non-linearities and interactions 
between variables. The non-linearities (knots) are represented by the so called 
‘hinge functions’ which are expressions of the type ‘max (a, b)’ where the value of 
this expression will be a if a>b, or else b. Interactions between each variable pairs 
can also be expressed in the formula. MARS model is developed by stepwise 
addition of basis function in pairs (forward pass) to reduce the sum-of-squares 
residual error, and then step-by-step removal of the least significant terms to 
achieve better generalisation (backward pass). The model created by this tool is 
easy to understand, compared to some other data mining models such as boosted 
trees. This tool sometimes is used as a method for finding the important predictor 
variables as important information for another analysis. The MAR Splines 
algorithm picks up only those basis functions (and those predictor variables) that 
makes a "sizeable" contribution to the prediction. Basis functions use a non-
parameter (break point) to find non-linear relationships. Increasing the maximum 
number of basis functions gives the potential for more complex model. Using the 
degree of interaction we can specify no interaction up to a very high order 
interaction term. Model subsets are compared using the GCV criterion (Generalized 
Cross-Validation). GCV is the adjusted form of residual sum-of-squares that 
penalises the addition of knots in order to limit the model flexibility and overfitting.  
In this investigation, in addition to using all the molecular descriptors in MARS 
analysis and allowing MARS to select the significant descriptors, we performed a 
pre-processing feature selection to select a limited number of molecular descriptors 
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for use in MARS analysis. The feature selection methods were different for 





4. QSAR Models for Biliary Excretion  
 
4.1. Introduction 
Biliary excretion is an important route for the elimination of some drugs and their 
metabolites (Rosenbaum, 2011). Although the liver is generally identified with its 
role in metabolism, one of the most important functions of the liver is formation of 
bile which is then stored in the gallbladder and discharged into the duodenum upon 
ingestion of food, with bile carrying also cholephilic xenobiotics. Bile which is a 
composition of bile acids and other components such as phospholipids, bilirubin 
and cholesterol is formed in the hepatocytes and is actively discharged across the 
canalicular membrane into canaliculus (Rollins and Klaassen, 1979). Once bile is 
released into the intestine, some metabolites and unchanged drugs continue their 
way of elimination through the faeces. Others, for example lipid-soluble drugs, are 
reabsorbed from the intestine and move to the systemic circulation (Rollins and 
Klaassen, 1979). This enterohepatic circulation affects pharmacokinetics by 
keeping the plasma concentration of drugs high (Rosenbaum, 2011). Enterohepatic 
cycling and biliary elimination can continue until the compound is ultimately 
eliminated from the body by faecal or renal excretion or metabolism. Uptake from 
sinusoidal blood and then secretion of bile salts across the canalicular hepatocyte 
membrane are the major factors controlling the rate of bile secretion.  





independent uptake systems (Kullak-Ublick et al., 2000). The main sodium-
dependent bile salt transporters are Na
+
-taurocholate co-transporting polypeptides 
(human and rat). On the other hand, the Na
+
-independent uptake of bile salts cannot 
be attributed to the function of a single transport system and several carrier systems 
have been implicated including sulphate/anion exchanger, dicarboxylate/anion 
exchanger and OH
−
/cholate exchanger. In rats, the organic anion transporting 
polypeptides (Oatp1, Oatp2 and Oatp4) have been indicated as the main sodium-
independent uptake proteins (Kullak-Ublick et al., 2000). The organic cation and 
organic anion transporters (OCT and OAT, respectively) also play important roles 
in the initial sinusoidal influx of drugs into hepatocytes (van Montfroot et al., 
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2003). These transporters have wide substrate specificities for a range of exogenous 
and endogenous substrates (Leabman et al., 2003). OCT1 can be found abundantly 
in hepatocytes and may be seen as the most important transporter for distribution of 
cationic compounds into the liver from sinusoidal membrane (Nies et al., 2009).   
Canalicular bile secretion is an osmotic process in which active excretion of organic 
solutes into the bile canaliculus is the main driving force for the passive inflow of 
water, electrolytes and nonelectrolytes from hepatocytes (Trauner and Boyer, 
2003). While products of the multidrug resistance gene family (Mdr), namely bile 
salt export pumps, Bsep (rat) and BSEP (human), transport monovalent bile salts 
(Rollins and Klaassen, 1979), excretion of non-bile salt organic anions and divalent 
sulphate or glucuronide bile salts is carried mainly by the multidrug resistance 
protein 2 (MRP2). Bile salt export pump has a limited role in drug excretion. 
However, drug inhibition of this pump can lead to hepatotoxicity (Morgan et al., 
2010). Another member of this family, P-glycoprotein, also has known as multidrug 
resistance protein 1, actively effluxes xenobiotics into the bile (Schinkek et al., 
1997). Breast cancer resistance protein (BCRP/ABCG2) is also involved in the 
transport of a range of drugs. For example, nitrofurantoin has a very high biliary 
excretion predominantly mediated by BCRP (Merino et al., 2005b). Other 
basolateral isoforms of the multidrug resistance-associated protein, MRP4 and 
MRP3, provide alternative routes for the elimination of organic anions from 
hepatocytes into the systemic circulation (Kullak-Ublick et al., 2000). Properties of 
the chemical structure as well as the characteristics of the liver such as specific 
active transport sites within the liver cell membranes are the main factors which 
determine the elimination of xenobiotics via the biliary tract (Rollins and Klaassen, 
1979). Despite the various transport systems involved in the biliary elimination of 
xenobiotics, there has been a number of attempts to identify common molecular 
features of highly excreted compounds. Molecular weight (MW) has been 
suggested as an important factor in biliary excretion levels of compounds. Anionic 
compounds with the MW higher than 325±50 kDa in rats, 400±50 kDa in guinea 
pigs, 475±50 kDa in rabbits and 500±50 kDa in human have been suggested as 
good candidates for biliary excretion (Hirom et al., 1972). Most compounds with 
lower molecular weights are quickly cleared through the kidneys and are not 
excreted in the bile (Abou-El-Makarem et al., 1967). Bile is rich in endogenous 
89 
 
organic anionic substrates (e.g., steroid hormones), organic cations (such as 
quaternary ammonium), bilirubin and bile acids (Rollins and Klaassen, 1979). 
Moreover, excretion route of anionic xenobiotics and some antibacterials is through 
the bile (Crosignani, 1996). Principally, for organic cationic compounds, biliary 
elimination depends on the molecular volume (Neef et al., 1984), lipophilicity of 
the compound and the number of cationic groups (Feitsma, 1989). 
Biliary excretion has major significance in determining the pharmacokinetic 
profiles of drugs. In several disease states, the excretion of drugs through bile is 
affected and toxicities may arise (Rosenbaum, 2011; Rollins and Klaassen, 1979). 
Knowledge of biliary excretion levels of compounds can help in identifying any 
possible mechanisms of hepatobiliary toxicity and potential drug-drug interactions. 
Therefore, an insight into the structural profile of cholephilic compounds through 
accurate modelling of the biliary excretion is important for predicting clinical 
pharmacokinetics. This is of a particular value during earlier stages of drug 
discovery where low-cost estimation procedures are required. Quantitative 
structure-activity relationships (QSARs) employ data mining techniques to explore 
the relationships between biological properties of interest, e.g. pharmacokinetic 
parameters of drugs, and the properties of the molecular structures (Ghafourian et 
al., 2006). Recently, a QSAR model developed using 2D molecular descriptors 
showed good prediction ability for a set of literature biliary excretion data measured 
under the same experimental model (Luo et al., 2010). However, re-evaluation of 
this simple model showed that the statistical significance of the model is lost when 
it is used for the prediction of a wide set of external compounds (Gandhi and 
Morris, 2012), suggesting that hepatobiliary excretion cannot be captured by simple 
physicochemical descriptors when examining chemically dissimilar compounds. 
Unfortunately, availability of in vivo biliary excretion data which is necessary for 
modelling is very limited. Yang et al. (Yang et al., 2009) have recently compiled a 
big dataset of percentage of dose eliminated in the bile in rats and humans. This 
offers an excellent resource for a detailed study on the structural determinants for 
high biliary excretion. Using this dataset, Yang and co-workers suggested a MW 
threshold of 400 Da for anions in rats and 475 Da for anions in humans. They also 
developed linear regression models for human and rat. The aim of this study was to 
use an expanded dataset and incorporate non-linear methods to develop statistically 
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valid QSAR models. Specifically, classification and regression tree (C&RT) is a 
flexible and yet simple and interpretable technique with embedded feature selection 
that selects the most significant molecular descriptor for partitioning the data into 
smaller subsets of similar observations (Breiman et al., 1984). This rule-based 
technique is a decision tree that splits the data in a recursive manner until the subset 
has all the same value of the target (dependent) variable, or when no gain in the 
prediction accuracy is achievable by further splitting. In this study, we aimed at 
using regression trees and two ensemble methods that construct many such decision 
trees and return the consensus prediction by the trees, namely random forest and 
boosted trees. The prediction accuracy of the models and the molecular descriptors 
selected by these methods were compared in order to clarify the structural elements 
controlling the biliary excretion. Moreover, regression trees were used to examine 
the significance of molecular weight and presence of carboxylic acid groups and to 
find the statistically significant threshold values. In this case, regression trees are 
useful since they can be used interactively so that a molecular descriptor of choice 
can be incorporated at any split level and the analysis may determine the 
statistically significant threshold value of the descriptor for splitting the data. 
 
4.2. Methods 
In this investigation RT models were made with log BE% as the dependent variable 
and predictors were selected by this statistical analysis from all the molecular 
descriptors used in the analysis. “observed” refers to the log percentage of intact 
dose excreted into the bile from in vivo studies. In all statistical analyses, logarithm 
of percentage dose excreted (log BE%) was used in the analysis instead of 
percentage of dose excretion. This was due to the normal distribution of log BE% 
as indicated by the skewness comparison with BE.  
 
4.2.1. The Dataset 
The biliary excretion dataset was that collated by Yang et al (2010) available at 
http://www.buffalo.edu/~memorris, with the addition of some new data from 
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literature (Hirom et al., 1972., Abou-el-makarem et al., 1967., Hughes et al., 1973., 
Fahrig et al., 1989., Funakoshi et al., 2005., Luo et al., 2010., Scott et al., 1994., 
Matsushita et al., 1992., Prueksaritanont et al., 2003., Niinuma et al., 1999., 
Vaidyanathan and Boroujerdi, 2000., Fukuda et al., 2008., Chu et al., 1997., Wu et 
al., 2008., Wright and Line, 1980., Chan et al., 2002., O’Reilly et al., 1971., 
Watkins Dykstra, 1987., Sasabe et al., 1999., Weinz et al., 2009., Mohri et al., 
2005., Kemmerer et al., 1979., Itagaki et al., 2003., Evanchik et al., 2009., Krishna 
et al., 1999., Broggini et al., 1980., Israel et al., 1978., Arimori et al., 2003., Itoh et 
al., 2004). It consists of in vivo biliary excretion expressed as percentage of dose 
excreted as the parent compound intact through the bile (BE%) for 217 compounds 
in rat after iv or intraperitoneal administration of the compound. The compounds 
are from different chemical classes such as bile acids, statins, dyes, penicillins and 
cephalosporines, macrolide antibiotics, quinolone antibiotics, NSAIDs, thrombin 
inhibitors, analgesics, anti-cancer drugs such as doxorubicin, folate, peptides, anti-
HIV agents, quaternary ammoniums, sulphanilamide and arylaminosulphonic acids. 
Biliary excretion in the database is presented by percentage of drugs excreted 
through bile, or bile clearance.  
Where several values were available for the same compound the mean values were 
used. Table 4.1 shows an example of this. 
Table 4.1. Example of different values for the same compound. 
Compound % Dose excreted in bile 
as parent compound 
Collection period 
Methotrexate 72 480 min (8 hr) 
Methotrexate 84.3 600 min (10 hr) 
Methotrexate 58.9 720 min (12 hr) 
Methotrexate 64 1440 min (24 hr) 
Average               69.8 
 




4.2.2. Model Development and Validation 
In this study, QSARs were established to relate the biliary excretion of compounds 
(log BE%) to the molecular descriptors. Molecular descriptors were calculated 
according to the procedures explained in section 3.1. Before building the models, 
the molecular descriptors were checked to find and discard those columns 
containing more than 98% constant values or more than 28 (out of 217) missing 
values. The total number of molecular descriptors used in all statistical analyses 
was 387.  
The compounds were divided into an external validation set and a training data. To 
divide the compounds, they were ordered according to BE%, and from every set of 
five compounds, four were allocated into the training and one into the external 
validation set randomly. In this way, training data consisted of 168 compounds and 
the external validation set consisted of 40 compounds. For the analytical methods 
that required parameter optimization, a fraction of training set compounds were 
randomly assigned into internal validation set, or alternatively, cross validation was 
used if the option was available in the statistical software. STATISTICA Data 
Miner was the software used for statistical analysis. The general idea of V-fold 
cross-validation is to divide the overall sample into a number of V-folds. The V-
fold cross-validation technique is used in various analytical procedures to avoid 
overfitting of the data (Burden, 1989). For the internal validation set, where 
applicable, the risk estimate and standard error were calculated in STATISTICA 
software and used as the performance indicators. Risk estimate is calculated as the 
proportion of residual variance incorrectly estimated by the model. Standard error 
measures the error of the prediction. 
Several linear and non-linear methods were used for the QSAR model 
development. These included stepwise regression analysis, stepwise regression 
analysis, Classification and Regression Trees (C&RT), Boosted trees (BT) and 
Random Forest (RF).  
The methods have been explained in section 3.2. In C&RT analysis, several 
stopping criteria were examined, including the default settings in STATISTICA. 
The default stopping criteria were minimum number of cases of 21 and the 
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maximum number of nodes set to 100. The default V-value of 10 was used in the 
V-fold cross-validation and the risk-estimate was used to check the reliability of the 
resulting RTs. In BT analysis, the default values for learning rate, the number of 
additive terms, random test data proportion and subsample proportion were 0.1, 
200, 0.2 and 0.5 respectively. Various subsample proportions of 0.4, 0.45, 0.50, 
0.55 and 0.60 were examined in combination with the learning rates of 0.1 and 
0.05. The best two models were selected based on the performance indicators for 
the internal validation set. In RF analysis, various subsample proportions of 0.40, 
0.45, 0.50, 0.55 and 0.60 were examined.  Different numbers of trees were tested at 
20, 50, 80, 100 and 200. The random test data proportion was 0.2 for the internal 
validation. The default settings were used for stopping conditions including 
minimum number of cases, maximum number of levels, minimum number in child 
node and the maximum number of nodes of 6, 10, 5 and 100, respectively. The best 
model was selected based on the estimation error for the internal test data. 
  
4.3. Results of QSAR Models for Biliary Excretion 
A total of 387 2D (e.g. kappa shape indexes, molecular connectivity indexes and 
electrotopological state indexes) and 3D molecular descriptors were used for the 
QSAR model development. Out of 217 compounds in the rat biliary excretion 
dataset, 9 compounds had excretion rate of 0%, and hence log BE% could not be 
calculated for them. The method of data allocation into training and test sets 
outlined above ensured that a similar biliary excretion and molecular property 
spaces were covered by both the training and the validation sets. BE% values 
ranged between 0.048 and 100 with mean log BE% values for the training and 
validation sets at 1.04 and 1.01, respectively. LogP was between -3.44 and 18.8 for 
the training set, and -3.17 and 7.83 for the validation set with similar mean values 
of 1.81 and 1.83, respectively. Molecular weights of the compounds were between 
122 and 1215 Da for the training set and 94 and 1255 Da for the validation set, with 
mean values of 457 and 390, respectively. Scores plot from principle component 
analysis using all the molecular descriptors also indicates similar chemistry space 
for the two sets (Figure 4.1). 
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Figure 4.1. Scores plot of PCA using all 387 molecular descriptors 
 
4.3.1. Regression Models 
Linear regression equations are the simplest and most straightforward QSAR 
techniques. This has the benefit of easy interpretation which can provide some 
mechanistic insight into the process under investigation (Patel et al., 2002). 
Stepwise regression analysis using in vivo rat biliary excretion data as the 
dependant variable resulted in the MLR (1) model below in which the number of 
molecular descriptors is limited to eight. The statistical terms of the equation are N 
the number of compounds, R-Sq the correlation coefficient, S the standard 
deviation and F Fisher’s statistics and the P value. Observed versus calculated log 
BE% by this equation has been plotted (Figure 4.2.), with training and validation 




















Scores plot of PCA using all molecular descriptors
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MLR (1) model 
Log BE% = 2.09 + 0.00129 Vsurf_HB4 - 9.33 PEOE_RPC+ - 0.0574 SsCH3 - 
0.377 fU - 0.00503 SlogP_VSA0 - 0.0573 SsssCH + 0.0403 AM1_dipole  + 0.378 
SddssS_acnt       
N = 168      S = 0.489       R-Sq = 0.608        F = 30.9        P = 0.000 
Molecular descriptors of this equation are not intercorrelated (R 
2
 < 0.4). 
Table 4.2 gives a brief description of molecular descriptors used in this model. 
Vsurf_HB4 is the first molecular descriptor selected by the analysis and it indicates 
that compounds with high H-bond donor capacity have higher biliary excretion 
level. AM1_dipole (dipole moment) is the other polarity descriptor which has a 
positive effect. On the other hand, the equation shows that drugs with greater 
relative positive partial charge (PEOE_RPC+) have lower biliary excretion. The 
value of this descriptor is large for small acidic molecules such as benzoic acid and 
salicylic acid, and therefore the small size of such compounds may be the reason 
for the reduced biliary excretion. In this equation, fU with a negative coefficient 
indicates that compounds with higher unionised fraction at pH 7.4 have lower 
biliary excretion. In other words, although according to fU, acidity and basicity 
(dissociation in general) increase the biliary excretion of compounds, this is true 
only for large dissociated molecules. The positive effect of polarity and dissociation 
on biliary excretion is in agreement with the literature, where for example polar 
surface area (Gandhi and Morris, 2012) and an acidity indicator (Luo et al., 2010; 




Figure 4.2. Observed vs predicted log BE% using MLR (1) 
 
Also according to this equation, compounds containing many methyl groups 
(SsCH3) and those that are highly branched containing >CH− groups (SsssCH) 
have lower biliary excretion. Examples are macrolid antibiotics (i.e. telithromycin, 
azithromycin, erythromycin, actinomycin) muscle relaxant pipecuronium and the 
chemosensitizer PSC 833. The predominant excretion routes in these compounds 
are metabolism (Lee and Lee, 2007; Amacher et al., 1991; Lam et al., 2006; Lahiri 
et al., 1970; Vereczkey and Szporny, 1980; Song et al., 1998) except for 
pipecuronium and azithromycin for which the main excretion route is renal and 
biliary excretion respectively. 
 In this equation, SlogP_VSA0 shows the negative impact of the presence of atoms 
with LogP(o/w) contribution of less than or equal to -0.4. SddssS_acnt indicates the 
direct effect of sulphate or sulphonamide groups. Sulphate and sulphonamide 
groups are found in sulphonamide drugs such as succinylsulphathiazole, dyes such 
as methyl orange and sulphate conjugates such as estrone 3-sulphate which may be 


















Scatterplot of Observed vs Predicted LogBE%
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Table 4.2. A brief description of the most important molecular descriptors selected 
and used by the models.  
Descriptor Model Description 
a_acc RF (1) Number of H-bond acceptor atoms. 
a_hyd BT (1) Number of hydrophobic atoms. 
AM1_dipole MLR (1),  
RT (1) 
Dipole moment calculated using AM1 
Hamiltonian. 
BCUT_PEOE_0 RF (1) The BCUT descriptor calculated from the 
eigenvalues of a modified adjacency matrix. The 
resulting eigenvalues are sorted and the smallest, 
1/3-ile, 2/3-ile and largest eigenvalues are 
reported, in this case the 2/3-ile. The diagonal 
takes the value of the PEOE partial charges. 
CASA- I-tree (2) Negative charge weighted surface area, ASA- 
times max {qi < 0}. 
chi1 RF (1) First order molecular connectivity index (Hall et 
al., 2007).  
COOH I-tree (2) Indicator variable for the presence of carboxylic 
acid group in the molecular structure. 
Docking energy 
(MOE) 
RF (1) Docking score (kcal/mol)for enzyme-ligand 
docking of the compounds into the active site of 
P-glycoprotein (Aller et al., 2009) calculated 
using MOE software 
FASA_H RT (1) Fractional ASA_H calculated (water accessible 
surface area of all hydrophobic atoms) as ASA_H 
/ ASA. 
FCASA- I-tree (1) Fractional CASA- calculated as CASA- / ASA. 
fU MLR (1),  
RT (1) 
Fractions of compounds unionised. 
GCUT_SLOGP_1 RT (1) The GCUT descriptors are calculated from the 
eigenvalues of a modified graph distance 
adjacency matrix. Each ij entry of the adjacency 
matrix takes the value 1/sqr(dij) where dij is the 
(modified) graph distance between atoms i and j. 
The resulting eigenvalues are sorted and the 
smallest, 1/3-ile, 2/3-ile and largest eigenvalues 
are reported. The diagonal takes the value of the 
atomic contribution to logP. 
Kier2 BT (1), BT 
(2) 





et al., 2007) 
Kier3 BT (1), BT 
(2) 





et al., 2007) 





 where s = n + a (Hall et al., 2007) 
KierA3 
BT (1), BT 
(2) 









 for even 
n where s = n + a (Hall et al., 2007).  
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Descriptor Model Description 
LogD (5.5) BT (2) Logarithm of distribution coefficient D of a 
compound between octanol and buffer layers at 
pH value 5.5. 
LogD (6.5) RT (1), I-
tree (1), 
BT (1), BT 
(2) 
Logarithm of distribution coefficient D of a 
compound between octanol and buffer layers at 
pH value 6.5. 
LogD (7.4) 
BT (1), BT 
(2) 
Logarithm of distribution coefficient D of a 
compound between octanol and buffer layers at 




Logarithm of distribution coefficient D of a 
compound between octanol and buffer layers at 
pH value 10. 
MW I-tree (1) 
RF (1) 
The molecular weight. 
N ratio RT (1) The weight ratio of nitrogen atoms in the 
molecule. 
PEOE_PC- I-tree (2) Total negative partial charge. 
PEOE_RPC+ MLR(1),  
BT (2) 
Relative positive partial charge: the largest 
positive atomic charge divided by the sum of the 
positive partial charges.  
PEOE_VSA_NEG I-tree (1) Total negative van der Waals surface area. 
PEOE_VSA-0 RT (1) Van der Waals surface area of atoms with atomic 
charge in the range [-0.05, 0.00). 
PEOE_VSA_FPPOS RF (1) Fractional positive polar van der Waals surface 
area. This is the sum of the VDW surface area 
such that partial charge of atom is greater than 
0.2. 
PEOE_VSA_HYD BT (1), BT 
(2) 
Total hydrophobic van der Waals surface area. 
This is the sum of the van der Waals surface area 
such that absolute value of atomic charge is less 
than or equal to 0.2. 
Q_PC+ RF (1) Total positive partial charge: the sum of the 
positive partial charge of atoms in the molecule.  
SddssS_acnt MLR (1) Count of all sulphur atoms (ddssS) E-state values 
in molecule.  
SlogP_VSA0 MLR (1) Sum of approximate accessible van der Waals 
surface area for atoms with atomic contribution to 
logP(o/w) of equal or less than -0.4. 
SMR_VSA7 I-tree (1) Sum of approximate accessible van der Waals 
surface area for atoms with atomic contribution to 
molar refractivity of Ri > 0.56. 
SsCH3 MLR (1) Atom type electrotopological state index (sum of 
the E-states) for (-CH3) groups. 
SsssCH MLR (1) Sum of E-State for all (>CH- ) groups in 
molecule. 
SssssC I-tree (1) Sum of all (> C <) E-State value in molecule. 





Descriptor Model Description 
VAdjEq RF (1) Vertex adjacency information (equality): This is 
an atom count /bond count descriptor calculated 
as:  
 -(1-f)log2(1-f) - f log2 f where f = (n
2
 - m) / n
2
, n 
is the number of heavy atoms and m is the 
number of heavy-heavy bonds. If f is not in the 
open interval (0,1), then 0 is returned. 
vsa_hyd BT (1) Approximation to the sum of VDW surface areas 
of hydrophobic atoms (Å
2
). 
vsurf_CW4 I-tree (1) Capacity factor is the ratio of the hydrophilic 
surface over the total molecular surface, 
calculated at eight different energy levels (from -
0.2 to -6.0 kcal/mol). 







H-bond donor capacity at -2.0 Kcal/mol with 
carbonyl oxygen probe. 
vsurf_ID7 RT (1) Hydrophobic integy moment (The "integy 
moment" is defined in analogy to the dipole 
moment and describes the distance of the centre 
of mass to the barycenter of hydrophobic 
regions). Small integy moment indicates that the 
hydrophobic moieties are either close to the 
centre of mass or they balance at opposite ends of 
the molecule, so that their resulting barycentre is 
close to the centre of the molecule. VolSurf 
computes ID at eight different energy levels 
(from -0.2 to 1.6 Kcal/mol). 
vsurf_IW2 I-tree (1), 
BT (2) 








4.3.2. Regression Tree Models Using C&RT 
Several RTs were generated using a combination of molecular descriptors while 
cross-validation was applied. The best RTs were selected based on the standard 
error for the internal test set. As seen in Table 4.3, in RT (1), molecular descriptors 
were selected by C&RT analysis, while in I-tree (1), the molecular weight and in I-
tree (2), the number of carboxylic acid groups were manually imposed as the first 
split descriptor using interactive C&RT routine in STATISTICA. These models 
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were developed using the training set while the validation set remained external. 
The RTs resulting from these trials have been presented in Figs. 4.3, 4.4 and 4.5. In 
the regression trees, N is the number of compounds, Mu is the average and Var is 
the variance of log BE% in each node. The molecular descriptors employed in the 
trees have been explained in Table 4.2.  
 
Figure 4.3. RT (1) developed using the training set with the descriptors selected by 
C&RT 
 
Table 4.3 provides the statistical parameters of the regression trees.  
Table 4.3. Description of the Regression Trees 
Model No Manually incorporated variables 
RT (1) None 
I-tree (1) Molecular weight 
I-tree (2) Carboxylic acid group 
 
Tree graph for log BE% 























ID=3  N=103 
Mu=1.397 
Var: 0.266 














































<= 417.56 > 417.56 
AM1_dipole 
<= 4.340 > 4.340 
LogD(6.5) 
<= 2.510 > 2.510 
N ratio 
<= 0.090 > 0.090 
PEOE_VSA-0 
<= 94.240 > 94.240 
FASA_H 
<= 0.500 > 0.500 
fU 
<= 0.052 > 0.052 
fU 
<= 0.001 > 0.001 
vsurf_ID7 
<= 0.760 > 0.760 
GCUT_SLOGP_1 
<= -0.350 > -0.350 
vsurf_EDmin3 
<= -2.600 > -2.600 
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According to RT (1), biliary secretion is much higher for compounds with large 
hydrophilic volume (vsurf_W3), especially if they are ionised with fU ≤ 0.001 
(negligible unionised fractions at pH 7.4). Within the hydrophilic drugs of higher 
fU values (node 7), those with higher separation of lipophilic interaction sites from 
the centre of mass (vsurf_ID7 > 0.760) have higher biliary excretion. Surfactant 
molecules and glucuronide conjugates are examples of such molecules with high 
VolSurf integy moment (vsurf_ID7) and high biliary excretion. This branch follows 
to partition the molecules further according to GCUT_SLOGP_1 with compounds 
of lower hydrophobicity (node 18), and large hydrophobic interaction energy 
minima (vsurf_EDmin3 > -2.60) showing high biliary excretion (node 23). 
According to RT (1), the less hydrophilic drugs with vsurf_W3 values below 
417.56 can be excreted heavily through the bile if they are highly dipolar (AM1-
dipole > 4.336) with high ratio of lipophilic to total surface area (FASA_H > 0.50), 
especially if they are predominantly in the ionised form at pH 7.4 (fU ≤ 0.052). On 
the other hand, compounds with low dipole moment have low biliary excretion 
specially if they are lipophilic with LogD(6.5) > 2.51 (node 9) or otherwise if they 
contain a high ratio of nitrogen atoms in the molecular structure (node 15). N ratio 
is low for larger alkaloids such as morphine or non-basic compounds, such as 
estrone 3-sulphate, which will have moderate biliary excretion especially if they are 
hydrophilic (PEOE_VSA-0 ≤ 94.24). 
I-tree (1) was a result of molecular weight being employed in the first split using 
the interactive C&RT analysis in STATISTICA (Figure 4.4). The statistically 
selected molecular weight threshold was 347.9 Da, with the compounds below this 
weight showing lower log BE% values than the larger compounds. The tree shows 
that large (MW > 347.9) hydrophilic compounds (vsurf_CW4 > 0.540) have higher 
biliary excretion, particularly those with large total negative van der Waals surface 
area (PEOE_VSA_NEG) and low surface area corresponding to highly polarisable 
groups (SMR_VSA7), especially if they are highly branched (SssssC > -1.812). 
Within this group of compounds, larger molecules with KierA1 > 21.135 will have 
even higher biliary excretion. Other parameters of I-tree (1) indicate that high 
hydrophilic integy moment (vsurf_IW2) (node 13) and fractional negative charge 
weighted surface area (FCASA-) (node 11) would result in high log BE% value. 
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Figure 4.4. I-tree (1) developed using interactive C&RT analysis using molecular 
weight as the first descriptor. 
 
Recent studies by Yang and co-workers show that presence of carboxylic acid 
group(s) may indicate a trend towards increased biliary excretion (Yang et al., 
2009). Therefore, the impact of presence of carboxylic acid group was examined 
using the interactive C&RT analysis with COOH used as the first partitioning 
molecular descriptor (Figure 4.5). According to I-tree (2), compounds containing at 
least one carboxylic acid group have higher biliary excretion levels. Furthermore, I-
tree (2) indicated that compounds with lower total negative partial charge 
(PEOE_PC-) have much higher biliary excretion (node 6). These are large 
hydrophilic compounds with many negatively charged atoms. Non-acidic 
compounds in node 2 will have high biliary excretion if the negative-charge 
weighted surface area for these molecules is high (node 5). CASA− has an element 
of size as well as indicating the presence of negatively charged groups such as 
sulphates. 
Tree graph for log BE% 




























































<= 347.870 > 347.870 
vsurf_CW4 
<= 0.540 > 0.540 
LogD(6.5) 
<= 2.630 > 2.630 
FCASA- 
<= 1.500 > 1.500 
PEOE_VSA_NEG 
<= 157.040 > 157.040 
vsurf_IW2 
<= 0.902 > 0.902 
SMR_VSA7 
<= 214.570 > 214.570 
SssssC 
<= -1.810 > -1.810 
KierA1 
<= 21.135 > 21.135 
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Figure 4.5. I-tree (2) using the number of carboxyl groups (COOH) as the first 
descriptor 
 
Table 4.4. Statistical parameters of the models for training and test sets; RT is 
regression tree; BT is boosted trees and RF is random forest model 
Model Group Risk Estimate Standard Error 
RT (1) Train 0.112 0.040 
Validation 0.583 0.116 
I-tree (1) Train 0.229 0.034 
Validation 0.348 0.081 
I-tree (2) Train 0.323 0.050 
Validation 0.349 0.075 
BT (1) Train 0.079 0.007 
Validation 0.328 0.103 
BT (2) Train 0.078 0.007 
Validation 0.329 0.107 
RF (1) Train 0.262 0.047 
Validation 0.311 0.076 
 
Tree graph for log BE% 






























      No   Yes 
CASA- 
<= 953.790 > 953.790 
LogD(10) 
<= -2.450 > -2.450 
PEOE_PC- 




4.3.3. Boosted Trees 
Boosted tree module computes a sequence of simple trees, where each successive 
tree is built for the prediction of the residuals of the preceding trees. The analysis 
using various combination of model parameters resulted in two best models 
selected based on the error level for the internal test set (Table 4.3). In models BT 
(1) and BT (2), the optimal numbers of trees were 145 and 147, with the learning 
rate of 0.10 and subsample proportions of 0.55 and 0.60, respectively.  
It is possible to elucidate the influential descriptors in boosted trees analysis using 
variable importance calculation. Variable importance in STATISTICA is calculated 
as the relative (scaled) average value of the predictor statistic over all trees and 
nodes; hence these values reflect on the strength of the relationship between the 
predictors and the dependent variable of interest, over the successive boosting steps 
(STATISTICA help file, 2009). Included in Table 4.2 are the top ten most 
important molecular descriptors of BT (1) and BT (2) models. Some of the 
descriptors used by BT models are those already observed in RT and MLR models. 
For example, LogD (6.5) is present in two RT models and it is amongst the top ten 
most significant descriptors of both BT models. Other descriptors selected by these 
models are topological/size descriptors (KierA3, Kier2 and Kier3) and other 
lipophilicity descriptors such as LogD at different pH values and vsurf descriptors. 
Table 4.4 shows the statistical significance of these models. Graphs of average 
squared error against number of trees for training and cross-validated test sets can 





Figure 4.6. Average squared error of log BE% against the number of trees in the 
boosted trees model BT (1) for the training and internal test set  
 
Figure 4.7. Average squared error of log BE% against the number of trees in the 
boosted trees model BT (2) for the training and internal test set  
Summary of Boosted Trees
Response: LogBE%
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4.3.4. Random Forest 
In RF, the number of trees specifies the number of simple regression trees to be 
computed in successive forest building steps. The model development used the 
default values of the software with the number of trees set at 100. The graph of 
average squared error against number of trees for training and cross-validated test 
sets indicates that the test and training set errors reach a plateau at around 10–15 
trees (see Figure 4.8). The best model was achieved with a subsample proportion of 
0.60, random test data proportion of 0.2 and number of trees of 100.  
 
Figure 4.8. Average squared error of log BE% against the number of trees in the 
random forest model (RF) for the training and internal test set  
Table 4.2 includes a description of the ten most significant descriptors employed in 
this model. Table 4.4 gives a summary of the statistical parameters of the RF 
model.  
 
Summary of Random Forest
Response: NewVar
Number of trees: 100; Maximum tree size: 100
 Train data
 Test data




























4.3.5. Validation of the Models 
All models were validated by the same external validation set which had been set 
aside and not used at any stage of model development. Table 4.5 shows the 
prediction accuracy of the QSAR models using external validation in terms of the 
mean absolute error and the number of outliers. In addition, an average estimate of 
log BE% using all regression trees (RT (1) – I-tree (2)) was calculated and 
compared with the observed values to investigate any possible improvements in 
prediction accuracy. Table 4.5 gives the performance of this estimation method 
(consensus RTs). 











Biliary excretion can play a significant role in the elimination of drugs, and, 
therefore, its prediction is an important target in drug discovery. In the 
pharmaceutical industry, drug candidates are routinely tested in animal studies to 
measure the extent of biliary excretion and propensity of enterohepatic cycling, 
which have significant roles in the pharmacokinetics of a drug. In drug discovery, a 
reliable, user friendly and low-cost model based on computer-generated molecular 
Model MAE for training set MAE for validation set 
MLR (1) 0.377 0.483 
RT (1) 0.304 0.373 
I-tree (1) 0.345 0.451 
I-tree (2) 0.424 0.468 
Consensus RTs 0.319 0.383 
BT (1) 0.229 0.412 
BT (2) 0.226 0.417 
RF (1) 0.403 0.496 
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properties can reduce the number of high-cost animal (mainly rat) studies. This 
investigation aimed to elucidate how secretion into bile of compounds is controlled 
by their molecular structure, and to develop predictive models based on the 
molecular structure. Linear regression analysis, regression trees and two ensemble 
methods, boosted trees and random forest, were used for the QSAR model 
development. 
 
4.4.1. Comparison of the Models 
Linear regression equation is one of the simplest and the most common QSAR 
techniques. This method has the benefit of easy interpretation and it can provide 
mechanistic insight into the process under investigation. However, it has been 
argued that many biological processes have more complex relationships with the 
molecular attributes of the compounds and hence linear regression models may fail 
to capture these (Guha and Jurs, 2004). RT offers a suitable alternative to MLR 
method with the advantage of being flexibly non-linear while retaining the 
interpretability (De'ath and Fabricius, 2000). Ensemble methods such as random 
forest (Breiman, 2001) provide consensus predictions which may have improved 
accuracy. But this is often accompanied by a loss of interpretability, as the 
ensemble of many models is often used as a ‘black box’ prediction tool. In this 
investigation, STATISTICA variable importance analysis was used to find the most 
significant molecular descriptors in the boosted trees and random forest models. 
According to Table 4.5, the most predictive model with the lowest estimation error 
for the external validation set is RT (1) followed by BT (1) and BT (2) and then I-
tree (1). In other words, increasing the complexity of the models by allowing non-
linear relationships and an ensemble of such models has been able to improve the 
prediction accuracy in comparison with a simple linear regression model (MLR). 
Table 4.5 shows the number of outliers from each of the models. According to this 
table, RT (1) followed by BT (2) and BT (1) and then I-tree (1) are the best 
externally validated models with the lowest numbers of outliers in the validation 
set. The advantage of RT is the obvious simplicity and interpretability which can 
make it more popular with the end users in drug discovery disciplines. For example, 
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when using the tree for a new compound, the molecular descriptors used in the tree 
will need to be calculated for the compound and then the terminal node (leaf) where 
the compound falls according to the molecular descriptor values should be 
identified. The average log BE% of the terminal node (Mu) is the estimate of the 
tree for this compound. Despite that RT provides discrete predictions of a 
continuous observation which is not ideal, this is a much more straightforward 
procedure than using BT or RF for the estimation of BE%. These models are 
ensemble of many trees, and therefore the prediction has to be performed by the 
computer rather than manually. 
An interesting observation was made as MW and COOH were not significant in 
MLR equation when forced into stepwise regression analysis (P > 0.05). Despite 
this, incorporation of these two parameters was statistically significant in C&RT 
analysis resulting in I-tree (1) and I-tree (2). This indicates the non-linear nature of 
the impact of these two parameters on biliary excretion. Average prediction by the 
three RT models was also considered and found to be of similar accuracy to RT (1) 
(Table 4.5). 
In this work, the MLR model based on the training set of 168 compounds had the 
second poorest prediction accuracy after RF. Studies by Yang et al. (Yang et al., 
2009) and Chen et al. (Chen et al., 2010) report MLR models based on training sets 
of 37 and 46 compounds, respectively. The proposed model by Yang et al. 
incorporated molecular connectivity indexes and atom-type electrotopological 
indexes which have also been used in this study. The model proposed by Chen et 
al. also incorporated similar molecular descriptors to our study, with the addition of 
Abraham descriptors representing polarisability and hydrogen bond acceptor 
capacity. Although we have not used Abraham’s descriptors, there are other 
molecular descriptors in our set of 386 descriptors that measure the same 
properties. Examples are the number of hydrogen bonding acceptor atoms and 
atomic charge on the most negatively charged atom in the molecule which may 
represent hydrogen bond acceptor ability (Dearden and Ghafourian, 1999) and 
molar refractivity descriptors which may indicate molecular polarisability (Verman 
and Hansch, 2005). 
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In another study, Luo et al. (Luo et al., 2010) used 50 proprietary compounds from 
Bristol-Myers Squibb Co. for model development. They also developed a multiple 
linear regression model, but in addition to more common molecular descriptors, 
they employed free energy of aqueous solvation calculated from a self-consistent 
reaction field method. In analysing this model, Gandhi and Morris (Gandhi and 
Morris, 2012) found that the model failed to generalise further to the new set of 
compounds and specifically free energy of aqueous solvation was not statistically 
significant. They argued that a complex process such as hepatobiliary excretion 
cannot be captured by simple physicochemical properties when examining 
chemically dissimilar compounds. Indeed, such extrapolations to external 
compounds will fail when the compounds are outside the domain of applicability of 
the QSAR models. Incorporation of a larger dataset in this work may provide the 
opportunity for capturing an extended chemical space. This will be discussed 
further when analysing the outliers in the next two sections. 
 
4.4.2. Structural Features of Compounds for Biliary Excretion 
Table 4.2 gives a brief description of the significant molecular descriptors used in 
the models. For the sake of this discussion, the descriptors in this work can be 
classified roughly into five categories as follows: lipophilicity, ionisation, 
molecular size and topological and constitutional descriptors. 
It can be seen in Table 4.2 that lipophilicity descriptors such as log D at different 
pH levels and surface area of hydrophilic molecules (SlogP_VSA0) are present in 
all models. In all interpretable models (except for the linear regression equation), 
lipophilicity descriptors show a negative effect on the biliary excretion of 
compounds. This may relate to the fact that highly lipophilic compounds are known 
to be highly extracted and metabolised in the liver (Proost et al., 1997) rather than 
being excreted unchanged through bile or kidney. For example, metabolism by 
cytochrome P450 enzymes (Lewis and Ito, 2010) and (UDP)-
glucuronosyltransferase (Smith et al., 2003) is mainly controlled by lipophilicity 
and increased for more lipophilic compounds. There have been inconsistent 
findings in the literature regarding the effect of lipophilicity on the biliary excretion 
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of xenobiotics. Proost et al. found no significant correlation between lipophilicity 
and biliary excretion of a series of bulky organic cations despite it being the 
predominant factor for the degree of plasma protein binding and hepatic uptake rate 
(Proost et al., 1997). Similar observations have been made for other compilations of 
biliary excretion data (Yang et al., 2009). Other studies indicate negative effect of 
lipophilicity on the biliary excretion within the range of compounds studied (Luo et 
al., 2010; Varma et al., 2012). Lipophilicity has been associated with many models 
of ADME properties (Hansch et al., 2004). It is a well-established fact that 
compounds with higher logP have poor aqueous solubility and are more likely to 
pass through lipid bilayer of biological membranes (Kerns and Di, 2008). The 
general trend in the literature with regards to the role of lipophilicity in 
pharmacokinetic processes indicates that more lipophilic compounds have higher 
oral absorption, plasma protein binding, and volume of distribution (van de 
Waterbeemd et al., 2001; Obach et al., 2008; Newby et al., 2013b) and are more 
prone to P450 metabolism (Lewis and Ito, 2010; van de Waterbeemd et al., 2001). 
This may lead to the reduced chance of excretion through bile as the intact drug. 
All models presented in this work indicate the significant role of ionisation and 
polarity through molecular descriptors such as COOH, fU, FCASA− and 
SddssS_acnt. Acids are able to ionise into anions which are substrates of several 
transporters (generally organic anion transporters). Compounds that carry positive 
as well as negative charge or partial charges can use both the ‘organic anion’ and 
the ‘organic cation’ transport systems (Koepsell et al., 2001). For example, OAT3 
accepts various kinds of bulky hydrophobic anions, while OAT1 can transport 
relatively hydrophilic small molecules, such as nucleoside analogues (Maeda et al., 
2010). Besides, monocarboxylate transporters (MCT1 to MCT14) constitute a 
family of proton-linked plasma membrane transporters that carry molecules having 
one carboxylate group. MCT1 is expressed nearly all over in every tissue in the 
human body and also in rat and calves hepatocytes (Kirat et al., 2007). MCT2 is 
abundant on the surface of human, rat and hamster hepatocytes (Halestrap and 
Meredith, 2004). MCT5 and MCT8 are also known to play transporting role in rat 
hepatocytes (Halestrap and Meredith, 2004). Studies of biliary excretion of 
exogenous compounds have indicated the relation between polarity and biliary 
excretion stating that possession of a strongly polar anionic group was important 
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factor in appreciable biliary excretion (Luo et al., 2010; Millburn et al., 1967). In 
all the interpretable models reported here, polarity descriptors show a positive 
impact on biliary excretion. Examples are the positive coefficients of dipole 
moment (AM1_dipole) in the linear regression equation and higher percent of 
compounds with lower unionised fractions at pH 7.4 (fU) in RT (1). 
Molecular size is the other important factor in biliary excretion represented in the 
models by molecular descriptors such as kappa shape indexes, hydrophobic 
volumes (vsurf_W1 and vsurf_W3) and surface areas of atoms with specific charge 
or lipophilicity ranges (e.g. PEOE_VSA_NEG and PEOE_VSA_HYD). These 
molecular descriptors show positive effect on biliary excretion level in all models. 
This is in line with the common understanding that a molecular weight threshold 
may apply to biliary excretion of compounds, and that high molecular weight 
compounds may be predominantly excreted through bile (Yang et al., 2009; Varma 
et al., 2012; Millburn et al., 1967). Yang et al. (Yang et al., 2009) suggested a 
molecular weight threshold value of 400 Da for biliary excretion of anionic drugs in 
rats using 164 drugs. In this study, regression tree analysis found the threshold 
value for molecular weight to be at 347.9 Da for biliary excretion in rat (I-tree (1)). 
Incidentally, this regression tree had the second highest prediction accuracy for the 
external validation set amongst the RT models. This was despite the fact that 
molecular weight was not the descriptor of choice by C&RT analysis. 
The incorporation of some structural fragments in the models gave interesting 
information regarding molecular requirements for biliary excretion. Examples 
include SddssS_acnt and SsssCH which indicate higher biliary excretion of 
compounds containing sulphate groups and non-branched structure (MLR). 
Compounds containing carboxylic acid groups are also more likely candidates for 
biliary excretion according to I-tree (2). Up to half of compounds in our dataset 
contain –COOH groups (103 compounds out of 217). Sixty-five out of 103 COOH 
containing compounds had biliary excretion of > 20%. Varma et al. (Varma et al., 
2012) have analysed the interconnection between physicochemical requirements of 
OATP substrates and the biliary excretion rates. It was then suggested that substrate 
specificity of OATPs including acidity may primarily indicate the elimination 
through bile (Varma et al., 2012). 
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4.4.3. Analysis of the Outliers 
There are a number of compounds that are outliers from majority of the models. 
Analysis of outliers may provide interesting information regarding the applicability 
of the models. Within the BE% range, it could be observed that compounds with 
low biliary excretion show a higher average error in general (Table 4.6). For 
example, the average error by all seven models was the highest for the six 
compounds with the extremely low biliary excretion (BE% < 0.23), followed by the 
compounds with 0.23 < BE% < 1.23 (-0.64 < log BE% < 0.09). A closer inspection 
of the data reveals that despite the high average error for the six compounds with 
low biliary excretion, the estimation may still be acceptable as all these compounds 
have been estimated to have a BE% value < 4% (average of all models) and below 
0.6% by RT1 model with only one exception (benzoic acid). A hypothesis here 
could be that these compounds may have suitable properties for higher biliary 
excretion, but other routes of elimination are predominating. For example, it has 
been shown for benzoic acid that when clearance by the kidney is prevented, biliary 
excretion increases by 10% (Abou-El-Makarem et al., 1967). Out of 217 
compounds in the dataset, the predominant routes of elimination are biliary 
excretion for 115 compounds, renal excretion for 65 compounds and metabolism 
for 37 compounds. However, the outlier compounds do not belong to any single 
groups above in terms of the predominant routes of elimination (see Figure 4.9 for a 
graph showing the predominant routes of elimination for the compounds in biliary 
excretion dataset). 
 
Table 4.6. Average MAE by nine models for compounds with various BE%, logP 
and molecular weight values 
BE% Average MAE n 
<= 0.23 1.12 6 
0.23 - 1.23 0.50 26 
> 1.23 0.30 a 176 
MW (Da) 
  > 280 0.31 173 




  > 5.35 0.63 13 
<= 5.35 0.33 195 
 
 
     
Figure 4.9. The main routes of elimination for compounds in the biliary excretion 
dataset 
According to Table 4.6, highly lipophilic compounds (log P > 5.35) and low 
molecular weight compounds (MW ≤ 280) also show higher error rates, and this 
may need to be considered when using the models for the prediction of external 
compounds. 
Table 4.7 gives a list of the compounds that are outliers in six or seven models out 
of the seven models proposed here. In addition, there are four compounds which 
were outliers in four or five models but had exceptionally high average error from 
the seven models. These compounds were part of the training or validation sets, but 
none were omitted from average error calculations. 
 
 









Table 4.7. Outlier compounds in training or validation sets with absolute error of > 
0.6 in more than five out of seven models and their BE% values. 
Outliers BE% Log 
BE% 
Over or under     
prediction 
Models           
with  error 
MW 
Benzoic acid 0.09 -1.07 over-predicted           
except for BT 
models 
4 122 
EMDP 0.20 -0.69 over-predicted 6 263 
Fosmidomycin 0.10 -1.00 over-predicted 7 183 
Nelfinavir 0.05 -1.32 over-predicted 5 567 
EDDP  36.31 1.56 under-predicted 6 277 
PAEB 31.62 1.50 under-predicted 7 222 
Tolrestat 53.70 1.73 under-predicted 6 357 
 
The outliers in Table 4.7 have been over- or under-predicted by the models. One 
compound in the table has shown underestimation by some and overestimation by 
other models; biliary excretion of benzoic acid was overestimated by all models 
except for BT (1) and BT (2). It can be seen in Table 4.7 that fosmidomycin, 
nelfinavir and 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP) are over-
predicted by five or more models. Benzoic acid is rapidly cleared by the kidney, so 
it may not have enough time to pass into the bile (Abou-El-Makarem et al., 1967). 
Abou-El-Makarem and his colleagues examined this possibility by tying up the 
renal pedicles in rats, so that clearance by the kidney was prevented, and the results 
indicated that when clearance by the kidney is prevented, biliary excretion 
increased by 10% (Abou-El-Makarem et al., 1967). Fosmidomycin has a short half-
life of 1.7 h and is rapidly cleared by the kidneys (Murakawa et al., 1982). It is a 
small molecular weight polar agent which may not be cleared in high quantities 
through bile according to the molecular weight threshold hypothesis. Despite the 
use of molecular size descriptors, this compound still appeared to be overestimated 
by all seven models, even using I-tree (1) which has employed MW for the first 
branching. The problem with I-tree (1) in relation to this compound is that although 
this compound falls into node 2 along with 44 other low molecular weight 
compounds, this node has an average log BE% of 0.42 which is much lower than 
node 3 with an average log BE% of 1.27 but not low enough for this compound. 
Likewise, other models have indicated low biliary excretion of small-sized 
compounds, but somehow, estimation is higher than what is actually observed. 
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Nelfinavir has a half-life of 3.5 to 5 h and is eliminated via metabolism by the 
cytochrome P450 enzyme system (Bardsleey-Elliot and Plosker, 2000). This is a 
highly lipophilic compound which is poorly excreted through bile, and is predicted 
as such by the models (predicted BE% below 2% using all models except for I-tree 
(2) and RF which predict 13 and 7.6%, respectively). 
EMDP is a major metabolite of methadone which has been over-predicted by most 
models despite a very low biliary excretion. As with nelfinavir, the predicted BE% 
for this compound by most models is quite low at < 4% (MLR is an exception) and 
the selected model, RT (1), predicts a biliary excretion value of ∼0.3%. Despite 
this, in comparison with the extremely low observed value of 0.05%, the predicted 
values are much higher, leading to a numerically large average error, even though 
qualitatively, the predicted biliary excretion may be reasonably low. 
EDDP, PAEB (procaine amide ethobromide) and tolrestat are the under-predicted 
compounds. All these compounds have high BE% values at 36, 32 and 54%. This is 
despite the relatively low molecular weights of EDDP and PAEB which are below 
the defined MW threshold of 347 Da for biliary excretion. The exact mechanism of 
high biliary excretion of these compounds warrants further investigation to explore 
the reasons behind such high biliary excretion despite the low molecular weight. 
Tolrestat has a relatively high molecular weight suitable for biliary excretion and a 
COOH group making it a suitable substrate for OATPs (Varma et al., 2012). 
Despite this, the hydrophilic volume calculated by the VolSurf descriptor vsurf-W3 
is not high enough to put this compound in node 3 rather than node 2 of RT (1) 
model. In I-tree (1), the compound falls into node 16, which is due to the lack of 
non-aromatic branched structure which would place it in node 17 with a higher 
predicted BE%. Likewise, in I-tree (2), this compound fails to be placed in node 7 
and falls in node 6 instead due to the low total negative charge (> -2.33) as a result 
of the low number of negatively charged atoms. This indicates a shortcoming in the 
abovementioned models which lack suitable parameters that can capture the relative 





This investigation focused on the development of computational models for a cost-
effective estimation of biliary excretion of compounds. This was made possible 
through the application of quantitative structure-activity relationships where 
molecular properties (descriptors) of a large dataset of compounds were related to 
the percentage of dose excreted intact via the bile through the use of statistical 
techniques. Some of the statistical techniques led to very promising results as 
evaluated by the prediction accuracy for the external validation set. The QSAR 
models also identified the important molecular properties (descriptors) that have the 
main influence on biliary excretion of compounds. The selected models were the 
regression tree (C&RT) model, RT (1), followed by boosted trees models BT (1) 
and BT (2). Regression trees also have the advantage of being simple, interpretable 
and user-friendly. The models generally indicated that larger, relatively hydrophilic 
molecules containing a carboxylic acid group are more prone to biliary excretion. 
For example, in the selected model, RT (1), compounds with increased hydrophilic 
volume and acidic dissociation have high biliary excretion. The significance of 
acidity and molecular size were further confirmed through interactive regression 
trees and a statistically validated MW threshold for effective biliary excretion was 
established. Detailed analysis of the error levels and outliers indicated that the 
models work best for larger compounds (MW > 280 Da) and are less accurate for 






5. Effect of P-gp Binding on Biliary Excretion 
 
5.1. Introduction 
One in four deaths in the United States is due to cancer and recently the American 
Cancer Society reported a total of 1,660,290 new cancer cases and 580,350 cancer 
deaths are projected to occur in the United States in 2013 (Siegel et al., 2013). The 
failure of cancer treatment can be attributed to a variety of different 
pharmacological and clinical reasons; but one major cause of the treatment failure 
is multidrug resistance (MDR) to chemotherapeutics (Song et al., 2010). MDR 
mechanisms can result in resistance to a number of structurally and functionally 
unrelated chemotherapeutic agents. The multidrug resistance behaviour is mainly 
linked to the activity of transmembrane efflux pumps such as P-glycoprotein 1 (P-
gp/ABCB1), breast cancer resistance protein (BCRP/ABCG2) and multidrug 
resistance-associated protein 1 (MRP1/ABCC1), which are members of ATP-
Binding Cassette transporter family (Krishna and Mayer, 2000). P-gp, also known 
as multidrug resistance protein 1 (MDR1), is a well-studied glycoprotein which was 
first discovered in 1976 by surface labelling studies in multidrug resistant Chinese 
hamster ovary cells (Juliano and Ling, 1976). Since then, it has demonstrated its 
function as a transporter of hydrophobic drugs, lipids, steroids and metabolic 
products.  
Overexpression of P-gp in cancer cells contributes significantly to the resistance of 
cancer cells against chemotherapeutic agents (Gottesman, 2002). As a strong efflux 
pump, P-gp is able to export a number of structurally diverse anticancer agents 
including anthracyclines, epipodophyllotoxins and vinca alkyloids. As a result, P-
gp has been suggested as a viable target to be inhibited in the treatment of 
multidrug resistant cancer (Szakács et al., 2006). Drugs such as actinomycin-D and 
azithromycin can strongly block the P-gp and limit the efflux of P-gp substrates. 
Inhibitors that block the transport of chemotherapeutics or other compounds may 
act as competitive or non-competitive inhibitors (Ambudkar et al., 1999). In recent 
years, the inhibitory activity against P-gp has been tested in many compounds in 
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order to overcome P-gp mediated resistance of cancer cells to the 
chemotherapeutics (Pajeva et al., 2009). 
In addition to its role in multidrug resistance, P-gp has a profound role in 
pharmacokinetics, affecting drug absorption, distribution and excretion (Lin and 
Yamazaki, 2003). It is found in high amounts at the apical surface of epithelial cells 
lining the colon and small intestine, hepatocytes, pancreas ductules, proximal 
tubules in kidneys, and the adrenal gland (Schinkel and Jonker, 2003; Dean, 2002). 
P-gp is also known to play a major role in transporting compounds out of the brain 
in the blood brain barrier (Malmo et al., 2013). In the BBB, only suitably lipophilic 
compounds can diffuse across the endothelial cells and enter the brain. However, a 
high proportion of P-gp that surrounds this area of the brain prevents their 
accumulation by distributing substrates back into the blood circulation (Malmo et 
al., 2013). In the gastrointestinal tract and in hepatocytes, P-gp is responsible for 
the efflux of drugs back into lumen/bile, thus reducing the bioavailability of 
substrate drugs (Giacomini et al., 2010). Similarly, in kidneys, P-gp is located 
primarily in glomerular mesangium and the apical membrane of proximal tubule 
epithelia and plays a significant role in the tubular secretion of organic cations 
(Giacomini et al., 2010). 
As stated earlier, P-gp is poly-specific and can efflux a very broad range of 
substrates. The substrates can have molecular weights ranging from 250 to 1850 
Da, different ionization states, acid/base properties, hydrophobicities or 
amphipathic properties (Kerns and Di, 2008). There are drugs and herbal products 
that can affect the function of P-gp transporters and the number of drugs that are 
found to be the P-gp substrates is incessantly growing. For instance, rifampin (an 
antituberculosis drug) induces the intestinal expression of P-gp (Ehrhardt and Kim, 
2008). Due to the broad substrate specificity of P-gp, drug-drug interactions 
involving P-gp are very likely (Lin, 2003). Drug–drug interaction is an important 
issue observed in cancer patients, especially because they often receive multiple 
medications concurrently with complex chemotherapy regimens (Wong et al., 
2008). Due to the importance of P-gp in drug interaction, the FDA has urged that 
every new molecular entity should be routinely checked for a possible interaction 
with P-glycoproteins (FDA Guidelines, 2014). 
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Multiple binding sites are available for P-gp. Generally, P-gp inhibition can happen 
in three different ways. Firstly by blocking the binding of substrate drugs this can 
be allosteric, competitive or non-competitive. Secondly by acting with ATP 
hydrolysis site, due to the fact that P-gp is inactive when ATP hydrolysis site is 
blocked (Shapiro and Ling, 1997; Urbatsch et al., 1995). Although majority of 
drugs block the P-gp by blocking the substrate binding sites (Varma et al., 2003), 
presence of multiple binding sites should be considered in the substrate or inhibitor 
studies. Besides, P-gp may be induced by various agents such as ritonavir (Perloff 
et al., 2001).  
Numerous well-known multispecific drug transporters are involved in liver 
canalicular efflux of many xenobiotics (Pfeifer et al., 2014). Of these transporters, 
P-gp characterizes as the most widely studied efflux transporter in biliary excretion. 
This transporter is responsible for transporting of mainly large lipophilic and 
cationic substrates into the bile canalicular (Oza, 2002). It has been shown in 
genetically modified mice lacking mdr1-type (drug-transporting) P-gp that substrate 
drugs such as digoxin may have a reduced elimination (Schinkel et al., 1997). 
Moreover, mutations in the human MDR3 gene responsible for P-gp lead to 
progressive familial intrahepatic cholestasis which lack biliary phospholipid 
excretion (de Vree et al., 1998). Another example regarding the importance of P-gp 
in biliary excretion of drugs is the P-gp substrate imatinib, which shows a 
significantly reduced fecal excretion in P-gp knockout mice or in the presence of P-
gp inhibitors (Oostendorp et al., 2009). 
Given the important clinical relevance of P-gp, it is important to elucidate the mode 
of interaction with the modulators and substrates of this enzyme. Higginis and 
colleagues suggested a model for the P-gp polyspecificity namely “hydrophobic 
vacuum cleaner” model (Higgins and Gottesman, 1992). In the proposed model, the 
hydrophobic substrates enter the transmembrane domain of P-gp and are 
transported outside the cell. A recent study by Aller et al (Aller et al., 2009) 
provided a detailed structural description of mouse P-gp, which indicates a 
substantial internal cavity comprising mostly hydrophobic and aromatic residues. 
Despite the substrate promiscuity, several studies have been valuable in identifying 
structure activity relationships for the modulators. Evidences from X-ray 
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crystallography (Aller et al., 2009), chromatography (Lu et al., 2001) and several 
biochemical techniques (Martin et al., 2000; Maki et al., 2006) suggest the presence 
of multiple substrate-binding sites and a number of inhibition mechanisms, which 
may be the cause of substrate promiscuity. As a result, it may be necessary to 
generate more than one pharmacophore for P-gp (Ekins and Erickson, 2002).  
The type of the quantitative data available for P-gp is mostly in terms of IC50 values 
for the inhibitors. On the other hand very few substrate Km measures are found in 
the literature, despite the availability of binary data of substrate/non-substrate 
(Matsson et al., 2009). As a vast majority of the reported IC50 values are for 
compounds that also act as substrates, with the exception of flavonoids which are 
believed to be able to bind to the ATP site as well as the substrate binding site 
(Kim, 2002), the inhibition constants may also indicate the binding capacity of the 
compounds. As a result, in this investigation, the IC50 and Ki values were collated 
for the QSAR studies. The use IC50 (concentration of inhibitor required for 50% 
inhibition) has the disadvantage of not allowing easy comparison of data from 
different substrate conditions. Unlike IC50, the inhibition constant, Ki, is a more 
universal parameter that is standardised according to the substrate concentration 
and Km values (Cheng and Prusoff, 1973). A Ki value is related to enzyme-
inhibitor complex and explains the strength of the interaction. 
The broad aim of this investigation was to study the effect of P-gp binding on the 
QSAR models for the estimation of P-gp. To achieve this, first, several data mining 
techniques were used to enable development of universal models for the prediction 
of P-gp inhibition constant (Ki). In these models, the use of molecular descriptors 
for the substrates in addition to the inhibitor parameters may be useful for splitting 
of the Ki data if the substrate type has an effect on the measured Ki values. 
Secondly, docking scores were investigated as a complementary parameter to 
investigate the significance of interaction energy between the ligands and P-gp in 
the models for estimation of the binding constants. Third, the selected QSAR 
models were used for the prediction of P-gp binding constants of the compounds in 
biliary excretion dataset. Finally, the predicted P-gp dissociation constant (briefly 




5.2. Methods  
5.2.1. P-gp Dataset 
IC50 and Ki values for P-gp inhibitors were collated from the literature (Cook et al., 
2010; Choo et al., 2000; Dantzing et al., 1996; Eberl et al., 2007; Ekins et al., 
2002a; Ekins et al., 2002b; Eriksson et al., 2006; Kakumoto et al., 2002; Katoh et 
al., 2001; Keogh et al., 2006; Lan et al., 1996; Lumen et al., 2010; Luo et al., 2002; 
Matsson et al., 2009; Neuhoff et al., 2000; Noguchi et al., 2009; Pauli-Magnus et 
al., 2000; Petri et al., 2004; Rautio et al., 2006; Richter et al., 2009; Shaik et al., 
2007; Tang et al., 2002a; Tang et al., 2002b; Wandal et al., 1999 and Wang et al., 
2001). IC50 values of P-gp inhibitors were used to calculate the Ki values using the 
Cheng-Prusoff equation below.  
   
    
  
   
  
                                                                                     Eq (1)  
In this equation [S] is the substrate concentration and Km is Michaelis–Menten 
constant for the substrate (the concentration of substrate at which enzyme activity is 
at half maximal). If Km values for the substrates were not reported in the 
publication, then they were obtained from the authors through personal 
communication. The rationale behind converting the IC50 values to Ki values is that 
the Ki is a more universal scale, which in theory should be independent of the 
substrate used. 
In case there were several IC50/Ki values available for a single inhibitor from 
different sources, the average Ki values were used, unless the probe substrate was 
different. If there was a significant difference in the reported IC50/Ki values, we 
contacted the authors to find out if they could provide an explanation for the 
observed differences before using the reported values. In total the dataset consisted 
of Ki values for 219 unique inhibitor/substrate pairs, with data measured in different 
cell systems including Caco-2, MDCK-MDR1, MDCK II-MDR1, K562-MDR, 
MDR1 transfected LLC-PK1 and P388 lymphoma cells. Human colon carcinoma 
cell line (Caco-2) and Madin-Darby canine kidney cells (MDCK) were the most 
common cell line used in our dataset. The inhibitors in the dataset are from 
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different chemical/pharmacological classes such as anticancer and anti-HIV agents, 
statins, antiretrovirals, cephalosporines, ergopeptides, antipsychotics, opiods, 
NSAIDs, analgesics, and antiarithmetic drugs.  The dataset is presented in 
Appendix II. 
 
5.2.2. P-gp-Ligand Docking 
Docking energy for all inhibitors was calculated using MOE software (version 
2012.10, Chemical Computing Group Inc. Montreal, Canada). Later, the docking 
score of inhibitors were used as an additional molecular descriptor by adding these 
score’s columns to the dataset.  
The X-ray structure of the mouse P-gp was obtained from the protein data bank 
(PDB code 3G60) [http://www.rcsb.org]. The use of this PDB structure was due to 
a previous docking investigation that showed better scoring poses using mouse 
3G60 structure in comparison with the other two mouse P-gp structures (PDB 
codes: 3G61 and 3G5U), or the human homology model of P-gp (Löschmann et al., 
2013). It should be noted that this structure of mouse P-gp was co-crystalised with a 
ligand and the complex had two stereo-isomers of cyclic hexapeptide inhibitors, 
cyclic-tris-(R)-valineselenazole (QZ59-RRR) and cyclic-tris-(S)-valineselenazole 
(QZ59-SSS) in the active site (Aller et al., 2009). The protein was protonated and 
protonatable residues were titrated using default parameters of the software before 
the docking exercise. Molecular structures of the ligands (P-gp inhibitors) were 
optimised after atomic charge calculation using SCF optimization (AM1 
Hamiltonian). In enzyme-ligand docking, default parameters of the software were 
used for ligand interactions. These are energy cut-off for H-bond and ionic 
interactions of -0.5 kcal/mol and maximum distance for non-bonded interactions of 
4.5 Å. In the MOE dock panel, the placement method was Triangle Matcher, the 
scoring methodology was set to London dG as the first and the second scoring 
functions, the refinement methodology was set to Forcefield, and finally, the 30 
best scoring poses, the mean energies and the mean energies and backbone root 
mean square deviation (RMSD) were retained. The binding site was defined in 
MOE software using the co-crystallised ligand QZ59-RRR.  
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Preparation of compounds for Docking 
Before docking could take place, the SDF file was imported into the MOE 
software. MOE is a suite of applications that can be used to manipulate and analyse 
a collection of compounds.  For docking to work efficiently, it is essential that each 
structure is in a form suitable for it to be docked to a ligand. As a result, the 
software’s ‘Wash’ application was used to clean the structures and neutralise the 
protonation state of each compound. This will neutralise all atoms and form the 
structure of the compound in its least charge-bearing state. The next step was to 
lower the potential energy of the structures. This was completed using the “Energy 
minimize” function from the software. The compounds in the database were now 
ready to be computed and molecular descriptors were calculated.   
Validation of docking experiment 
The published X-ray crystallography structures (Aller et al., 2009, Gutmann et al., 
2010) were used to validate our docking model by comparing the geometries of the 
docked Abcb1a/QZ59-RRR structure and the structure of the Abcb1a/QZ59-RRR 
complex from X-ray crystallography and measuring root-mean-square deviation 
(RMSD) between them. 
 
5.2.3. Model Development and Validation 
Development of models for P-gp  
To perform QSAR analyses, P-gp inhibitors were divided into validation and 
training sets. To divide the inhibitors, they were ordered with ascending Ki values, 
and then from every five compounds, four were allocated into the training and one 
into the validation set randomly. This ensured similar Ki ranges for the validation 
and training sets. In this way, training data consisted of 176 compounds and 
external validation set consisted of 43 compounds.  
In this study, QSARs were established to relate the P-gp binding effect of 
compounds (log Ki) to the molecular descriptors and P-gp docking scores. 
Molecular descriptors were calculated according to the procedures explained in 
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section 3.1. Before building the models, the molecular descriptors were checked to 
find and discard those columns containing more than 98% constant values or more 
than 10% missing values. The total number of molecular descriptors used in all 
statistical analyses was 388.  
STATISTICA Data Miner version 11 was used for the statistical analysis. 
Statistical methods consisted of decision tree methods and ensemble methods 
including Classification and Regression Tree (C&RT), Chi-square Automatic 
Interaction Detector (CHAID), Boosted Trees (BT) and Random Forest (RF). 
Moreover, Multivariate Adaptive Regression Splines (MARS) model was also 
developed. These methods have been explained in Chapter 3. Log Ki was the 
dependent variable and the predictors were selected by the embedded feature 
selection methods in C&RT, CHAID, BT and RF from all the molecular descriptors 
and docking scores available for the inhibitors and substrates. In C&RT analysis, 
several stopping criteria were examined, including the default settings in 
STATISTICA. The default stopping criteria were minimum number of cases of 24 
to allow further splitting, and the maximum number of nodes set to 100. The V-
values of 10 or seven was used in the V-fold cross-validation. In CHAID analysis, 
STATISTICA default setting for stopping criteria were used, including minimum 
number of cases for splitting of 22, maximum number of nodes of 1000, probability 
for splitting of 0.05 and probability for merging of 0.05. In BT analysis, the default 
values for learning rate, the number of additive terms, random test data proportion 
and subsample proportion were 0.1, 200, 0.2 and 0.5 respectively. Various 
subsample proportions of 0.45, 0.50, 0.55 and 0.60 were also examined in 
combination with the learning rates of 0.10, 0.03, 0.05 and 0.08. In RF analysis, 
various subsample proportions of 0.45, 0.50, 0.55 and 0.60 were examined. The 
random test data proportion was 0.3 for the internal validation and number of trees 
was 100. The default settings were used for stopping conditions including minimum 
number of cases, maximum number of levels, minimum number in child node and 
the maximum number of nodes of 5, 10, 5 and 100, respectively. 
For the development of MARS model, several pre-processing feature selection 
techniques were examined. Feature selection methods were a Chi-square method as 
implemented in STATISTICA v11 (StatSoft Ltd.) developed by Hill and Lewicki 
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(Hill and Lewicki, 2006), stepwise regression analysis, and variable importance 
rank from random forest and boosted trees analyses. The Chi-square-based feature 
selection in STATISTICA picks a subset of descriptors from the descriptor pool 
without assuming that the relationships between the predictors and the dependent 
variables are linear or even monotone. In this feature selection, the range of 
continuous variable values was divided into 10 intervals. The best variables picked 
by STATISTICA feature selection, the best descriptors selected by stepwise 
regression analysis, as well as the top 5, 10, 15, 20 and 25 descriptors picked by 
RF, and the top 5, 10 and 15 descriptors picked by BT were examined in separate 
MARS analyses and the resulting models were compared. In MARS analysis, the 
default model specifications for maximum number of basis functions, degree of 
interactions, penalty and threshold were 21, 1, 2 and 0.0005 respectively. 
The best model from each analytical method was selected based on the performance 
indicators for the internal validation set. 
 
Development of models for biliary excretion incorporating predicted P-gp activity  
The selected P-gp dissociation constant (Ki) models above were used to predict the 
log Ki values for compounds in biliary excretion dataset (n = 217). QSAR models 
were developed for biliary excretion using the dataset and methods explained in 
Chapter 4. In addition to the molecular descriptors, the P-gp effects predicted by the 
selected models from section 5.2.3 were used as the independent variables of the 
analyses. In addition to stepwise regression analysis, C&RT, boosted trees and 
random forest methods, two additional methods, CHAID, and MARS, were also 
used for development of QSARs for biliary excretion using the procedure explained 
above for P-gp models. In some C&RT models, the predicted Ki effects were 
manually incorporated in the models, when they were not picked by C&RT feature 





This chapter will present the results of QSAR development for P-gp binding 
followed by the QSAR models for biliary secretion that incorporate predicted p-gp 
binding values as molecular descriptors. 
 
5.3.1. Modelling the P-gp Dissociation Constant (Ki) 
P-gp is an important polyspecific transporter protein that can significantly affect the 
pharmacokinetics of various pharmaceuticals as well as the effectiveness of 
chemotherapeutics. Due to the major effect of P-gp efflux system in biliary 
excretion of compounds, it is important to investigate the structural requirements 
for P-gp binding and predict the binding constants using QSAR. In this 
investigation, a large dataset of inhibition constant was collated to investigate the 
development of a universal model for P-gp binding. To help overcome the problem 
of heterogeneity of the data from various laboratories, that incorporate various 
substrates at differing concentrations in the design of their experiments, several 
strategies were implemented. First, the IC50 values were converted to Ki values, 
which is a more comparable measure of inhibitory activity. Secondly, the molecular 
descriptors of the probe substrates were also used in the analyses and model 
development process. Third, docking scores from ligand-P-gp docking experiments 
were incorporated as a molecular descriptor to aid the prediction accuracy of the 
models. Fourth, the non-linear decision trees and MARS methods were employed 
that are flexible; therefore, in theory they should be able to deal with more 
heterogeneous data.  
 
5.3.1.1. P-gp Ligand Docking 
Docking energy for all compounds was calculated using MOE software and was 
used as a molecular descriptor. First in order to verify the docking methodology 
using MOE software, the geometries of the docked P-gp/QZ59-RRR and P-
gp/QZ59-RRR complexes from X-ray crystallography were compared and RMSD 
between them was calculated. The RMSD value for this structure after 
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superimposing the docked and co-crystal structures was 0.77; the absolute RMSD 
range without superposing was 0.89-6.2 for the top 30 poses.  
Figure 5.1 shows the 3D structure of P-gp using MOE software. An example 
substrate can be seen in yellow at the internal cavity corresponding to QZ-RRR 
binding site.  
              
Figure 5.1. Ribbon drawing (front stereo view) of mouse P-gp (PDB id: 3G60) 3D 
structure in MOE screen shot. The yellow bulb at the lower parts represents the 
potential binding residues of mouse P-gp in the internal cavity. QZ59-RRR binding 
site is located in binding pocket in lower side of P-gp cavity. Spiral alpha traces and 




Examples of docking results 
Below are examples of P-gp docking of two P-gp substrate/inhibitors namely BMS-
387032 (Figure 5.2 and Table 5.1) and SNS-032 (2D diagram is presented in Figure 
5.3 and 3D diagram is presented in Figure 5.4). These two compounds have been 
assessed as potential drugs in multidrug resistant cancer treatment (Michaelis et al., 
2014; Löschmann et al., 2013).  
 
Figure 5.2. The docked conformation of BMS-387032 in the binding pocket of 
mouse P-gp with the lowest docking energy; blue arrows are strong hydrogen bonds 
(limited within 4.5 Å) between residues of Ser725 and Gln721 and nitrogen in 
thiazole and piperidine respectively. Val978 and Phe974 are other residues with pi-
H and pi-pi interactions with the BMS-387032 respectively. 
Table 5.1. Ligand interactions parameters for binding of BMS-387032 to mouse P-
gp (3G60) at the QZ59-RRR binding site (first docking pose) 
Fragment of Ligand Receptor Interaction Distance (Å) E (kcal/mol) 
Nitrogen in Thiazole SER725 H-acceptor 3.47 -0.7 
Piperidine GLN721   H-acceptor 3.10 -1.9 
Thiazole VAL978   pi-H           3.44 -0.9 
Thiazole PHE728   pi-pi 3.92 -0.0 





             
Figure 5.3. 2D graph of interaction of SNS-032 with the QZ59-RRR binding site of 
P-gp using MOE software; the diagram indicates the polar and non-polar 
interactions by pink or green coloured amino acids; hydrogen bonding is indicated 
by green dotted arrows and Pi-H interactions with green dotted line. In this 
diagram, the energy cut-off for H-bond and ionic interactions were -0.5 kcal/mol 
and the maximum distance for nonbonded groups was 4.5 Å. Proximity contour are 
dotted lines surrounding the ligand and indicate the shape of the binding site and 
available space to the more outward-facing parts of the ligand. Blue shadows in 
some amino acids indicate the receptor exposure differences by the size and 
intensity of the quoits discs. The directions of the shadow indicate the directions of 
the amino acids towards the ligands. The blue clouds around the ligand atoms 






Figure 5.4. 3D diagram of the interaction of SNS-032 with QZ59-RRR binding site 
of P-gp; the pocket surface is mostly hydrophobic (green colour) and it matches 
well with hydrophobic rings of the ligand.  
 
8653 poses were obtained after P-gp docking with 219 compounds and the top pose 
docking energy for each ligand was used as an additional descriptor. The docking 
study of P-gp inhibitors was carried out using 3D structures of mouse P-gp (Aller et 
al., 2009). 
 
5.3.1.2. QSAR Models for P-gp Binding 
Various decision trees and ensemble models as well as Multivariate Adaptive 
Regression Splines (MARS) model were developed for the prediction of P-gp 
inhibition constant. Table 5.2 summarises the selected models developed using 
various statistical methods. All models obtained are cross-validated and pruned 
automatically, and the selected models are those with the lowest standard error for 
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the internal and external test sets. Models listed in Table 5.2 are results of various 
feature selection and data analysis methods.  Majority of these models can be easily 
interpreted in terms of the molecular characteristics required for an effective P-gp 
inhibitor. Here we provide a brief description of the models and the inferred 
molecular characteristics. The molecular descriptors employed in these models 
have been described in Table 5.3.  











RT (2) All 
descriptors 
- Train 0.246 0.028 
Test 0.810 0.118 
CHAID (1) All 
descriptors 
- Train 0.420 0.054 
Test 0.672 0.077 




Train 0.448 0.050 
Test 0.785 0.148 
BT (3) All 
descriptors 
- Train 0.146 0.013 
Test 0.572 0.126 
RF (2) All 
descriptors 
- Train 0.438 0.057 
Test 0.607 0.127 
MARS (1) Selected 
descriptors 
- Train - 0.048 
Test - 0.128 
 
 
Table 5.3. A brief description of the most important molecular descriptors selected 
and used by the models. 
Descriptor Model Description 
balabanJ RT (2) Balaban averaged distance sum connectivity index 
b_double RT (2) Number of double bonds. 
Docking energy 
(MOE) 
I-trees (3) Docking score (kcal/mol)for enzyme-ligand docking of 
the compounds into the active site of P-glycoprotein 
(Aller et al., 2009) calculated using MOE software 
GCUT_SMR_2 
 
BT (3) The GCUT descriptors using atomic contribution to 
molar refractivity (4 descriptors). 
GCUT_SMR_3 
 
MARS (1) See GCUT_SMR_2. 
logP (o/w) MARS (1) Log of the octanol/water partition coefficient. 
Num Rings 3 CHAID (2) Number of rings 3 
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opr_leadlike CHAID (2) This is one if and only if there are fewer than two 
violations from Oprea’s lead like rules, otherwise zero 
PEOE_VSA+0 RT (2) van der Waals surface area of atoms with atomic charge 





Total hydrophobic van der Waals surface area 
SaaN_acnt CHAID (2) Count of all E-states for aromatic nitrogen atoms 
SdsCH CHAID (2) Sum of all (H-C=) E-State value in molecule. 
S-FRB 
 
BT (3) The number of free rotatable bonds in a substrate. 
S-HAcceptors 
 
BT (3) The number of hydrogen bond acceptors in substrate. 
SHBint4_Acnt CHAID (2) Sum of H-bond donors and acceptors indexes separated 
by four skeletal bonds 
S-LogD(2) RT (2) Logarithm of distribution coefficient D of a substrate 





octanol/water partition coefficient 
S-logP 
MARS (1),  
I-tree (3) 
octanol/water partition coefficient in substrates. 
SMR_VSA2 
RT (2) Sum of approximate accessible van der Waals surface 
area for atoms with atomic contribution to molar 
refractivity in (0.26,0.35]. 
SMR_VSA4 
MARS (1) Sum of approximate accessible van der Waals surface 
area for atoms with atomic contribution to molar 




MARS (1)  
The substrate polar surface area. 
SssCH2 RT (2) Count of all CH2 groups E-state values in molecule. 
SssS_acnt CHAID (2) Count of all sulphur atoms (SssS) E-state values in 
molecule. 
SsssN BT (3) Atom-type electrotopological index for tertiary 
ammonium groups. 
Substrate CHAID (1) P-gp substrate 
vsurf_CW3 
 
RF (2) Capacity factor is the ratio of the hydrophilic surface 
over the total molecular surface, calculated at eight 
different energy levels (from -0.2 to -6.0 kcal/mol) 
vsurf_CW4 I-tree (3) See vsurf_CW3. 
vsurf_D2 
 
MARS (1) Hydrophobic volume at -0.4 kcal/mol 
vsurf_D4 
 
RF (2) Hydrophobic volume at -0.8 kcal/mol 
vsurf_D7 
 
RF (2) Hydrophobic volume at -1.4 kcal/mol 
vsurf_D8 RT (2),      
RF (2)  
Hydrophobic volume at -1.6 kcal/mol 
vsurf_DW13 I-tree (3) Contact distances of the lowest hydrophilic energy 
descriptors (vsurf_EWmin). 
vsurf_EWmin2 MARS (1) Second lowest hydrophilic energy 
vsurf_R 
 
RF (2) The surface rugosity related to hydrophobicity volume 




vsurf_W4 CHAID (2) Hydrophilic volume. 
 
 
5.3.1.2.1. Regression Trees 
Figures 5.5 and 5.6 show the regression trees obtained using RT and CHAID (1) 
respectively. In the regression trees, N is the number of P-gp inhibitors, Mu is the 
average and Var is the variance of log Ki in each node. It can be seen in Figure 5.5 
of the RT model that the molecular descriptor selected by C&RT algorithm for the 
first split of the data is SlogP (octanol/water partition coefficient). The tree 
indicates that compounds with lower lipophilicity than SlogP=3.179 are less potent 
inhibitors of P-gp with average log Ki of 1.90. This group of compounds (node 2) 
may be considered as non-inhibitors, although further splitting in the tree indicates 
a group of compounds with large non-polar surface area (PEOE_VSA+0 > 75.6) 
and more than three double bonds to be reasonably good inhibitors (node 37). On 
the other hand, potent inhibitors are very lipophilic (node 3) especially those having 
a Balaban topological index (balabanJ) of ≤ 0.977. This is in agreement with 
previous studies that have described LogP as an important parameter in drug 
binding to P-gp (Lu et al., 2001; Matsson et al., 2009; Wang et al., 2003). The 
significance of LogP in P-gp inhibition is due to the presence of several lipophilic 
and aromatic residues in the binding sites of P-gp (Aller et al., 2009). BalabanJ is a 
highly discriminating topological index which represents the extended connectivity 
and the shape of molecules (Thakur et al., 2004) and has been shown to be related 
to properties such as melting point and solubility (Ghafourian and Bozorgi, 2010). 
This indicates the favourable interaction of certain molecular shapes with P-gp.  
Nature of the substrate used for the measurement of IC50 and log Ki values has an 
effect on the measured inhibitory activity, as can be seen from the division of 
compounds in node 11 according to the substrate’s apparent distribution coefficient 
at pH 2 (S-LogD(2), where S indicates the parameter refers to the substrate). 
Substrates such as daunomycin and quinidine are basic in nature which will result 
in very low distribution coefficient at pH 2 (LogD(2) ≤ -1.265). According to the 
RT model in Figure 5.5, such substrates will result in higher measured IC50 and log 
Ki for the inhibitors. Compounds of high lipophilicity (SlogP > 3.179) may be 
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potent P-gp inhibitors despite the lipophilic substrates if they contain a large 
hydrophobic volume at the highest hydrophobic interaction level (vsurf_D8) and a 
large surface area of non-polar atoms (PEOE_VSA_HYD), especially if they are 
not more lipophilic than SlogP threshold 5.587 (node 51). In node 13, if the 
lipophilic volume is not larger than 83.75, then compounds with many –CH2- 
groups (which may represent less branching) can be reasonable inhibitors (average 
log Ki of 1.34). 
 
 
Figure 5.5. RT (2) developed using the training set with the descriptors selected by 
C&RT algorithm 
 
Figure 5.6 is the selected model developed by CHAID (1) method. Similar to 
C&RT method above, the hydrophobicity descriptor, SlogP, is the first (most 
important) descriptor in this CHAID (1) model. In this case compounds have been 
split into three nodes, with the most lipophilic drugs having the highest inhibition 
effect (node 4) and the least lipophilic compounds being the least potent or non-
Tree graph for Log Ki 
Num. of non-terminal nodes: 10,   Num. of terminal nodes: 11 
Model: C&RT 
 ID=1    N=176 
Mu=1.24 
Var= 0.90 
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inhibitors (node 2). The non-inhibitors in node 2 have been partitioned further to 
separate 7 compounds with an aromatic nitrogen group in the structure (SaaN_acnt) 
as the least effective inhibitors with an average log Ki of 2.78. Node 3 contains 
compound with intermediate inhibitory activity and SlogP between 2.308 and 
3.831. These compounds will be more potent if they contain a double bonding CH 
group which is seen in compounds such as cyclosporine, valspodar, bromocriptine 
and quinidine. The most hydrophobic compounds in node 4 are all considered to be 
strong to moderate inhibitors of P-gp with the log Ki in the terminal nodes ranging 
from -1.46 to 1.60. In this group, compounds containing 3-membered rings (node 
10) and non-lead-like molecules according to Oprea’s definition (Oprea, 2000) in 
node 11 are strong P-gp inhibitors. This observation regarding the higher inhibitory 
activity of non-lead-like compounds is in agreement with a recent study by Wang et 
al where lead-like compounds had lower propensity to be P-gp substrates (Wang et 
al., 2011). Among these inhibitors, those with fewer H-bond donor/ acceptor pairs 
than two (SHBint4_Acnt) are less strong inhibitors (node 13). In node 13, 
compounds containing a thioether group are exceptions with a relatively high 
average log Ki value of 1.60 (SssS_acnt). The remaining 44 compounds (node 17) 
have high inhibitory activity towards P-gp. Oprea’s Lead-like compounds in node 
12 may also have strong inhibitory activity towards P-gp if the probe substrate used 
in the inhibition study is daunomycin.  
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Figure 5.6. CHAID (1) developed using the training set  
 
Despite using P-gp/ inhibitor interaction energies from docking studies as one of 
the molecular descriptors, none of the decision tree algorithms above, C&RT and 
CHAID (1), picked docking scores as a significant parameter for partitioning of the 
log Ki data. This was explored further by using the docking scores in interactive 
tree, I-tree (3) model (Figure 5.7). In this analysis ‘Cross-validate tree sequence’ 
was used in addition to V-fold cross-validation to ensure the validity of each level 
of the tree for accurate prediction of log Ki in both training and validation sets. 
Docking score was incorporated as the first variable for partitioning of the data and 
this was found statistically significant by the cross validations. Figure 5.7 shows 
that the statistically selected threshold for docking energy is -13.44 (kcal/mol). 
Inhibitors with docking energy below this value (node 2) will be more effective if 
they contain a low ratio of hydrophilic to total surface area (vsurf_CW4 ≤ 0.539), 
particularly those with a higher distance between their local hydrophilic energy 
minima (vsurf_DW13). The tree shows that high docking energy compounds (> -
13.44 kcal/mol) are weak inhibitors unless when the probe substrate used in Ki 
measurement is hydrophilic (S-LogP ≤ 0.850).  
 
 Tree graph for Log Ki  
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Figure 5.7. I-tree (3) developed using docking energy as the first variable 
 
5.3.1.2.2. Significance of P-gp Docking Energies 
Docking is a very useful tool in computer-aided drug discovery due to the 
importance of shape-matching in drug-macromolecule interactions. It has been 
postulated that compounds with shape and chemistry similar to those of a known 
active molecule have a high probability of being active (Hawkins et al., 2007). On 
the other hand, the interaction energy can be notoriously misleading with large 
molecular weight compounds often achieving the most negative interaction 
energies, which is due to the additive nature of the energy formula (Schulz-Gasch 
and Stahl, 2004; Lipkowitz and Boyd, 2002). In our training set, the top ten 
molecules with the most negative interaction energies had an average molecular 
weight of 925 Da in comparison with 461 Da for the remaining compounds in the 
training set. On the other hand, these ten compounds had a lower average log Ki of 
0.75 in comparison with 1.28 for the remaining compounds in the training set.   
The lack of flexibility of the target protein during docking should also be taken into 
consideration when assessing docking results. Docking experiments are most 
reliable when interaction between a rigid protein target and a flexible ligand is 
investigated (Davis and Teague, 1999).  For docking results to successfully guide 
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the predictions of inhibitors and substrates of P-gp, it should take into account the 
very flexible nature of this transporter enzyme (Teague, 2003). Previous studies 
have described the importance of protein flexibility in P-gp ligand interactions (Loo 
et al., 2003; Loo et al., 2009). Induced fit mechanism explains the fact that both 
drug and protein are flexible, and can modify their shape to generate more 
favourable contacts (Alonso et al., 2006). Current evidence shows that P-gp is able 
to accommodate a wide range of substrates due to the mobile nature of its 
transmembrane helices (Loo et al., 2003; Ambudkar et al., 2003). From this 
hypothesis, it is possible that compounds in the dataset may not be correctly 
identified as substrates or inhibitors of P-gp, because the docking process does not 
allow the protein to be mobile and therefore some compounds are not recognised as 
substrates in the drug binding pocket. Moreover several different but overlapping 
binding sites have been identified for P-gp (Aller et al., 2009). In this study we used 
the binding site defined by the cyclic hexapeptide, QZ59-RRR, in the X-ray 
structure of the protein reported by Aller and co-workers. 
 
5.3.1.2.3. Ensemble Decision Trees 
Studies have shown that an ensemble of several trees may result in better prediction 
accuracy when there is a significant diversity among the models (Kuncheva and 
Whitaker, 2003). In this investigation boosted trees and random forest were used. 
Boosted trees method is an ensemble method that computes a sequence of simple 
trees, each built for the prediction of residuals of the preceding tree. Various 
combinations of subsample proportions and learning rates were examined and the 
best model was selected based on the prediction error for the test set. The best result 
was obtained with the subsample of 0.6 and learning rate of 0.05, using the 
optimum number of trees of 161. The top ten most important descriptors as 
calculated by STATISTICA software has been described in Table 5.3. The 
categorical variable indicating the nature of the substrate was the most important 
BT (3) descriptor, followed by hydrophobic volume (measured by Volsurf 
descriptor) and polarity descriptors including total polar van der Waals surface area 
and total positive and negative partial charges.  
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Random Forest is another ensemble method which develops a number of decision 
trees using a random selection of training set compounds and molecular descriptors. 
The graph of average squared error against number of trees for training and cross-
validated test sets indicated that the test error reaches a plateau at around 50-60 
trees. Therefore, the final RF model (RF (2)) containing 60 trees was used. In this 
selected model, descriptors of molecular topology of the inhibitor such as distance 
and adjacency matrix descriptors as well as lipophilicity indicators and Volsurf 
molecular interaction descriptors were ranked as the most important descriptors. 
Unlike the BT (3) model, here there was only one substrate descriptor amongst the 
top 10 and that ranked as the 10
th
 most important molecular descriptor of the model.   
 
5.3.1.2.4. MARS Model 
Many combinations of molecular descriptors picked by several pre-processing 
feature selection methods were used in MARS analysis to obtain the best possible 
model as explained in the methods section. The feature selection methods included 
Chi-square method, stepwise regression analysis, and variable importance rank 
from random forest and boosted trees analyses. Previous investigations have shown 
that predictor importance using random forest is a very successful feature selection 
method that can be applied for reducing the data dimensionality prior to C&RT 
analysis (Newby et al., 2013a). Here, the best MARS model (Mars (1)) was 
obtained when the top 15 molecular descriptors from RF model together with the 
top two substrate descriptors from BT model (S-logP and S-PSA) were given as the 
independent variables. Subsequently, as a result of the pruning function in MARS 
analysis, eight out of the 17 molecular descriptors were used in the selected model 
(summarized in Table 5.4 below). The MARS (1) model in Table 5.4 consists of 11 
basis functions with three descriptors employed in two basis functions each and 
each of the remaining five descriptors are involved in one basis functions. This 
model does not contain any interaction term. In this MARS model, molecular 
descriptors have been presented according to the rank order of their importance, 
with the most important descriptor being the first one in the equation.  
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An interesting finding from the MARS (1) model in Table 5.4 is a knot at 5.29 for 
octanol/water partition coefficient, logP(o/w); increasing the lipophilicity of the 
inhibitors leads to a reduction in log Ki values up to this point. On the other hand, 
compounds with extremely high lipophilicity (logP(o/w) > 5.29) will have an 
increased log Ki values (low potency) with increasing their lipophilicity. The 
second and the third most important descriptors of the MARS model are substrate 
properties, partition coefficient (S-logP) and polar surface area (S-PSA). Inhibitors 
will appear less effective (higher measured log Ki values) when the substrate is 
more lipophilic at S-logP values higher than 2.14. Likewise, substrates of larger 
polar surface area lead to increased log Ki values. The molecular descriptor derived 
from the adjacency matrix of the inhibitors (GCUT_SMR_3) is the next most 
important parameter of the model, which is involved in two basis functions. In this 
molecular descriptor, the diagonal of the adjacency matrix takes atomic 
contribution to molar refractivity. The basis functions indicate a positive 
relationship between log Ki and this molar refractivity indicator for compounds 
with GCUT_SMR_3 > 3.30; while the opposite (a negative relationship) is 
observed for compounds having lower molar refractivity indicator. In other words, 
compounds with high molar refractivity are better inhibitors up to a certain 
GCUT_SMR_3 threshold. In agreement with this finding, a previous study on P-gp 
substrates has also indicated a minimum required molar refractivity for the 
classification of compounds into the substrate category (Demel et al., 2009), but a 
maximum level of molar refractivity had not been specified. vsurf_D2 is a Volsurf 
molecular descriptor (Cruciani et al., 2000a), indicating the hydrophobic part of the 
molecular volume. For the minority compounds with vsurf_D2 < 493 (only 9 
compounds), the smaller hydrophobic volumes leads to lower log Ki values. 
Another molecular descriptor indicating the hydrophobic size of the molecule, 
(PEOE_VSA_HYD) has appeared in two basis functions with a knot at the 
descriptor value of 465. For compound with PEOE_VSA_HYD above this 
threshold value, there is a negative relation with log Ki (the higher the hydrophobic 
surface area the more effective the inhibitor). The similar trend, but with a much 
higher gradient, is observed for compounds with PEOE_VSA_HYD < 465. The 
second lowest hydrophilic energy (vsurf_EWmin2) (Cruciani et al., 2000a), has a 
negative effect on log Ki, i.e. compounds are less effective inhibitors if the 
minimum hydrophilic energy is lower than -8.64. This negative impact of a 
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hydrophilic interaction is only seen for the second hydrophilic region on the 
molecular surface (not for the first hydrophilic region). Finally, SMR_VSA4 is 
surface area corresponding to atoms with an atomic contribution to molar 
refractivity of 0.39-0.44; these are mainly conjugated nitrogen atoms such as those 
in amide bonds. The MARS equation indicates that presence of more such groups 
will reduce the log Ki values (better inhibitory effect).  
Table 5.4. The selected MARS (1) model  
Log Ki = -0.452 + 0.388*max(0, logP(o/w) – 5.29) + 0.255*max(0, 5.29 - 
logP(o/w)) – 0.475*max(0, 2.14 – S-LogP) + 0.00463*max(0, S-PSA – 45.6) + 
3.06*max(0, GCUT_SMR_3 – 3.30) + 0.938*max(0, 3.30 – GCUT_SMR_3) – 
0.00684*max(0, 493 – vsurf_D2) – 0.00252*max(0, PEOE_VSA_HYD – 465) + 
0.00512*max(0, 465 – PEOE_VSA_HYD) + 0.492*max(0, -8.64 – 
vsurf_EWmin2) + 0.115*max(0, 3.19 – SMR_VSA4) 
N = 176 GCV error = 0.548  Mean residual = 0.000 SD(residual) = 0.645 
 
 
5.3.1.2.5. Validation of Models 
All models were validated using an external validation set of 43 compounds. Table 
5.5 shows the error of the selected models for the prediction of log Ki values of the 
external validation set and the training set. It can be seen that the RT (2) model 
gives the most accurate prediction of log Ki followed by BT (3) and then MARS 
(1). For the training set, BT (3) calculates the most accurate log Ki values followed 
by RT (2) and then the CHAID (1) model. The difference between model accuracy 
for training and validation sets may indicate the possibility of overfitting into 
training data. In this case, amongst the top three models listed above, MARS (1) 
has the lowest difference between the training and the validation set errors, while 










5.3.2. Prediction of Biliary Excretion Using Predicted P-gp Binding 
Values 
Predicted log Ki by the six models reported in section 5.3.1 were used as 
independent variables along with the molecular descriptors for the prediction of 
biliary excretion (log BE%). These were log Ki (RT), log Ki (CHAID), log Ki (I-tree), log 
Ki (BT), log Ki (RF), and log Ki (MARS). Models for log BE% were developed using 
stepwise regression analysis, C&RT, CHAID, boosted trees, random forest and 
MARS. The results of these analyses have been summarised in Table 5.6. As it can 
be seen in this table, none of the predicted log Ki values were picked by C&RT, 
CHAID, stepwise regression analysis (eight parameters), Chi square feature section, 
MARS feature selection (based on GCV error) or the 20 most important features by 
random forest, as a significant factor in the estimation of biliary excretion of 
compounds; the exception to this was the selected BT model. As a result, the 
multiple linear regression model was the same as MLR (1) (section 4.3.1), and 
regression trees and random forest models were those reported in section 4.3 (RT 
(1) and RF (1)).  
  
Model MAE for training set MAE for validation set 
RT (2) 0.398 0.543 
CHAID (1) 0.471 0.603 
I-tree (3) 0.690 0.706 
BT (3) 0.316 0.568 
RF (2) 0.501 0.618 
MARS (1) 0.487 0.577 
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Table 5.6. Summary of model development for log BE% using molecular 
descriptors and predicted log Ki values 
 
In this study, in addition to the methods investigated in chapter 4, CHAID and 
MARS methods were also used for model development. The resulting CHAID 
model (CHAID (2) in Table 5.6) did not pick any predicted log Ki parameter. This 
CHAID model has been presented in Figure 5.8. 
Figure 5.8 shows that hydrophilic volume (vsurf_W4) is the dominant variable of 
this tree (node 1), with a binary classification. According to this model, compounds 
with large hydrophilic volumes are excreted in higher quantities through bile. Other 
descriptors of CHAID (2) show similar trend to C&RT models presented in Chapter 
4 for biliary excretion. For example, hydrophilic compounds with higher acid/base 
ionisation have higher biliary excretion (node 6), especially if they are non-lead like 
(node 12). Even compounds with small hydrophilic volumes can have considerable 
biliry excretion if they are non-lead like (node 4). The high biliary excretion of non-
lead-like compounds is in agreement with the results in section 5.3.1 that indicated 
non lead-like compounds to be suitable P-gp substrates, thereby aiding their 
excretion by the efflux system. The prediction accuracy of CHAID (2) model is 
reasonably good (see Table 5.7). The risk estimate and standard error are 0.322 for 
training set and 0.254 for the validation set.  
 
Method Predicted log Ki parameter picked Resulting Model 
Stepwise regression none MLR (1) 
C&RT none RT (1) 
RF  none RF (1) 
CHAID none CHAID (2) 
BT Log Ki (MARS), 
Log Ki (RF) 
BT (4) 
MARS  none MARS (2) 
MARS Log Ki (RF) MARS (3) 
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Figure 5.8. CHAID (2) Developed using the training set with the descriptors 
selected by CHAID algorithm 
 





As seen in Table 5.6, log Ki predicted by MARS (1) and RF (2) (log Ki (MARS) and 
log Ki (RF)) models were two of the most important features in the boosted trees 
analysis for the prediction of biliary excretion. The selected BT model (BT (4)) has 
similar prediction accuracy to the BT models without P-gp information (compare 
BT (1) and BT (2) models in Table 4.5 with BT (4) in Table 5.7). Lipophilicity 
parameters (LogD (6.5), LogD (7.4)), shape indexes (Kier2, Kier3 and Kier A3) 
Model MAE for training set MAE for validation set 
BT (4) 0.339 0.416 
CHAID (2) 0.432 0.359 
MARS (2) 0.438 0.428 
MARS (3) 0.436 0.442 
CHAID graph for log BE% 
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and Volsurf descriptors indicating hydrophilic ratio (vsurf_CW2 and vsurf_CW4) 
were amongst the top 15 descriptors of BT (4) model. The optimal number of trees 
in this graph was 156 (Figure 5.9). Statistical parameters of this boosted tree are 
reported in Table 5.7.  
 
   
Figure 5.9. Average squared error of log BE% against the number of trees in the 
boosted trees model BT (4) for the training and internal test sets 
 
MARS models were developed using a number of descriptor sets as explained in 
the methods section. The best MARS model was MARS (2) using the features 
selected by Chi square feature method (Table 5.8). The second best model was 
MARS (3) in which, in addition to Chi square feature predictors, the predicted log 
Ki values (from RF model) were also used as independent variables. According to 
MARS (2) and (3), increasing the number of sulphur atoms upto two will increase 
biliary excretion, with no further increase observed with more sulphore atoms. All 
the remaining molecular descriptors of MARS (2) are volsurf descriptors of 
hydrophilic volume and hydrogen bond donor capacity measured at different 
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energy levels. MARS (3) equation in Table 5.9 indicates that weaker P-gp binders 
(compounds with higher predicted log Ki values) will have reduced the log BE%. In 
MARS (3), in addition to the Volsurf (vsurf) variables similar to MARS (2), 
lipinski’s lead-like compounds have been indicated to have lower biliary excretion 
which is a similar pattern to that observed with P-gp binding.  
 
Table 5.8. The selected MARS (2) model (Feature selection) 
Log BE% = -3.14 + 4.99*max(0, vsurf_HB3-8.58) - 3.74*max(0, 9.12-vsurf_W2) 
+ 1.63*max(0, vsurf_W4-1.49) + 3.21*max(0, vsurf_W2-1.24) - 1.99*max(0, 2.00-
a_nS) - 1.17*max(0, vsurf_W3-8.07) + 8.547*max(0, 8.07-vsurf_W3) - 
1.14*max(0, vsurf_HB4-1.96) 
N = 168 GCV error = 0.398 Mean residual = 0.000 SD(residual) = 0.573 
 
 
Table 5.9. The selected MARS (3) model (Feature selection and RF predictor) 
Log BE% = 8.270- 1.240 (0, vsurf_HB4-2.67) + 2.867*max(0, vsurf_HB3-8.58) + 
5.52*max(0, 8.58-vsurf_HB3) - 3.98*max(0, vsurf_W2-9.12) + 6.88*max(0, 
vsurf_W4-1.49) + 3.33*max(0, vsurf_W2-1.24) - 1.59*max(0, 2.00-a_nS) - 
5.70*max(0, log Ki (RF)-1.90) - 3.66*max(0, lip_druglike-0.00) 




5.4.1. Structural Determinants of Potent P-gp Inhibitors  
Inhibitors of P-gp can be competitive inhibitors that may bind to the substrate 
binding site, or non-competitive which may bind to other distinct binding sites such 
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as the ATP-binding site. An investigation that involved docking of multispecific 
inhibitors into the ATP-binding domain of P-gp has shown that some of the less 
lipophilic inhibitors can bind to this site, which may contribute to their inhibitory 
activity (Neuhoff et al., 2000). On the other hand, the more common, lipophilic 
inhibitors do not interact with the ATP-binding domain of P-gp. Inhibitors from 
steroid and flavonoid chemotype are examples that may bind to the ATP-binding 
site (Conseil et al., 1998; Broccatelli et al., 2011). The inhibitors in the training set 
in this study did not contain any flavonoids but did contain five steroid structures, 
testosterone, progesterone, spironolactone, digoxin and cortisol. These steroids are 
also expected to bind to the substrate binding site. For example, studies for several 
sex-steroid hormones have shown that these are substrates of P-gp mediated 
transport as well as being a P-gp enzyme inducer (Kim and Benet, 2004) and 
digoxin is also a known substrate of P-gp as well as acting as an inhibitor (de 
Lannoy and Silverman, 1992).  
From the description of the models outlined above, it can be seen that lipophilicity 
is the key factor for P-gp inhibition along with the molecular topology and the size 
of the inhibitors as well as the nature of the substrate probe. In terms of the 
lipophilicity, a higher partition coefficient than what is recommended for drug-like 
molecules (based on Lipinski or Oprea’s rules) seems to improve the inhibitory 
activity towards P-gp. According to the best model (RT), the ideal lipophilicity is 
SlogP value in the range (3.179, 5.587]. A similar pattern can be observed in 
MARS model where a lipophilicity threshold of 5.29 has been indicated. Previous 
studies using classification models have found a higher lipophilicity (log P) for 
multispecific inhibitors of P-gp in comparison with non-inhibitors (Broccatelli et 
al., 2011; Matsson et al., 2009), although these studies have not specified a 
maximum lipophilicity threshold. For P-gp substrates, an even higher lipophilicity 
requirement has been reported in an investigation using a large set of proprietary 
GSK compounds, i.e. a log P > 4 for the substrate class (Gleeson, 2008).  
In addition to the partition coefficient, other lipophilicity measures, which also 
indicate the size of the lipophilic regions, are found to have an impact. A large 
hydrophobic volume (vsurf_D8) (Cruciani et al., 2000a), in the RT model and a 
large hydrophobic surface area (PEOE_VSA_HYD) in MARS and RT models 
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improve potency of the inhibitors. These two parameters are indicators of both size 
and lipophilicity. The positive impact of large molecular size and lipophilicity is in 
agreement with the known structure of P-gp and its proposed substrate binding 
pocket where the large binding site of P-gp consists of a considerable number of 
lipophilic amino acids (Song et al., 2010). The descriptor PEOE_VSA_HYD has 
also been used by Demel et al for the classification of substrates/nonsubstrates, 
which indicates compounds with PEOE_VSA_HYD > 300, log P < 7 and hydrogen 
bond acceptor groups more than seven are substrates of P-gp (Demel et al., 2009). 
Lipophilicity and molecular size have also been indicated in local QSAR models 
for individual classes of modulators/ substrates (Wang et al., 2003).  
In addition, the higher inhibitory activity of non-lead-like compounds (based on 
Oprea’s definition) in CHAID model (CHAID (1)) may also indicate the positive 
effect of high molecular size and higher lipophilicity than lead-like molecules. 
Compounds that accommodate the opera’s test are defined as compounds with 
molecular weight ≤ 460 Da, -4 ≤ Log P ≤ 4.2, Log Sw ≥ -5, number of 
rotatable bonds ≤ 10, number of  rings ≤ 4, number of hydrogen donors ≤ 5, and 
number of hydrogen acceptors ≤  9 (Oprea, 2000). According to this CHAID 
model, compounds that violate more than two of the above rules are better 
inhibitors of P-gp. A close observation of such compounds indicates higher 
lipophilicity or hydrogen bonding groups, as well as higher molecular size and 
number of rings are the reason for the violations that results in compounds being 
potent inhibitors. Examples are paclitaxel, nicardipine and vinblastine.    
Other significant molecular determinant of P-gp inhibitors is the molecular 
topology and shape as described by the adjacency and distance matrix descriptors 
such as the connectivity index BalabanJ in the RT (2), GCUT descriptors in the 
MARS model and VDistMa in the BT (3). Broccatelli and co-workers (Broccatelli 
et al., 2011) have also hypothesised that an optimal shape may exist for P-gp 
inhibitors, but the optimal shape needs to have adequate lipophilicity and H-bond 
acceptor ability. H-bond acceptor ability has also been emphasised by Demel et al 
(Demel et al., 2009) which show the importance of a high number or a large surface 
area of H-bond acceptor groups. In the models presented in this study, the effect of 
H-bond can be seen in the CHAID (1) where compounds containing more than 2 
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internal H-bonding are more effective inhibitors. MARS model also indicate the 
positive impact of presence of conjugated nitrogen groups (e.g. amides). A number 
of molecular descriptors which may indicate H-bonding effect are present in RF 
and BT models, including negative charge weighted surface area (CASA-) and 
partial charge descriptors which are indicators of H-bonding (Dearden and 
Ghafourian, 1999). It must be noted that these parameters as well as the parameters 
of Demel et al. may also relate to the molecular size as larger molecules are more 
likely to contain many H-bond groups. 
 
5.4.2. Effect of Substrate on the Ki Measured for the Inhibitors  
It has been suggested that there are several binding sites for the molecularly diverse 
spectrum of P-gp substrates, inhibitors and modulators. For example, using 
equilibrium and kinetic radioligand binding assays, Martin et al established the 
presence of at least four distinct interaction sites on P-gp which were able to 
communicate allosterically (Martin et al., 2000). Moreover, various competitive, 
cooperative allosteric and anticooperative allosteric interactions are possible 
between the substrates and the regulators (Lu et al., 2001). As a result, the 
inhibitory activity measured using different substrates will be different for the same 
inhibitor (Rautio et al., 2006). The x-ray structure of mouse P-gp with 87% 
sequence identity to human P-gp has recently been described (Aller et al., 2009). It 
was found that P-gp can distinguish between different 3D shapes, and that 
stereoisomers may bind to different binding locations. Given the complexity of the 
binding locations and modes of inhibition, it has been suggested that a single 
pharmacophore cannot effectively describe the inhibitors of various P-gp substrates, 
and therefore, for the inhibition of the transport of different P-gp substrates 
different pharmacophores have been proposed (Ekins and Erickson, 2002). The 
modelling strategy in this investigation should be able to deal with the diversity of 
the binding sites. In particular, molecular descriptors of the substrates were 
incorporated in the model development in addition to molecular descriptors of 
inhibitors. Moreover, a categorical variable was implemented in all the decision 
tree models and ensembles. Regression tree is a powerful data mining tool that is 
able to select the important features for dividing the data into high or low activity 
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groups (distinct groups of compounds with high or low average log Ki values). The 
models described above indicate the importance of substrate in the measured 
inhibitory activity as all the models contain at least one substrate descriptor selected 
by the feature selection methods.  
The average prediction error separately for the inhibitors of different substrates has 
calculated. Table 3 gives the average error of log Ki prediction for inhibitors of 
different substrates using the selected models. The table shows that in average, 
models predict the inhibitory activity of calcein substrates with the highest 
accuracy. The rank order of the average prediction error (for the external validation 
set) from the lowest to the highest is for the inhibitors of calcein, digoxin, 
vinblastine, daunomycin, irinotecan and quinidine as the probe substrates. The 
lower average error for a specific substrate’s inhibitors may be associated with the 
number of inhibitors of that substrate in the training set, an indication of which is 
the number in the validation set shown in Table 5.10.  
Table 5.10. Number of inhibitors of different substrates and MAE of log Ki 
prediction for the validation set 
Substrate n RT (2) CHAID (1) I-tree (3) RF (2) BT (3) MARS (1) 
Calcein 14 0.388 0.556 0.609 0.356 0.380 0.300 
Daunomycin 4 0.668 0.658 0.869 0.850 0.735 0.735 
Digoxin 18 0.574 0.985 0.754 0.601 0.634 0.611 
Irinotecan 2 1.005 0.726 1.223 1.365 1.418 1.517 
Quinidine 1 1.270 0.033 1.809 1.771 1.249 2.582 
Vinblastine 5 0.668 0.934 0.866 0.696 0.435 0.559 
 
 
5.4.3. Effect of P-gp Binding on Biliary Excretion Models 
It can be seen from the results that the use of predicted P-gp binding values did not 
lead to improved models for biliary excretion, and Log Ki was selected only by the 
BT (4) and MARS (3) models. However, similarities can be observed between 
molecular determinants of P-gp binding and biliary excretion. For example, Oprea’s 
lead-like compounds have lower P-gp binding (as seen in CHAID (1) in Figure 5.6) 
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as well as having lower biliary excretion (CHAID (2) in Figure 5.8). Also, 
Lipinski’s drug like compounds with a similar definition to Oprea’s rule show 
lower biliary excretion according to and MARS (3) in Table 5.9. This may relate to 
larger MWs observed for both the prominent substrates of P-gp and cholephilic 
compounds. However, there are also differences in structural requirements for these 
two biological properties. Lipophilicity is a major contributor to P-gp binding 
(Gleeson, 2008), which requires even higher log P than drug-like molecules as seen 
from MARS (1), CHAID (1) and RT (2) models in section 5.3.1. The effect of 
lipophilicity on biliary excretion is different with large hydrophilic molecules being 
more prone to biliary excretion as lipophilic compounds go through metabolism 
instead (Sharifi and Ghafourian, 2014). This result should not be considered as 
contradictory, as metabolism and biliary excretion are simultaneous processes in 
hepatocytes and the overall effect is determined by the kinetics. It may be 
speculated that large lipophilic compounds would be able to be excreted through 
bile if their metabolism was limited/ slowed down.  
In analysing the effect of P-gp binding on the observed in vivo biliary excretion 
levels of compounds one should also consider the fact that P-gp binding data has 
been obtained from in vitro experimentations using different cell cultures. This 
model may not realistically represent the in vivo situation with healthy hepatocytes 
in their natural liver environments. Moreover, P-gp is only one of the several efflux 
pumps that operate in hepatocytes.  
One possible reason for the ‘predicted P-gp binding’ not being selected by several 
feature selection methods could be the poor prediction of P-gp binding for the 
external (biliary excretion) dataset. Although the prediction accuracy for the 
external validation set in P-gp binding QSARs have been tested to be satisfactory 
(Table 5.5), the accuracy of prediction of P-gp binding for biliary excretion cannot 
be assessed as the experimental values are not available for this dataset. The poor 
prediction accuracy may happen if the diversity of compounds is different between 
the two datasets, which may result in the biliary excretion dataset to fall outside the 
applicability domain of P-gp models. According to Netzeva et al (2005) an 
applicability domain need to be defined for QSAR models when using for external 
predictions. In order to investigate this, principle component analysis (PCA) was 
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performed using all the molecular descriptors. Figure 5.10 show the scores plot of 
PC1 against PC2. It can be seen in the figure that despite a very good overlap, there 
are many compounds in BE dataset on the left hand side of the figure which are 
outside the range of, and further away from, the P-gp dataset. 
 
  
Figure 5.10. Scores plot indicating biliary excretion dataset (BE) and the P-gp 
binding dataset (P-gp) 
 
5.5. Conclusion 
In order to develop accurate models for the P-gp inhibition, this study used Ki 
values of large set of P-gp inhibitors calculated from the reported IC50 and the 
probe substrate’s Km and concentration values from the literature using Cheng and 
Prusoff’s equation. In comparison with IC50, this parameter allows a better 
comparison between inhibitory activities measured using different probe substrates 
and substrate concentrations. In addition to the molecular descriptors of the 


















Principle Component Analysis Score Plot 
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for the probe substrate as the nature of the substrate used in the experiment may 
affect the inhibitory activity of the inhibitor. 
The study resulted in a few predictive models based on the accuracy of the 
prediction for the external validation set. The results indicated that substrate 
parameters were important for the prediction of the inhibitory activity as all feature 
selection procedures selected at least one substrate molecular descriptor in addition 
to the molecular descriptors of the inhibitors. This study also showed that docking 
scores are not good predictors of inhibitory activity. When used as a molecular 
descriptor, docking scores were not selected by any of the feature selection methods 
described here. When docking scores were incorporated manually in C&RT 
analysis, the resulting regression tree had a high error for the prediction of the 
validation set. The most significant models indicated a higher lipophilicity of the 
potent inhibitors than lead-like compounds. The potent inhibitors contained a high 
molecular weight, a high number/surface area/volume of hydrophobic groups and 
conjugated nitrogen groups (e.g. amides). 
The best model was a regression tree that was obtained using C&RT analysis. A 
boosted trees model was the second best followed by a MARS equation. Both the 
regression tree and the MARS model are simple and interpretable and the statistical 
parameters indicate that they have a lower chance of overfitting in comparison to 
the boosted trees model. 
When the P-gp models were used for the prediction of P-gp binding for the 
compounds in the biliary excretion dataset, the predicted log Ki values were not 
picked by several feature selection methods, or when picked (boosted trees and 
MARS methods), the accuracy of the resulting biliary excretion models were not 
improved (compare BT (4) with BT (1) and BT (2) or MARS (2) with MARS (3)). 
This may be attributed to a number of factors including: 1) P-gp is only one of the 
several efflux pumps operating in hepatocytes, and 2) the poor similarity between 
the diversity of compounds in the dataset used for P-gp binding models and the 
biliary excretion dataset may have led to poor prediction of Ki values for 
compounds in biliary excretion dataset.  
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6. Inhibitory Effect of OATPs in Biliary Excretion 
 
6.1. Introduction 
Several members of the organic anion transporting polypeptide (OATP) family 
have been shown to be specifically expressed in the liver and facilitate the liver 
uptake of their substrate drugs. Mechanistic studies suggest an important role for 
OATP family in the uptake of compounds from blood to hepatocyte, across the 
basolateral (sinusoidal) membrane (Yamazaki et al., 1996). After transporting the 
compounds into hepatocytes, these compounds are either metabolised or secreted 
into the bile using ATP-depandent transporter proteins such as P-gp and MRP2 
(Ayrton and Morgan, 2001). In fact, uptake by OATP transporters has often been 
regarded as the single most important uptake mechanism involved in biliary 
excretion (Fenner et al., 2012; Varma et al., 2012). For example, studies on lipid-
lowering drugs have shown that inhibition of OATP1B1 hepatic uptake can 
considerably increase statin concentration in blood after administration of 
cyclosporine, a potent inhibitor of various OATPs (Shitara et al., 2003; Ho et al., 
2006), and similar results have been obtained later by Neuvonen and co-workers for 
other statins (Neuvonen el al., 2006).  
Through their role in biliary excretion, OATPs also contribute to drug-drug 
interaction events (Koenen et al., 2011). As mentioned above, cyclosporin is a 
potent inhibitor of OATPs (in particular OATP2B1 and OATP1B1) and it is, at the 
same time, a substrate of CYP3A4, thereby functioning as a competitive inhibitor 
resulting in increased exposure of other CYP3A4 substrates (Wacher et al., 1998). 
In addition, this compound interacts with P-gp (Foxwell et al., 1989) and MRP2 
(Tang et al., 2002a). These efflux pumps are expressed in the canalicular membrane 
of hepatocytes. As a result of all these enzyme and transporter interactions, this 
drug has an impact on the biliary elimination of substrate compounds.  Due to the 
importance of transporters in drug-drug interactions, recently, in drug evaluation 
process, the identification and kinetic characterization of OATP ligands early on 
has become important for successful drug development (De Bruyn et al., 2013). 
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Unfortunately, studies on OATP are limited due to the lack of very specific 
inhibitor/substrates for this family of transporters. For example, in sinusoidal 
hepatocyte membrane, apart from OATP1B1 and OATP1B3 which are expressed 
abundantly, OATP1A2 is also localized in a smaller quantity. All of these three 
transporters are able to uptake pitavastatin in human hepatocyte. To elucidate which 
OATP is actually responsible for the pitavastatin uptake, Hirano and colleges 
investigated the relative contribution of OATP1B1 to the hepatic uptake of 
pitavastatin. This was done by inhibition of hepatic uptake of pitavastatin by using 
estradiol-17β-D-glucuronide as an OATP1B1/OATP1B3 inhibitor and estrone-3-
sulphate as an OATP1B1/OATP2B1 inhibitor, and comparing their results. The 
study supported the idea that OATP1B1 is the predominant transporter for the 
hepatic uptake of pitavastatin (Hirano et al., 2006).  
The lack of an X-ray crystal structure is a further limitation with OATP research in 
the design of the specific modulators. For example, ligand-enzyme docking requires 
an accurate high-resolution structure of the protein (Rognan, 2013). In a recent 
investigation, a high-throughput in vitro transporter inhibition assay was reported 
for the OATP1B subfamily (De Bruyn et al., 2013). This approach was able to 
identify 212 and 139 molecules as inhibitors of OATP1B1 and OATP1B3.  
Many OATPs share common substrates. OATP substrates are relatively large from 
334 Da in benzylpenicillin to 1143 Da in cholecystokinin octapeptide, in terms of 
the currently known substrates. Structural templates of many OATP substrates are 
steroidal or peptidic (You and Morris 2007). The substrate specificity of OATP1B1 
is similar to OATP1B3 and both transport a varied range of compounds including 
bile acids, conjugates of sulphate and glucuronate, steroid conjugates, thyroid 
hormones, peptides and amphiphilic organic drugs (Glaeser and Kim, 2006; 
Leuthold et al., 2009; Hagenbuch and Meier, 2003; Tirona et al., 2001; Hsiang et, 
1999; Konig et al., 2000a). Many solutes transported by OATPs are negatively 
charged, however there are several examples of neutral (e.g. digoxin) and cationic 
(e.g. N-methylquinidine) substrates. Several OATP substrates are promiscuous but 
there are also some selective substrates. For example, the cholecystokinin 






The aim of this investigation was to incorporate information from OATP binding in 
order to improve accuracy of the predicted biliary excretion. This work was carried 
in two stages: 1) developing the predictive models for OATP inhibition; and 2) 
using the models for the prediction of OATP effect for the compounds in biliary 
excretion dataset. OATP models consisted of both regression type (continuous) 
models and classification type models. Unfortunately, there is a lack of sufficient 
quantitative data on OATP substrates and non substrates (especially for OATP1B3 
and OATP2B1). In a recent study, Varma et al (2012) compared the chemical space 
of a list of OATP substrates with that of cholephilic compounds. This study suffers 
from a lack of non-substrate compounds that limits any quantitative conclusion. 
Karlgren and co-workers (2012a) have recently published a relatively large dataset 
of OATP inhibition effect measured using high-throughput methods. The measured 
values are percentage inhibition of a probe substrate’s uptake by a large set of 
compounds. It is noted that a single-point inhibition measure (percentage 
inhibition) that uses only one inhibitor concentration is not as reliable as IC50 for 
measuring the inhibition activity. Moreover, direct kinetics measures for the 
substrates would have been the ideal parameter for this investigation. Despite this, 
considering that most enzyme inhibitors are usually also the substrates of the same 
enzyme (competitive inhibition), this percentage inhibition dataset was used in this 
investigation. The single point inhibition assays have proven useful in the past for 
fast screening of compound activity and selectivity. An example is comparable 
accuracy of models based on single point CYP inhibition measures, with those built 




The dataset of 225 compounds collated, or experimentally determined, by Karlgren 
and co-workers (2012a) were used in this study. The OATP subfamilies, 
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OATP1B1, OATP1B3 and OATP2B1 were included in the dataset.  A total of 142 
compounds in this dataset was from an earlier investigation (Karlgren et al 2012b), 
which was then expanded to include compounds known to interact with OATPs or 
CYP enzymes (Karlgren et al., 2012a). The compounds were from the chemical 
space of oral drugs (Karlgren et al., 2012a). Data consisted of percentage OATP 
inhibition by the compounds.  
The experimental measurements were performed using the human embryotic 
kidney 293 (HEK293) cells stably transfected with OATP1B1, OATP1B3 or 
OATP2B1. In the screening experiments to measure interaction of the 225 
compounds with each individual OATP, a concentration of 20 µM of the 
compounds was used. The substrates used in the inhibition studies were estradiol-
17β-glucuronide for OATP1B1 and OATP1B3, and estrone-3-sulfate for 
OATP2B1. The substrate concentration was 0.52 µM in the inhibition of OATP1B1 
mediated estradiol-17β-glucuronide uptake. In the inhibition of OATP1B3 
mediated estradiol-17β-glucuronide uptake, the substrate concentration was 
1.04 µM and in the inhibition of OATP2B1 mediated estrone-3-sulfate uptake, the 
substrate concentration was 1.02 µM. 
The PCA of the dataset indicates that compounds are well distributed in the oral 
drug space with 95% confidence interval. The dataset included 43% neutral 
compounds, 29% negatively charged, 22% positively charged and 6% zwitterionic 
compounds at pH 7.4 (Karlgren et al., 2012a).  
For development of QSAR models for OATP interaction, both classification and 
prediction (regression based) methods were used. The continuous (numerical) 
percentage inhibition data were used for regression based analyses. For 
classification methods, compounds were considered as inhibitors if they 
significantly decreased the uptake of the substrate by at least 50%. In this case, 78 
compounds (out of 225 compounds) were OATP1B1 inhibitors, while 46 and 45 
compounds (out of 225) were OATP1B3 and OATP2B1 inhibitors, respectively. In 
the dataset, a few compounds stimulated OATP mediated transporter (instead of 
inhibition). Clotrimazole, fendiline, progesterone and testosterone are the example 
of stimulators (Karlgren et al., 2012a). In this investigation all such compounds 
were considered as non-inhibitors in classification studies. 
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A total of 387 2D and 3D molecular descriptors were calculated for OATP dataset 
using the same methods and software as explained in Chapter 4. 
 
6.2.2. QSAR Model Development and Validation 
6.2.2.1. OATP Models 
Both regression-based and classification models were developed for OATP 
interaction. The regression based models were linear and non-linear methods of 
stepwise regression analysis, C&RT, BT, RF and MARS. The classification method 
was C&RT. All statistical analyses were performed using STATISTICA Data 
Miner v11 (StatSoft Ltd.). 
The compounds were divided into external validation set and training data. Models 
were developed using training set compounds and assessed using external 
validation sets. To divide the compounds, they were ordered according to their 
inhibition percentage and from every set of five compounds, four were allocated 
into the training and one into the external validation set by random. In this way, 
training data consisted of 180 compounds and external validation set consisted of 
45 compounds. For the analytical methods that required parameter optimization, a 
fraction of training set compounds were randomly assigned into internal validation 
set, or alternatively cross validation was used if the option was available in the 
statistical software. For the internal validation set, where applicable, the risk 
estimate and standard error were calculated in STATISTICA software and used as 
the performance indicators.  
In OATP modelling using boosted trees, the default values for learning rate, the 
number of additive terms (number of trees), random test data proportion (fraction of 
data points in testing pool) and subsample proportion were 0.1, 200, 0.2 and 0.5, 
respectively. In addition to the default values, various subsample proportions of 0.4, 
0.45, 0.50, 0.55 and 0.60 were examined in combination with the learning rates of 
0.1 and 0.05. The best OATP models were selected based on the performance 
indicators for the internal validation set.  
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6.2.2.2 Biliary Excretion Models 
QSAR models were developed for biliary excretion using the dataset and methods 
explained in Chapter 4. In addition to the molecular descriptors, the OATP effects 
predicted by the selected models from section 6.2.2.1 were used as the independent 
variables of the analyses. To this end, the selected OATP models from section 
6.2.2.1 were used to predict OATP interaction (percentage inhibition values or 
inhibitor/non-inhibitor classes) for the compounds in biliary excretion dataset (n = 
217). In addition to C&RT method, interactive C&RT was used in which the 
predicted OATP effects were manually incorporated in the models, when they were 
not picked by C&RT feature selection automatically. 
 
6.3. Results 
It has been cited in the literature that presence of OATPs in the hepatocytes may 
indicate their significance in biliary excretion process (Matsushima et al., 2005; 
Pfeifer et al., 2014; Shitara et al., 2013). Binding of 225 compounds to three major 
sub-family members of hepatic organic anion transporting polypeptides (OATP 
transporters) were available for this analysis. These sub-families were OATP1B1, 
OATP1B3 and OATP2B1. The ratios of inhibitors to non-inhibitors were different 
for each of these three proteins, as can be seen in Table 6.1. A total of 387 
molecular descriptors were used for the QSAR model development for the training 
set consisting 180 compounds. The method of data allocation into training and test 
sets outlined in the methods section ensured that these sets contained similar ranges 
of percentage inhibition values. The lipophilicity (LogP by ACD software) was 
between -4.73 and 8.51 for the training set, and -3.26 and 7.28 for the validation set 
with similar mean values of 2.43 and 2.58 respectively. Molecular weights of the 
compounds were between 129-1214 Da for the training set and 94-1202 Da for the 




Table 6.1. Number of inhibitor/non-inhibitor compounds based in 50% inhibition 
for each OATP sub-family members 
Transporter Inhibitor Non-inhibitor Total 
OATP1B1 78 147 225 
OATP1B3 46 179 225 
OATP2B1 45 180 225 
 
Several QSAR models were developed for each sub-family of OATP transporter 
using the training set compounds. Based on the prediction error for the validation 
sets, two QSAR models were selected for the prediction of binding to each OATP 
for the biliary excretion dataset. Section 6.3.1 gives a brief description of the 
regression based models, while section 6.3.2 gives description of classification 
models for OATP interaction. The results of using the predicted OATP effects as 
the independent variables (descriptors) of biliary excretion models have been 
presented in section 6.3.3. 
 
6.3.1. Regression Models for Binding to OATP Transporters 
Percentage inhibition of OATP transport of a probe substrate by compounds were 
analysed in this study to develop QSAR models. Distribution of the inhibition data 
showed normal distributions with ‘Skewness’ values of 0.163, 0.328 and -3.03; 
logarithmic transformation of this data led to more skewed data distribution. As a 
result, QSAR models were developed with percentage inhibition as the dependents 
variable (non-logarithmic scale). Several QSAR models were developed for each 
sub-family members of OATP including multiple linear regression analysis, C&RT, 
boosted trees, random forest, MARS and support vector machine analysis. Two best 
models for each OATP sub-family based on the lowest error rate in the validation 





6.3.1.1 Selected OATP1B1 Models 
Random Forest  
A random Forest model was the best model for the estimation of OATP1B1 
percentage inhibition values of the external validation set. The selected best RF 
model was achieved using the number of trees set at 100, a subsample proportion of 
0.50, and the random test data proportion of 0.3. Figure 6.1 shows the error 
reducing as the number of trees increases, and reaching a clear plateau by 100 trees. 
Prediction accuracy of this model has been presented in Table 6.2 and 6.3. Mean 
absolute error value for the training and validation sets are ~18 and ~21 
respectively. It must be noted here that the errors correspond to the percentage 
inhibition values in non-logarithmic scale which explains the higher order of the 
observed error.   
The most important descriptor (based on predictor importance in STATISTICA) for 
this model is VAdjMA, which is a bond count descriptor and defines the number of 
heavy-heavy bonds in the molecule. The other molecular descriptors, in the top ten 
important molecular descriptor list, were Chi1, the molecular connectivity index, 
b_heavy, number of bonds between heavy atoms, SMR_VSA3, the surface area 
corresponding to atoms with (0.35, 0.39] atomic contribution to molar refractivity, 
VSA, the total van der Waals surface area, Kier1, molecular shape index, logP 
calculated by ACD software, and the maximum positive hydrogen atom-level E-
state value in a molecule (Hmaxpos).   
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Figure 6.1. OATP1B1-RF model. Average squared error of OATP1B1 against the 
number of trees in the random forest model (RF) for the training and internal test 
set 




Model Group Risk Estimate Standard 
Error 
OATP1B1 OATP1B1-RF Train 525 61.1 
Validation 737 135 
 OATP1B1-RT Train 512 58.1 
Validation 690 141 
OATP1B3 OATP1B3-BT Train 487 61.7 
Validation 775 212 
OATP1B3-RF Train 473 104 
Validation 704 165 
OATP2B1 OATP2B1-BT Train 1959 729 
Validation 1068 239 
OATP2B1-RF Train 1693 698 
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Table 6.3. Summary of the prediction accuracy of the selected QSAR models for 
the training and external validation sets  
 
 Regression Tree (RT) 
The second best QSAR model for OATP1B1 inhibition was a regression tree from 
C&RT analysis. RT was generated using all molecular descriptors while cross-
validation was applied with default V-value of 10 and using interactive C&RT 
routine STATISTICA. This RT has only one split based on Chi1_C, the carbon 
valence connectivity index (a topological descriptor). According to this tree, 
compounds with Chi1_C > 9.698 can bind more strongly to OATP1B1 with an 
average percentage inhibition of ~68% (node 3). This RT has been presented in 
Figure 6.2. Table 6.3 shows that despite the very simple nature of this regression 
tree, the prediction accuracy for the external validation set is similar to the RF 
model explained earlier.  
OATP 
subfamily 
Selected Model MAE for training 
set 
MAE for validation 
set 
OATP1B1 OATP1B1-RF 17.6 21.0 
OATP1B1-RT 20.6 21.0 
OATP1B3 OATP1B3-RF 15.8 20.1 
OATP1B3-BT 16.6 20.3 
OATP2B1 OATP2B1-RF 24.3 24.9 
OATP2B1-BT 27.3 25.2 
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Figure 6.2. The selected RT model for OATP1B1 inhibition developed using 
C&RT analysis. 
 
6.3.1.2 Selected OATP1B3 Models 
Random Forest 
The best model for the prediction of OATP1B3 inhibition for the external 
validation set was achieved using random forest analysis when with a subsample 
proportion of 0.60 was used and the other statistical parameters were set to default 
including random test data proportion of 0.3 and the number of trees of 100 (Figure 
6.3).  
The most important molecular descriptor of the RF model for OATP1B3 is 
VAdjEq, which is a bond count descriptor and defines the number of heavy-heavy 
bonds in the molecule. Other most important descriptors of the model are the 
number of single bonds (b_single), volsurf descriptors indicating hydrogen bonding 
donor capacity, molecular wrinkled surface and molecular volume (vsurf_HB6, 
vsurf_R and vsurf_V) and molar refractivity (SMR).  
Tree graph for OATP1B1 











<= 9.698 > 9.698 
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Figure 6.3. Average squared error of prediction of OATP1B3 inhibition against the 
number of trees in the selected RF model. 
 
Boosted Trees 
Boosted trees analysis using various combinations of model parameters resulted in 
the second best model for the prediction of the OATP1B3 percentage inhibition of 
the external validation set. In this BT model, the optimal number of trees was 54, 
with the learning rate of 0.05 and subsample proportions 0.55. Tables 6.2 and 6.3 
give a summary of the statistical parameters for the OATP1B3 models. The graph 
of average squared error against number of trees for training and cross-validated 
test sets has been presented in Figure 6.4.  
The top ranked most significant molecular descriptors of this model in descending 
order of significance are LogD(10), the apparent partition coefficient at pH 10, FiA, 
fraction of compound that is ionised as an acid at pH 7.4, SaaCH, atom-type 
electrotopological index for aromatic CH groups, SaaCH_acnt, the number of 
aromatic CH groups, the volsurf descriptors, vsurf_IW4 and vsurf_IW5 (indicating 
hydrophilic integy moments at different levels from -0.2 to 1.6 Kcal/mol), 
Summary of Random Forest
Response: OATP1B3
Number of trees: 100; Maximum tree size: 100
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vsurf_W5 (hydrophilic volume) and SHBint4, internal hydrogen bonding index 
separated by four skeletal bonds. 
        
Figure 6.4. Average squared error against the number of trees in the selected BT 
model for OATP1B3 inhibition. 
 
6.3.1.3 Selected OATP2B1 Models 
Random Forest 
A Random forest model was the best model for the prediction of OATP2B1 binding 
of the external validation set compounds. The prediction error for the training and 
internal test sets as a function of the number of trees has been presented in Figure 
6.5. This model was obtained with a subsample proportion of 0.55 and the default 
parameters of the software. Hmaxpos (the maximum positive hydrogen atom-level 
E-state value in a molecule) is the most significant molecular descriptor of this 
selected RF model for OATP2B1. Two BCUT descriptors with atomic 
contributions to molar refractivity (BCUT_SMR_3) and lipophilicity 
(BCUT_SLOGP_3), as well as total polar van der Waals surface area 
(Q_VSA_POL) and fractional negative van der Waals surface area 
(Q_VSA_FNEG) were the other most important variables of this model. 
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Figure 6.5. Average squared error for the training and internal test sets against the 
number of trees in the selected RF model for OATP2B1 inhibition.  
 
Boosted Trees 
The second best QSAR for the prediction of OATP2B1 binding for the external 
validation set was obtained using BT analysis when the maximum numbers of trees 
was 200, with the learning rate of 0.05 and subsample proportions of 0.45 
respectively. In the selected BT model the optimum number of trees for predicting 
OATP2B1 binding of the internal test set was only two (Figure 6.6). Tables 6.2 and 
6.3 give a summary of the statistical parameters for the OATP2B1 models.  
The most important descriptors using boosted trees analysis were a_ICM, the 
entropy of the element distribution in the molecule, ratio of carbon atoms in the 
molecule (C ratio), atom type electrotopological state indexes for various types of 
carbon atoms (SssssC, SsssCH and SdssC), and the maximum hydrogen atom-level 
E-state value in a molecule (Hmaxpos and Hmax). 
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Figure 6.6. Average squared error for the training and internal test sets against the 
number of trees in the selected BT model for OATP2B1 inhibition.   
 
6.3.2. Classification Models for Binding to OATPs 
Due to lower accuracy of percentage inhibition data in comparison with more ideal 
Ki or IC50 data, in addition to prediction (regression) type QSAR models, 
classification models were also investigated. Classification using C&RT analysis 
was carried for the dataset of OATP sub-family members. Initially all 387 
molecular descriptors were set as independent variables and inhibitor or non-
inhibitor class (based on a 50% inhibition threshold) was set as dependent 
categorical variable.  In this way, the classification tree selects the most significant 
descriptors from the 387 descriptor pool for each split. Figures 6.7, 6.8 and 6.9 
show the classification trees for OATP1B1, OATP1B3 and OATP2B1, 
respectively. Table 6.4 shows the predictive performance measures of the 
classification trees for OATP models. Sensitivity (SE) shows the percentage of 
inhibitors predicted correctly and specificity (SP) indicates the percentage of non-
inhibitors predicted correctly. Recall that SE, SP and SP × SE should be 
maximized. 
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Figure 6.7 shows the classification tree for OATP1B1 binding (CT (1)). Similar to 
the RT model for OATP1B1 (Figure 6.2), the descriptor chi1_C is the first split 
variable of CT (1). The cut-off point for the inhibitor class is Chi1_C  > 9.68, which 
is also similar to OATP1B1 RT model. Larger molecules containing many carbon 
atoms are classed as inhibitors with very few exceptions. An example of exceptions 
is the compounds with a very low ratio of hydrophilic to lipophilic regions 
(vsurf_HL1 ≤ 0.05). Compounds classed as non-inhibitor compounds in node 2 are 
further divided to allow compounds classed as inhibitors if they are very lipophilic 
(LogD(2) > 4.06), or if they contain an acidic group (partially charged hydrogen 
atom) (Hmin > 1.39), or if they have a large total negative van der Waals surface 
area (PEOE_VSA_NEG  >  204.43).  
 
Figure 6.7. CT (1) graph for the best model selecting all descriptors for OATP1B1 
50% inhibition  
The classification tree for OATP1B3 (CT (2)) is presented in Figure 6.8. The most 
important molecular property for OATP1B3 inhibitors is a high ratio of rotatable 
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(single) bonds to total number of bonds in the molecule (b_rotR > 0.3). These 
flexible molecules need to have a relatively small fraction of polar (to total) surface 
area to be classed as OATP1B3 inhibitors (Q_VSA_FPOL ≤ 0.36). On the other 
hand, more rigid molecules can be inhibitors if they have a large total negative 
polar surface area (Q_VSA_PNEG > 175.05) or a large BCUT_SMR_1 or 
otherwise, for compounds with large difference between positively charged and 
negatively charged surface area (DASA), a low BCUT_SMR_2 (≤ 0.067) as well as 
a low BCUT_SLOGP_1 (≤ -0.47), whereas for compounds with small difference 
between positively charged and negatively charged surface area, they need a  large 
contact distance between the hydrophilic interaction centres of the molecule 
(vsurf_DW13).  
 
Figure 6.8. CT (2) graph for the best model selecting all descriptors for OATP1B3 
50% inhibition  
Figure 6.9 shows the classification tree for OATP2B1 (CT (3) model). The first 
split variable here is vsurf_W1, indicating more hydrophilic drugs (vsurf_W1 > 
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1412.81) to be inhibitors of this transporter especially if they have a low total 
positive partial charge calculated by PEOE method (PEOE_PC+ ≤ 4.52), but higher 
than 4.04 total partial positive charge calculated by AM1 semiempirical method. 
Less lipophilic compounds will need a GCUT_SLOGP_0 value higher than -0.79 
(node 15) to be classed as OATP2B1 inhibitor.  
 
                            
Figure 6.9. CT (3) graph for the best model selecting all descriptors for OATP2B1 
50% inhibition  
Table 6.4 shows that sensitivity and specificity values are generally good especially 
for the classification model for OATP1B1 inhibition (CT (1)). All models show 
better statistics for the training set than for the validation set. The specificity of CT 
(2) is particularly low for the external validation set. This means that CT (2) cannot 
classify the non-inhibitors of OATP1B3 accurately, whereas it can predict the 
inhibitors reasonably well. 
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Table 6.4. Results of classification analysis using C&RT routines for OATP1B1, 
OATP1B3 and OATP2B1 
OATP subfamily Model Set SP × SE SE SP 
OATP1B1 CT (1) Train 0.938 0.989 0.949 
Validation 0.593 0.806 0.736 
OATP1B3 CT (2) Train 0.753 0.942 0.800 
Validation 0.300 0.828 0.363 
OATP2B1 CT (3) Train 0.622 0.882 0.705 
Validation 0.447 0.773 0.578 
 
6.3.3. QSAR Models for Biliary Excretion Using OATP Effects 
The selected regression based models from section 6.3.1 were used for the 
prediction of percentage OATP inhibition by compounds in the biliary excretion 
dataset. The predicted OATP binding parameters included percentage OATP1B1 
inhibition by RF and RT methods (OATP1B1-RF and OATP1B1-RT), percentage 
OATP1B3 inhibition by RF and BT methods (OATP1B3-RF and OATP1B3-BT) 
and percentage OATP2B1 inhibition by RF and BT methods (OATP2B1-RF and 
OATP2B1-BT). These parameters were used as numerical variables in the QSAR 
model development for biliary excretion of compounds. Moreover, the 
classification trees from section 6.3.2, CT (1) – CT (3), were used for the prediction 
of OATP inhibitor/non-inhibitor classes of the compounds in biliary excretion 
dataset. The predicted classes were used as categorical variable in the QSAR model 
development using biliary excretion dataset. 
 
6.3.3.1. Regression Tree Models Using Predicted OATP Effects 
C&RT analysis was used for the development of a regression tree where log BE% 
was the dependent continuous variable and the predicted OATP effects along with 
the molecular descriptors were the independent variables (predictors of the model). 
The resulting RT (3) model for the training set is presented in Figure 6.10. The 
molecular descriptors employed in the trees have been explained in Table 6.5.  
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It can be seen in Figure 6.10 that one of the predicted OATP effects, percentage 
inhibition of OATP1B3 predicted by RF model (OATP1B3-RF), has been selected 
by the tree. According to this model, and in agreement with the QSARs discussed 
earlier (MLR (1), MARS (2) and MARS (3)) for biliary excretion, compounds with 
large H-bond donor capacity (vsurf_HB3) have higher biliary excretion. The biliary 
excretion rises further if compounds have high acid/base dissociation (fU ≤ 0.001) 
as seen with previous models such as RT (1) (Figure 4.3). On the other hand, 
compounds with lower H-bond donor capacity and small negatively charged 
surface area (Q_VSA_NEG ≤ 195.42) are mainly non-inhibitors of OATP1B3 (45 
out of 49 compounds node 4) with a low biliary excretion level. Few compounds in 
node 7 which have been predicted by RF method to be OATP1B3 inhibitors have a 
very low log BE% (node 7). It must be noted that this result is contradictory to the 
expectations that compounds with OATP1B3 binding should have more 
predisposition for biliary excretion. Tables 6.6 and 6.7 provide the statistical 
parameters of this regression tree, along with all the other models. 
 
Figure 6.10. RT (3) developed using the training set with the descriptors selected by 
C&RT 
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Table 6.5. A brief description of the most important molecular descriptors selected 
and used by the models. 
Descriptor Model Description 
a_count RF (3) Number of atom. 
ASA- 
RF (3) Water accessible surface area of all atoms with 
negative partial charge (strictly less than 0). 
balabanJ 
CT (2) Balaban averaged distance sum connectivity index 
(Balaban, 1982). 
b_1rotN 
RF (3) Number of rotatable single bonds (Conjugated 
single bonds are not included (e.g. ester and peptide 
bonds)). 
b_rotR 
CT (2) Fraction of rotatable single bonds (b_rotN divided 
by number of bonds between heavy atoms). 
b_single RF (3) Number of single bonds. 
BCUT_PEOE_2 
BT (5),        
I-Tree (9) 
The BCUT descriptor (see Table 4.2) using PEOE 
atomic partial charges. 
BCUT_SLOGP_1 
CT (2) The BCUT descriptor using atomic contribution to 
logP instead of partial charge. 
BCUT_SMR_1 
CT (2) This BCUT descriptor using atomic contribution to 
molar refractivity. 
BCUT_SMR_2 
CT (2) This descriptor using atomic contribution to molar 
refractivity. 
chi1v RF (3) Atomic valence connectivity index. 
chi1_C CT (1) Carbon connectivity index. 
DASA 
CT (2) Absolute value of the difference between ASA+ and 
ASA-. 
dens 
BT (5) Mass density: molecular weight divided by van der 
Waals volume as calculated in the vol descriptor. 
density 





CT (1) The fractions of compounds ionised at pH 7.4 as 
base. 
fU 
RT (3),        
I-Tree (4),     
I-Tree (5),    
I-Tree (6),    
I-Tree (9) 
Fractions of compounds unionised at pH 7.4. 
GCUT_PEOE_0 
I-Tree (4) The GCUT descriptors (see Table 4.2) using PEOE 
atomic charge.  
GCUT_PEOE_2 




CT (3) The GCUT descriptors using the atomic 
contribution to logP. 
GCUT_SLOGP_3 I-Tree (7) See GCUT_SLOGP_0 
glob 
I-Tree (9) Molecular globularity. Globularity or inverse 
condition number is the smallest eigenvalue divided 
by the largest eigenvalue of the covariance matrix of 
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Descriptor Model Description 
atomic coordinates. A value of 1 indicates a perfect 
sphere while a value of 0 indicates a two- or one-
dimensional object. 
Hmax 
BT (5) Maximum hydrogen E-State atom-level value in a 
molecule. 
Hmaxpos 
BT (5) The maximum positive hydrogen atom-level E-state 




Minimum hydrogen E-State atom-level value in a 
molecule. 




 (Hall et 
al., 2007). 
KierA2 





 where s = n + a 
KierFlex 
I-Tree (6) Kier molecular flexibility index: (KierA1) (KierA2) 
/ n (Hall et al., 2007). 
LogD(10) 
BT (5) Logarithm of distribution coefficient D of a 
compound between octanol and buffer layers at pH 
value 10. 
LogD(5.5) 
BT (5) Logarithm of distribution coefficient D of a 
compound between octanol and buffer layers at pH 
value 5.5. 
LogD(6.5) 
BT (5),        
I-Tree (5) 
Logarithm of distribution coefficient D of a 
compound between octanol and buffer layers at pH 
value 6.5. 
LogD(7.4) 
BT (5) Logarithm of distribution coefficient D of a 
compound between octanol and buffer layers at pH 
value 7.4. 
LogD(2) 
CT (1) Logarithm of distribution coefficient D of a 
compound between octanol and buffer layers at pH 
value 2. 
MW I-Tree (7) Molecular weight. 
OATP1B1-RF 
I-Tree (4),    
I-Tree (7) 
Percentage inhibition of  OATP1B1predicted by RF 
model with subsample proportion ratio of 0.50 
OATP1B3-RF 
RT (3) Percentage inhibition of  OATP1B3 predicted by RF 
model with subsample proportion ratio of 0.60 
OATP1B3-BT 
I-Tree (5),    
I-Tree (7) 
Percentage inhibition of  OATP1B3 predicted by BT 
model (with subsample proportion ratio of 0.55 and 
learning rate of 0.05). 
OATP2B1-RF 
I-Tree (6) Percentage inhibition of  OATP2B1 predicted by BT 
model (with subsample proportion ratio of 0.55). 
PC+ CT (3) Total positive partial charge. 
PEOE_PC+ 
RF (3),      
CT (3) 
Total positive partial charge. 
PEOE_VSA_HYD I-Tree (5) Total hydrophobic van der Waals surface area. This 
is the sum of the van der Waals surface area such 
that absolute value of atomic charge is less than or 
equal to 0.2. 
PEOE_VSA_NEG CT (1) Total negative van der Waals surface area. 
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Descriptor Model Description 
PEOE_VSA+0 
I-Tree (5) Van der Waals surface area of atoms with atomic 
charge in the range [0.00,0.05). 
PEOE_VSA-0 
I-Tree (9) Van der Waals surface area of atoms with atomic 
charge in the range [-0.05,0.00). 
PEOE_VSA+4 
RF (3),         
I-Tree (10) 
Van der Waals surface area of atoms with atomic 
charge in the range [0.20,0.25). 
Predicted 
OATP1B1 Class  
I-Tree (8) This is a categorical descriptor (0 and 1) shows 
percentage inhibition of OATP1B1 predicted by 
C&RT routine model. 
Predicted 
OATP1B3 Class  
I-Tree (9) This is a categorical descriptor (0 and 1) shows 
percentage inhibition of OATP1B3 predicted by 
C&RT routine model. 
Predicted 
OATP2B1 Class  
I-Tree (10) This is a categorical descriptor (0 and 1) shows 
percentage inhibition of OATP2B1 predicted by 
C&RT routine model. 
Q_VSA_FPOL 
CT (2) Fractional polar van der Waals surface area. This is 
the sum of the van der Waals surface area such that 
absolute value of atomic charge is greater than 0.2 
divided by the total surface area. 
Q_VSA_PNEG 
CT (2) Total negative polar van der Waals surface area. 
This is the sum of the van der Waals surface area 
such that absolute value of atomic charge is less 
than -0.2. 
Q_VSA_NEG 
RT (3),    I-
Tree (5) 
Total polar negative van der Waals surface area. 
This is the sum of the van der Waals surface area 
such that absolute value of atomic charge is greater 
than 0.2. 
SMR_VSA2 
I-Tree (7) Sum of approximate accessible van der Waals 
surface area for atoms with atomic contribution to 
molar refractivity in (0.26, 0.35]. 
vdw_area 
I-Tree (4) The van der Waals surface area (Å
2
) calculated 
using a connection table approximation. 
vsurf_D7 CT (1) Hydrophobic volume (8 descriptors). 
vsurf_ID8 CT (1) Hydrophobic integy moment (The "integy moment" 
is defined in analogy to the dipole moment and 
describes the distance of the centre of mass to the 
barycenter of hydrophobic regions). Small integy 
moment indicates that the hydrophobic moieties are 
either close to the centre of mass or they balance at 
opposite ends of the molecule, so that their resulting 
barycentre is close to the centre of the molecule. 
VolSurf computes ID at eight different energy levels 
(from -0.2 to 1.6 Kcal/mol). 
vsurf_CP 
I-Tree (6),    
I-Tree (9) 
Critical packing parameter. This parameter defines a 
ratio between the lipophilic and hydrophilic part of a 
molecule. It is defined as: volume (lipophilic 
part)/[(surface(hydrophilic part)(length of lipophilic 
part)]. Therefore, critical packing refers to 
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Descriptor Model Description 
molecular shape as well as lipophilicity/ 
hydrophilicity ratio. 
vsurf_CW2 
BT (5) Capacity factor is the ratio of the hydrophilic 
surface over the total molecular surface, calculated 
at eight different energy levels (from -0.2 to -6.0 
kcal/mol). 
vsurf_CW4 
I-Tree (4),    




CT (2) Contact distances of the lowest hydrophilic energy 
descriptors (vsurf_EWmin) (3 descriptors). 
vsurf_EDmin3 I-Tree (6) The lowest hydrophobic energy. 
vsurf_HB1 
RF (3) H-bond donor capacity at -2.0 Kcal/mol with 
carbonyl oxygen probe (8 descriptors). 
vsurf_HB3 
RT (3),        
I-Tree (5),    
I-Tree (9),     
I-Tree (10) 
H-bond donor capacity at -2.0 Kcal/mol with 
carbonyl oxygen probe (8 descriptors). 




Hydrophilic-Lipophilic balance; it is the ratio 
between the hydrophilic regions measured at -3 and 
-4 kcal/mol and the hydrophobic regions measured 
at -0.6 and -0.8 kcal/mol. The balance describes 
which effect dominates in the molecule, or if they 
are roughly equally balanced. 
vsurf_W1 CT (3) Hydrophilic volume. 
vsurf_W3 I-Tree (8) Hydrophilic volume. 
vsurf_W4 RF (3) Hydrophilic volume. 
 
Table 6.6. Statistical parameters of the models for training and test sets  
Model Group Risk Estimate Standard Error 
RT (3) Train 0.107 0.031 
Validation 0.583 0.118 
I-Tree (4) Train 0.211 0.041 
Validation 0.242 0.053 
I-Tree (5) Train 0.201 0.026 
Validation 0.341 0.087 
I-Tree (6) Train 0.177 0.021 
Validation 0.365 0.086 
I-Tree (7) Train 0.213 0.020 
Validation 0.268 0.069 
I-Tree (8) Train 0.210 0.055 
Validation 0.380 0.067 
I-Tree (9) Train 0.188 0.033 
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Model Group Risk Estimate Standard Error 
Validation 0.360 0.096 
I-Tree (10) Train 0.247 0.039 
Validation 0.366 0.088 
BT (5) Train 0.087 0.008 
Validation 0.267 0.085 
RF (3) Train 0.280 0.043 
Validation 0.267 0.066 
 








6.3.3.2. Interactive Tree Models Using Predicted OATP Effects 
Interactive C&RT analysis was used here to inspect the effect of OATPs more 
closely. In these analyses one of the most accurately predicted OATP binding 
(percentage inhibition) or the predicted OATP class was manually used as the first 
variable in the regression trees for the biliary excretion, and then the tree was 
allowed to grow automatically using the features selected by the analysis. Hence, 
we examine the significance of OATPs, namely OATP1B1, OATP1B3 and 
OATP2B1 in biliary excretion using I-tree analysis. Table 6.8 describes summary 
of I-tree models in terms of the type of the predicted OATP effect in the model.   
  
Model MAE for training set MAE for validation set 
RT (3) 0.236 0.420 
I-Tree (4) 0.343 0.379 
I-Tree (5) 0.335 0.409 
I-Tree (6) 0.332 0.443 
I-Tree (7) 0.362 0.392 
I-Tree (8) 0.454 0.455 
I-Tree (9) 0.334 0.446 
I-Tree (10) 0.448 0.474 
BT (5) 0.242 0.362 
RF (3) 0.387 0.411 
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Table 6.8. Brief description of the interactive C&RT models 
Model no Manually incorporated variables 
I-Tree (4) Predicted percentage OATP1B1 inhibition using OATP1B1-RF 
model 
I-Tree (5) Predicted percentage OATP1B3 inhibition using OATP1B3-BT 
model 
I-Tree (6) Predicted percentage OATP2B1 inhibition using OATP2B1-RF 
model 
I-Tree (7) Predicted percentage OATP1B1 and OATP1B3 inhibitions using 
OATP1B1-RF and OATP1B3-BT models 
I-Tree (8) Predicted OATP1B1 inhibitor/non-inhibitor class using CT (1) 
I-Tree (9) Predicted OATP1B3 inhibitor/non-inhibitor class using CT (2) 
I-Tree (10) Predicted OATP2B1 inhibitor/non-inhibitor class using CT (3) 
 
I-Tree (4) (Figure 6.11) shows that compounds with high OATP1B1 binding, as 
predicted by OATP1B1-RF, have higher biliary excretion. The statistically selected 
OATP1B1-RF threshold is 37.12. Literally, compounds in biliary excretion dataset 
that have been predicted to inhibit OATP1B1 by > 37.12% (representing stronger 
binding to the transporter), are predicted by this model to have higher biliary 
excretion. Exceptions to this are compounds in node 13, with low hydrophilic 
surface ratio and high GCUT_PEOE_0. According to this tree, log BE% is low for 
the non-inhibitors of OATP1B1 with a small van der Waals surface area (vdw_area 
≤ 297.08) and especially if they have GCUT_PEOE_0 values below -0.85 (node 9). 





           
Figure 6.11. I-Tree (4) developed using interactive C&RT analysis using OATP1B1 
descriptor as the first descriptor  
When predicted OATP1B3 effect (OATP1B3-BT) was used in the analysis, I-Tree 
(5) was obtained which has been presented in Figure 6.12. According to this tree, 
28 OATP1B3 inhibitors (> 52.10% inhibition) have a slightly lower average log 
BE%. This is due to the effect of 8 compounds in this group with low total 
hydrophobic surface area (PEOE_VSA_HYD ≤ 254.04), which have extremely low 
biliary excretion (node 6). For OATP1B3 non-inhibitor compounds, log BE% is 
moderate to high if they have a high H-bond donor capacity (vsurf_HB3 > 298.22) 
(terminal nodes 10, 14 and 15) or alternatively if they have a large negatively 
charged surface area (Q_VSA_NEG > 200.31).  
  Tree graph for log BE% 
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Figure 6.12. I-Tree (5) developed using interactive C&RT analysis using OATP1B3 
descriptor as the first descriptor.  
Figure 6.13 presents the regression tree using predicted OATP2B1 effect 
(OATP2B1-RF) as the first split variable (I-tree (6)). The predicted percentage of 
OATP2B1 inhibition by RF method for compounds in biliary excretion dataset 
ranged from -1 to 28%. According to this tree, compounds with percentage 
inhibition above 22.05 have generally higher biliary excretion, except when the 
compounds are extremely weak acid or bases (fU > 0.001 at pH 7.4) and in addition 
to their large lipophilic to hydrophilic region ratio (vsurf_Cp > 0.13). On the other 
hand, OATB2B1 non-inhibitors are generally less excreted through bile, unless if 
they are large (Kier2 > 8.26) especially if they have GCUT_PEOE_2 > 0.06 (node 
11). Statistical parameters of the model can be seen in Tables 6.6 and 6.7.
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Figure 6.13. I-Tree (6) developed using interactive C&RT analysis using OATP2B1 
descriptor as the first descriptor  
 
To examine the impact of different OATP subtypes at one single model, predicted 
OATP1B1 and OATP1B3 effects (OATP1B1-RF and OATP1B3-BT) were 
imposed at the first and the second levels of a regression tree using interactive tree 
analysis module in STATISTICA. The best model (most accurate in the prediction 
of external validation set) from this exercise has been presented in Figure 6.14 (I-
Tree (7)). According to this model, compounds with inhibitory effects on both 
OATP1B1 and OATP1B3 (14 compounds in node 7) have slightly higher biliary 
excretion than compounds with inhibitory effect on just OATP1B1 (compare nodes 
7 and 6). Interestingly, compounds with no binding to either one of the OATPs 
(compounds in node 4), may still be highly excreted through bile if they have a high 
H-bond donor capacity (vsurf_HB4 > 150.18).   
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 Figure 6.14. I-Tree (7) using predicted percentage OATP2B1 and OATP1B3 
inhibition as the first and second level parameters  
 
Interactive Tree Using Predicted Class  
We also employed various OATP “predicted class” in the interactive tree as an 
alternative approach to “predicted percentage OATP inhibition” for the prediction 
of biliary excretion. Prediction of OATP inhibitor/non-inhibitor class for 
compounds in biliary excretion dataset was obtained from CT (1)-CT (3). In this 
way, both training and validation set compounds were predicted as class one or zero 
(one for inhibitor or zero for non-inhibitor). The interactive trees using predicted 
OATP1B1, OATP1B3 or OATP2B1 class as the first partitioning variable (I-Tree 
(8) – I-Tree (10)) are presented in Figures 6.15-6.17 respectively. The molecular 
descriptors employed in the trees have been explained in Table 6.1. Statistical 
parameters of these tree models can be seen in Tables 6.7 and 6.8. 
I-Tree (8) in Figure 6.15 shows a slightly higher average biliary excretion for non-
inhibitors of OATP1B1, which is contrary to the expectations and also different 
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from the result seen in I-Tree (4) employing percentage inhibition of OATP1B1 
using RF (Figure 6.11).  This may be due to poor prediction accuracy of CT (1) for 
the compounds in the biliary excretion dataset, or due to the threshold of 50% 
inhibition used for the classification of inhibitors/ non-inhibitors. It can be noted in 
I-Tree (4) that a threshold value of 35.80% (rather than 50%) has been selected by 
the analysis to split the compounds. Figure 6.15 also shows that both classes 
(inhibitors and non-inhibitors) may be divided into compounds with similarly high 
(nodes 5 and 7) and similarly low (nodes 4 and 6) biliary excretion using specific 
molecular descriptors. According to this model, in agreement to the results seen in 
Chapters 4 and 5 (e.g. RT (1)), compounds with large hydrophilic volume 
(vsurf_W3 > 418) and large hydrophilic surface ratio (vsurf_CW4 > 0.69) are 
excreted more in the bile.  
                                      
Figure 6.15. I-Tree (8) using predicted OATP1B1 inhibition class as the first 
parameter 
 
Figure 6.16 (I-Tree (9)) shows that the predicted OATP1B3 inhibitor class (node 3) 
has higher biliary excretion, except for the compounds with extremely weak acid or 
base dissociations which are also composed of mainly lipophilic parts (vsurf_CP > 
0.10). It can be seen in Figure 6.16, that the numbers of non-inhibitor compounds is 
more than inhibitors (as predicted by CT (2)) (102 vs 65). Non-inhibitors of 
OATP1B3 have considerable biliary excretion (terminal nodes 15, 16 and 17), 
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when they have high H-bond donor capacity (vsurf_HB3 > 295) and more spherical 
shape (glob > 0.10), or if they are not spherical, they have a strongly acidic group 
(Hmin > 0.64). 
 
 Figure 6.16. I-Tree (9) using predicted OATP1B3 inhibition class as the first 
parameter  
 
I-Tree (10) in Figure 6.17 shows the effect of using predicted OATP2B1 inhibition 
class (by CT (3)) as the first parameter of the regression tree. According to I-Tree 
(10), OATP2B1 inhibitors have higher biliary excretion especially if they have a 
high polar surface area (PEOE_VSA+4 > 19.7). On the other hand, the 55 non-
inhibitor compounds in node 4 with a low H-bond donor capacity have low biliary 
excretion. 
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Figure 6.17. I-Tree (10) using predicted OATP2B1 inhibition class as the first 
parameter 
 
6.3.3.3. Boosted Trees Model Using Predicted OATP Effects 
BT analysis with various parameters as explained in Chapter 4, including various 
learning rates and subsample proportions were examined and the best model was 
selected based on the internal validation set error. The selected model (BT (5)) was 
obtained with the optimal number of trees of 141, learning rate of 0.1 and 
subsample proportion of 0.50 (see Figure 6.18). 
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Figure 6.18. Average squared error of log BE% against the number of trees in the 
boosted trees model BT (5) for the training and internal test set 
Variable importance was calculated for the BT model using STATISTICA 
software. Included in Table 6.5 are the top 10 most important molecular descriptors 
of BT (5) model. Lipophilicity descriptors (LogD(5.5), LogD(6.5), LogD(7.4) and 
LogD(10)), hydrogen atom level E-state descriptors (Hmax and Hmaxpos) and 
vsurf and density descriptors (vsurf_CW2 and dens) are among the top important 
BT (5) descriptors. Although the predicted OATP binding parameters are not 
amongst the top 10 descriptors of the model, they appear to be very important in 
this model in terms of improving the prediction accuracy for the external validation 
set (Tables 6.3). The previous BT models obtained from molecular descriptors (BT 
(1) and BT (2) in Chapter 4), and the BT model using predicted P-gp binding in 
addition to molecular descriptors (BT (4) in Chapter 5) have similar MAE values of 
0.412, 0.417 and 0.416, respectively. BT (5) appears to be considerably more 
accurate with MAE of 0.362. 
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6.3.3.4. Random Forest Model Using Predicted OATP Effects 
The method for the development of a random forest (RF) model has been explained 
in Chapter 4. Based on the accuracy for the internal test set, the selected RF model 
(RF(3)) was obtained using a subsample proportion of 0.50, numbers of trees of 
100, random test data proportion of 0.2 the software’s default settings for stopping 
conditions including minimum number of cases, maximum number of levels, 
minimum number in child node and the maximum number of nodes of 6, 10, 5 and 
100, respectively. Figure 6.19 shows the plot of prediction error against the number 
of trees. Tables 6.2 and 6.3 show the statistical significance of this model. 
Similar to BT model, the variables importance was calculated for RF (3). Included 
in Table 6.1 are the top 10 most important molecular descriptors of model. These 
are vsurf descriptors (vsurf_W4 and vsurf_HB1), number of single bonds (b_single 
and b_1rotN), kappa shape indexes (KierA2 and chi1v), number of atoms (a_count) 
and water accessible surface area of atoms with a negative partial charge (ASA-). 
Despite the absence of predicted OATP binding parameters in the top ten important 
parameters list, the use of these parameters in model development has resulted in a 
reduction in external validation set error when comparing RF (1) with MAE of 




         
Figure 6.19. Average squared error of log BE% against the number of trees in RF 
(3) for the training and internal test set 
 
6.4. Discussion  
Although in the past decade the knowledge of OATP transporters had an enormous 
increase in the literature, most of OATP sub-family are still anonymous (Giacomini 
et al., 2010). Various member of OATP transporter family contribute to drug 
disposition and, as a result, are involved in drug-drug interactions. A major 
contribution of OATP transporters to drug disposition is through their function in 
hepatocytes for the uptake of substrate compounds from the blood (Fenner et al., 
2012). Recently, OATP1B1 inhibition measures have been suggested as a suitable 
surrogate for the more complicated human hepatic uptake assays (Soars et al., 
2012). This was based on a comparison between uptake measures in human 
hepatocytes (in vitro intrinsic clearance) and IC50 values for the inhibition of 
OATP1B1-mediated uptake of a model substrate for 42 compounds from several 
chemically distinct series. In this investigation the aim was to use the OATP 
inhibition measured in vitro for the prediction of biliary excretion in rats.  
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6.4.1. QSAR Models for the Prediction of OATP Inhibition 
Despite the wide distribution and important implications of OATP transporter 
family, unfortunately, there are several limitations in the study of OATP transporter 
ligands (Karlgren et al., 2012a). This has resulted in a limitation in the availability 
of high quality data for QSAR studies. In this investigation, the inhibition of OATP 
uptake of a substrate by 225 compounds measured as percentage inhibition by a 
single concentration of the compound (Karlgren et al., 2012a) was used as the 
inhibition measure. Data was available for three major OATP subfamilies, 
OATP1B1, OATP1B3 and OATP2B1. OATP1B1 and OATP1B3 are liver-specific 
transporters, mainly expressed on the basolateral membrane of human hepatocytes 
(Kalliokoski and Niemi, 2009; Giacomini et al., 2010), whereas, OATP2B1 is 
relatively ubiquitous with its localization in several tissues in addition to the liver 
(Kobayashi et al., 2014; Varma et al., 2011). 
After examining several prediction (regression based) statistical techniques 
(stepwise regression analysis, C&RT, BT, RF and MARS), the two best models 
were selected for each OATP subfamily. In addition a classification tree was 




For OATP1B1, RF and C&RT analysis resulted in the best prediction models 
(OATP1B1-RF and OATP1-RT). There is only one molecular descriptor used in 
OATP1-RT model, Chi1_C, which is mainly an indicator of molecular size. Despite 
previous investigations suggesting that ligands of this transporter are mainly acidic 
(Hsiang et al., 1999) this has not been indicated in this model. In comparison with 
the regression tree, the classification model for OATP1B1 (CT (1)) has more 
branches and nine terminal nodes. The importance of acidic nature of OATP1B1 
ligands has been indicated in CT (1). In CT (1), in order to be classed as inhibitors, 
compounds of smaller size (defined by Chi1_C < 9.68) need to have acidic group 
shown by partially positively charged hydrogen, as in –COOH group (Hmin), or 
high apparent partition coefficient in acidic pH (logD(2)). The crucial impact of 
192 
 
large molecular size for OATP ligands is very well established from previous 
studies. Whereas OATs transport low MW compounds, OATPs mediate the uptake 
of larger substrates such as digoxin (Shitara et al., 2002; Hagenbuch and Meier, 
2003), erythromycin (Sun et al., 2004) and atorvastatin (Lau et al., 2006). This is 
also in line with a study by Hagenbuch and Meier which reports that compounds 
with molecular weight higher than 350 can be OATP1B1 substrates (Hagenbuch 
and Meier, 2004).  
A recent QSAR model by Soars and colleagues using IC50 values for 262 
proprietary compounds found that maximal hydrogen bonding strength and 
lipophilicity (cLogP) were the most important molecular descriptors of their 
random forest model for predicting OATP1B1 inhibitors (Soars et al., 2014). Our 
random forest model also supports this finding as lipophilicity (LogP) and 
maximum positive hydrogen atom-level E-state value in a molecule (Hmaxpos) 
were dominant molecular features in OATP1B1-RF model. In addition, CT (1) also 
suggests the importance of lipophilicity (LogD(2)) for inhibitors of OATP1B1. De 
Bruyn and co-workers in a recent study, noted the polar surface area as the key 
molecular feature for an increase in OATP1B1inhibition (De Bruyn et al., 2013), 
which is in agreement with CT (1) indicating the positive impact of a high 
hydrophilic/lipophilic balance of the molecular surface (vsurf_HL1) and a large 
negative polar surface area (PEOE_VSA_NEG) for the compounds to be classed as 
inhibitors of OATP1B1.  
The accuracy of the regression based models for the external validation set is 
similar to the training set (MAE for the percentage inhibition is ~21%). This 
percentage error must be viewed considering the innate error levels associated with 
the single point measurements. Karlgren et al. (2012) have developed classification, 
rather than regression based, QSAR models using this dataset. Their classification 
accuracy for the training and validation sets was 73% and 79% respectively, which 
is similar to CT (1) model (accuracy of 81% for inhibitors and 74% for non-






The selected regression based models for OATP1B3 inhibition were a RF and a BT 
model (OATP1B3-RF and OATP1B3-BT). Despite allowing for identification of 
the most important features, these two methods cannot be interpreted as directly as 
single classification or regression trees. CT (2) has a very low classification 
accuracy for the non-inhibitors in the external validation set (36%), despite 
performing well for the classification of inhibitors in the same set (83%). Therefore, 
consideration must be given to the accuracy levels when interpreting the molecular 
properties of inhibitors and non-inhibitors. An inspection of CT (2) provides 
required features for inhibitors as explained in Section 6.3.2. Mainly, the inhibitors 
are either flexible with a relatively small fraction of polar surface area, or they are 
more rigid with large negative polar surface area or with a specific molecular 
topology with various BCUT descriptors. The BCUT descriptors have been 
reported to be very useful in terms of capturing sufficient structural detail in 
molecular diversity-related tasks (Stanton, 1999; Pearlman and Smith, 1997). 
Despite this, the incorporation of this parameter to explain variations in the 
biological properties is not successful in this model.  
As explained in the resuts section, the most important molecular descriptors of 
OATP1B3-BT are LogD at pH 10, acidity, aromatic rings, and hydrophilicity or 
hydrogen bonding descriptors. This is in agreement with the findings of De Bruyn 
and co-workers that indicate a LogD value between 3.4 and 7.5 and a medium/ low 
number of hydrogen bond donors are positively correlated with OATP1B3 activity 
(De Bruyn et al., 2013). The most important molecular descriptors of OATP1B3-
RF are similar to CT (2) model and indicate the importance of the bond count and 
the number of single bonds. In addition, this model also indicates the importance of 
hydrogen bonding donor capacity, molecular shape, and volume. The prediction 
accuracy of the regression based OATP1B3 models is similar to the models for 







A recent study by Shirasaka and colleges (Shirasaka et al., 2014) on OATP2B1-
mediated uptake of pravastatin and fexofenadine showed the presence of multiple 
binding sites on OATP2B1. The structure of OATP2B1 has been shown to be very 
similar to OATP1B3 using in silico homology modeling studies (Meier-abt et al., 
2005), which suggest that most OATPs share similar features. Very few literature 
data are available for OATP2B1 ligands. For instance, out of 45 OATP2B1 
inhibitors identified in Karlgren’s investigation, 29 compounds were were believed 
to be novel inhibitors not studied before (Karlgren et al., 2012a). As a result, 
despite a few QSAR/ pharmacophore models published for OATP1B1 (Chang et 
al., 2005; De Bruyn et al., 2013; Soars et al., 2012; Karlgren et al., 2012b), there is 
little in silico results available for OATP2B1 (Karlgren et al., 2012a). Based on the 
similarities with other OATP transporters, it may be speculated that OATP2B1 
pharmacophores may share the similar molecular features for the consideration of 
the substrate binding at the positively-charged region (El-Kattan and Varma, 2012). 
Its substrates may have features such as a hydrophobic core to form the π-stacking 
interaction with the imidazole ring of amino acid H579, or a hydrogen bond donor 
group to directly interact with the nitrogen atom of the imidazole ring (El-Kattan 
and Varma, 2012).  
The selected regression based models for OATP2B1 ligands are RF and BT models 
(OATP2B1-RF and OATP2B1-BT) and CT (3) is the classification model. CT (3) 
model has correctly classified 77% and 58% of the inhibitors and non-inhibitors in 
the external validation set, respectively. The accuracy of the PLS-based 
classification model suggested by Karlgren et al. (2012a) for this transporter was 
75%, but they had used a different classification cut-off point of 32%. CT (2) model 
indicates that inhibitors of OATP2B1 are generally large hydrophilic molecules or 
otherwise they have a specific topological property defined by a GCUT molecular 
descriptor.  
Both regression based models for OATP2B1 had a prediction error of ~25% (MAE 
= 25 for percentage inhibition data) for the external validation set (see Table 6.3). It 
can be seen in the results section that both these models show the importance of 
hydrogen bond donor ability with the molecular descriptors Hmaxpos and Hmax. 
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Moreover the importance of polarity is shown with polar surface area and negative 
polar surface area, and ratio of carbon atoms. 
In brief, physicochemical variables detected as important for inhibition of each 
OATP sub-family, show similarities but there are also some differences observed. 
 
6.4.2. Effect of OATP Binding on Biliary Excretion Models 
For hepatobiliary elimination of compounds, it has now become progressively clear 
that the movement of solutes and compounds into and out of cells is often 
dependent on transporter proteins. After compounds enter the hepatocytes, they 
either undergo the metabolism process, or, the intact compounds or their metabolite 
molecules excrete into the bile canaliculus. The uptake transporters enhance biliary 
excretion by importing more compounds into hepatocytes. Among the various 
uptake transporters, OATP family members appear to have remarkably broad 
substrate specifications (Kim, 2003). In human and rat hepatocyte, the hepatic 
uptake of many compounds is mediated by OATP family. Nevertheless, the 
physiological role of the OATP family is still not fully understood (Mikkaichi et 
al., 2004). Varma et al (2012) in their research paper comparing biliary excretion of 
compounds and the chemical space of substrates of human OATPs and rat oatp1b2 
observed that there is a significant overlap between these substrates and compounds 
with a rat biliary excretion higher than 10%. 
In this investigation, the predicted OATP inhibition values were used as parameters 
(predictors) for the development of QSAR models for the biliary excretion of 
compounds. In assessing the effect of predicted OATP binding on the QSAR 
models for biliary excretion, it must be noted that QSAR has been used for the 
prediction of OATP effect and that these original OATP QSARs are based on 
percentage inhibition data which is a fast measure of inhibition activity but is less 
reliable than IC50 values.  
Using C&RT embedded feature selection, only OATP1B3 inhibition is selected in 
the tree structure, and even this is at lower branches of the tree indicating less 
significance of the parameter (RT (3) in Figure 6.10). Moreover, the effect seen by 
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this parameter is in contrast to the expectations that a higher OATP binding should 
result in higher biliary excretion. It must be noted here that the number of OATP 
binding parameters (two numerical predicted percentage inhibition and one 
categorical inhibition class for each subfamily of OATP, making nine in total) is 
much lower than the number of molecular descriptors used (more than 300 in total). 
This gives a higher statistical probability to the molecular descriptors to be selected 
by any statistical feature selection. The OATP descriptors were therefore 
incorporated in the tree structure manually using Interactive Tree analysis in 
STATISTICA. Table 6.8 gives the details of I-Tree (4) – (10) models, and Table 
6.7 gives the prediction accuracy for the training and external validation sets. Table 
6.7 shows that I-Tree models (8) – (10), using the categorical predicted class 
variables are less accurate than the corresponding I-Tree (4) – (7) using the 
numerical predicted percentage OATP inhibition. This may indicate a higher 
prediction accuracy for the regression based models for the prediction of OATP 
effect of compounds in the biliary excretion dataset.  
Among the OATP member family, the role of OATP1B1 in elimination of 
compounds has become clear over the last decade (Soars et al., 2012). Accordingly, 
comparing accuracy of I-Tree (4) – (7), it is clear that, out of different OATP 
subfamilies, incorporation of OATP1B1 inhibition results in the most successful 
model (I-Tree (4) followed by I-Tree (7)). Moreover, incorporation of predicted 
OATP2B1 subfamily results in the least accurate model (I-Tree (6)). This may be 
due to a lower prediction accuracy of the original OATP2B1 model (OATP2B1-RF 
in Table 6.3 with MAE of 25%) rather than a lower significance of OATP2B1 
binding in hepatic uptake and biliary excretion.  
It can be seen that the prediction accuracy of I-Tree (4) is better than RT (3) with 
statistically selected variables. I-Tree (4), indicates that, in general, OATP1B1 
ligands have higher biliary excretion and, in addition to this, eight different levels 
of log BE% values may be identified by this tree based on several molecular 
properties. The molecular properties have been explained in the results (section 
6.3.3.2) and are similar to the observations from Chapter 4.  
The best QSAR model for the estimation of biliary excretion, using the predicted 
OATP binding in addition to the molecular descriptors as the predictors, was 
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achieved by the boosted trees model, BT (5). BT (5), with incorporation of 
predicted OATP binding effects along with molecular descriptors, is much more 
accurate than the corresponding BT (1) and BT (2), with only molecular 
descriptors, and BT (4), with incorporation of P-gp binding and molecular 
descriptors.  
Since the biliary excretion dataset is completely external and there is no OATP data 
for these compounds, it is difficult to comment on the prediction accuracy of OATP 
inhibition for this dataset using the QSAR models other than the error indication 
given by the external validation set (MAEs reported in Table 6.3 and SP and SE 
values in Table 6.4). In terms of the chemical space, there seems to be a good 
overlap between the molecular properties of the two training sets, as indicated by a 
visual inspection of the scores plot from principle component analysis (PC1 vs PC2 
plot in Figure 6.20). 
 
Figure 6.20. The plot between the first and the second principle components of 
PCA using all the molecular descriptors 
 
In conclusion, incorporation of OATP effects in the prediction of biliary excretion 





















trees. Furthermore, a BT model was achieved when OATP effects were used in 




7. General Conclusion 
 
Biliary excretion is one of the major elimination routes for drugs and as a result, it 
has a major impact on pharmacokinetics including drug half-life and dosing 
regimen. Moreover, biliary excretion has implications in drug-drug and food-drug 
interactions through the possible involvement of same transporter proteins. As a 
result, early estimation of biliary excretion may be useful for modification of drug 
structure in drug design to have an ideal drug and can be used as a surrogate for 
more time-consuming and expensive in vivo and in vitro studies. In this project, we 
were able to estimate rat biliary excretion based on physicochemical properties 
using various computational modelling techniques. In addition, the roles of P-gp 
and OATPs, as two important hepatobiliary influx and efflux transporters were 
investigated using QSAR.  
The statistical techniques used for the QSAR development included a range of 
linear, non-linear and ensemble methods to allow the best possible prediction 
accuracy. The methods were multiple linear regression analysis, decision trees 
developed by C&RT and CHAID, MARS, and ensemble decision trees developed 
by random forest and boosted trees methods. Simple models such as classification 
or regression trees, multiple regression analysis and MARS, use manageable 
number of features and allow for easy interpretation of the results. In this way, the 
selected molecular descriptors resulted in some insight into major factors that can 
affect biliary elimination of drugs.  
The biliary excretion dataset used in this project consisted of a diverse dataset of 
217 compounds with percentage of dose excreted intact into bile measured in vivo 
in rat. The first aim of the investigation was to develop a predictive QSAR model 
for this dataset. Table 7.1 gives a brief summary of the prediction accuracy of all 
the biliary excretion models described in this thesis. The most accurate models in 
terms of the prediction accuracy for the external validation set in descending order 
of accuracy are CHAID (2), BT (5), RT (1) and I-Tree (4). This shows that simple 
regression trees such as CHAID (2) and RT (1) are as powerful in the prediction of 
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biliary excretion as the more sophisticated ensemble methods of boosted trees and 
random forest techniques.  
Table 7.1 MAE values of all the biliary excretion models described in the thesis; 
the selected models have been highlighted in bold. 
Model Training set Validation set 
BT (1) 0.229 0.412  
BT (2) 0.226 0.417  
BT (4) 0.339 0.416  
BT (5) 0.242 0.362  
CHAID (2) 0.432 0.359  
I-tree (1) 0.345 0.451  
I-Tree (10) 0.448 0.474  
I-tree (2) 0.424 0.468  
I-Tree (4) 0.343 0.379  
I-Tree (5) 0.335 0.409  
I-Tree (6) 0.332 0.443  
I-Tree (7) 0.362 0.392  
I-Tree (8) 0.454 0.455  
I-Tree (9) 0.334 0.446  
MARS (2) 0.438 0.428  
MARS (3) 0.436 0.442  
MLR (1) 0.377 0.483  
RF (1) 0.403 0.496  
RF (3) 0.387 0.411  
RT (1) 0.304 0.373  
RT (3) 0.236 0.420 
  
 
From these models, we obtained an insight into the structural profile of cholephilic 
compounds through accurate modelling of the biliary excretion. Molecular 
descriptors selected by all these models including the top ten incorporated in 
boosted trees and random forest models indicated a higher biliary excretion for 
relatively hydrophilic compounds especially if they have acid/base dissociation 
(anionic or cationic), and have a large molecular size.  
Interactive regression trees analysis was a very useful tool that helped investigate 
the effects of specific properties. One such property with regards the previous 
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literature was molecular weight. Despite the established role of molecular weight in 
biliary excretion, the molecular weight thresholds in previous literature are 
generally based on qualitative inference from available data, rather than a 
statistically established threshold (Yang et al., 2009). In this project a statistically 
validated molecular weight threshold established for significant biliary excretion at 
MW = 348 Da.  
Analysis of outliers in majority of the models in Chapter 4 showed the models 
perform best when lipophilicity is not too extreme (log P < 5.35) and for 
compounds with molecular weight above 280 Da. It was also observed that 
compounds with low biliary excretion are more likely to show a higher average 
error. This could be attributed at least in part to the method used for calculation of 
error as, for example, despite the prediction of low biliary excretion at 1% for a 
compound, the difference with the observed value of 0.1% leads to a high absolute 
error of 1. Such estimations may still be acceptable as these low biliary excretion 
compounds had been estimated a BE% value < 4%.  
P-gp is a major efflux pump that operates in hepatocytes and aids with excretion of 
its substrates into bile. Based on the hypothesis that the substrates of this transporter 
may have a higher tendency to be excreted through bile, this project looked at the 
structural features of P-gp ligands. A very accurate measure of ligand binding to 
proteins is the inhibition constant (Ki). Ki is believed to be a more universal 
parameter allowing easy comparison of data from different substrate conditions. To 
investigate the molecular requirements of P-gp binding and the effect of P-gp 
binding on biliary excretion levels of compounds, a dataset of 219 unique P-gp 
inhibitor/substrate pairs were collated from original literature.  QSAR models were 
developed for Ki using P-gp-ligand docking scores as well as the molecular 
descriptors of the inhibitors and the descriptors of probe substrates used for the 
determination of Ki values. The QSARs indicated that the molecular descriptors are 
more significant in the prediction of P-gp binding than the ligand-enzyme docking 
scores. Models indicated that the potent P-gp inhibitors have higher lipophilicity 
and molecular weights than drug-like molecules identified by Oprea's rule. The 
QSAR models indicate that potent inhibitors of P-gp have higher lipophilicity and 
molecular size than lead-like compounds as defined by Oprea and the limiting 
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lipophilicity is log P > 5.3 for this dataset. Classification and regression tree 
(C&RT) model had the lowest Ki prediction error for the external validation set 
with a mean absolute error of 0.543. 
  
Although the QSARs established for P-gp had reasonable accuracy for the 
prediction of Ki values of the external validation set, these predictions may not be 
as reliable for the external compounds in the biliary excretion dataset. This can 
occur in case the compounds in the biliary excretion dataset are outside the domain 
of applicability of the QSAR models for P-gp binding. A scores plot from PCA 
showed a considerable difference between the chemical spaces of the two datasets.  
Therefore it was not unexpected when the predicted P-gp inhibition constant could 
not significantly improve the prediction accuracy of the QSAR models.  
OATPs are major uptake transporters that mediate the uptake of a wide range of 
compounds from blood into hepatocytes as the first step of hepatobiliary 
elimination process. To study the significance of OATP binding in biliary 
excretion, a recently published dataset consisting of percentage inhibition of three 
OATP subtypes, OATP1B1, OATP1B3 and OATP2B1 by 225 compounds was 
employed. Despite the lower quality of this binding measure in comparison with 
IC50 or Ki, QSARs of reasonable accuracy (MAE of 20-25%) were established for 
the three OATP subtypes. In addition, a classification method, i.e. classification 
tree, was also used. Both regression type and classification methods were most 
successful for the prediction of OATP1B1 binding when compared to OATP1B3 
and OATP2B1 binding. This may be attributed to a more balanced inhibitor/non-
inhibitor ratio in the dataset for this particular OATP. The results showed large 
hydrophilic compounds with hydrogen bonding donor ability (such as carboxylic 
acid groups) are better inhibitors of OATP1B1 and OATP2B1, while flexibility was 
an additional factor for OATP1B3.  
A comparison of the chemical spaces of compounds in OATP dataset with 
compounds in biliary excretion dataset using PCA indicated a good overlap of 
properties. The OATP models were used for the prediction of OATP binding of the 
compounds in biliary excretion dataset and the predicted values were used as 
additional parameters for the estimation of biliary excretion using QSAR. Although 
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majority of these predicted OATP binding parameters were not picked by C&RT 
algorithm, and they were not ranked within the top ten most important features of 
BT or RF models, they were important in improving the prediction accuracy of BT 
model and the regression trees, when they were incorporated manually using 
interactive trees. In the selected I-Tree model, the predicted OATP1B1 binding was 
the most significant parameter and this constitutes one of the best models over all 
for the prediction of biliary excretion with an absolute error of 0.38 (I-Tree (4), 
Table 7.1). The BT model has a slightly lower prediction error of 0.36 for the 






8. Future Work 
 
As a result of the research carried out in this PhD project, it can be seen that there is 
a need to further explore the role of individual ABC transporters as the efflux 
pumps. In addition to the role and impact of efflux drug transporters in the 
hepatocyte, further investigation of the impact of both uptake and other efflux 
hepatic transporters in biliary excretion as well as search for new transporter dataset 
for biliary excretion such as Pept1, Pept2, MRP2, MRP3, MRP4, MRP6, MATE1, 
OAT2, OAT7, OCT1, NTCP, BSEP, PHT1 and PHT2 can elucidate and bring more 
clear aspects of elimination pathways to light. 
In terms of P-glycoprotein there are large datasets of substrate/non-substrate type, 
some of which are proprietary data and some (smaller datasets) are available in the 
literature (Wang et al., 2011; Broccatelli et al., 2011). Although the data is 
categorical which is not ideal, the chemical space of these datasets may be closer to 
the compounds in biliary excretion dataset. In addition to P-gp, two other efflux 
pumps are also very important in biliary excretion. These are MRP2 and BCRP 
which have high localisation in hepatocytes. The work may involve cutting edge 
QSAR models along with classic QSAR model development, as well as drug-
enzyme docking methods. These transporter enzymes have also been indicated to 
play roles in the anticancer drug resistance and also pharmacokinetic processes 
such as intestinal absorption and blood brain barrier transport. Therefore the models 
will be useful from other perspectives as well as biliary excretion. 
The lack of high resolution structures of several important transporters including P-
glycoprotein and OATPs has severely limited work in this field. For example, if 
higher resolution models of P-glycoprotein were made available, this may improve 
the docking energies and allow us to visualise the interactions between P-
glycoprotein and compounds. In terms of P-gp docking, in this work the binding 
pocket was defined using the location of a single co-crystallised ligand. P-gp is 
known to have several binding sites and can accommodate more than one ligand at 
a time. A more detailed investigation may look at docking at several binding sites 
and then, from QSAR perspective, the lowest energy binding could be selected for 
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each compound from the various binding sites to be used as a QSAR parameter. 
Besides, building structure-based pharmacophore models of P-glycoprotein 
especially with pharmacophore features of hydrophobic, aromatic rings, hydrogen 
bond acceptors or donor, cations, and anions can be helpful.  
In order to further confirm the external applicability and predictive ability of the 
models built in this study as good predictors of P-glycoprotein and OATP binding 
and predictors of biliary excretion, new sets of compounds should be used as 
external validation set to test the constructed models. A major practice, which 
should be carried for the models presented in this thesis, is to investigate diversity 
of the compounds in the datasets and to define the applicability domain of the 
models.  
Furthermore, it will be pertinent to ensure that datasets are robust. For example, for 
P-glycoprotein substrates the goodness of the methods used for the measurement of 
activity should be scrutinised, and several sources of data should be compared if 
compounds or dataset to be used for model building have been repeatedly identified 
in several studies as either substrates or non-substrates of P-glycoprotein.  
Apart from key continuous and classification computational methods for estimation 
of biliary excretion used in this study, other statistical techniques can be utilized to 
predict the biliary excretion e.g. neural networks, support vector machines and 
semi-supervised learning. Neural networks and support vector machines can be 
used as a helpful alternative when there are problems of prediction or classification. 
Semi-supervised learning is a class of supervised learning techniques that make use 
of unlabelled data for training and has emerged as an exciting new direction in 
machine learning research. For example, in the biliary excretion dataset, when 
biliary excretion values are converted to log BE%, there are a few missing values 
for a few compounds (nine) with zero biliary excretion. Semi-supervised learning 
methods can improve models generalizability and applicability by predicting the 
values for these compounds.  
In this investigation, we searched for biliary excretion or clearance data for other 
species before analysis of rat biliary excretion database. For human, we could 
collect a biliary excretion data of 68 compounds. There are some biliary excretion 
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data available for dog and rabbit. However, we did not analyse these datasets owing 
to the limited number of compounds in the datasets. As a part of future work of this 
thesis, to cope with the lack of human biliary excretion dataset, we suggest the 
extrapolation to human pharmacokinetic parameters mainly from rat data (but also 
from dog, and monkey data).  
It should be noted that the uptake of drugs via the sinusoidal membrane and drug 
efflux by transporters is a complicated process; further studies of transporter-
mediated drug-drug interaction in hepatocyte, additional investigation on in silico 
and in vitro transporter methods, linking and utilising the pharmacokinetic 
parameters which will affect the net hepatic clearance such as area under the curve 
(AUC), excretion rate and ratio and half-life is necessary and can elucidate the 
overall elimination process in the liver hepatocyte.  
The relationship between biliary excretion and hepatic metabolism is beyond the 
scope of the present study, however, this should be possible with more data on 
metabolism and using statistical techniques such as partial least squared regression 
(PLS) which allows predicting more than one variable at the same time. 
Finally, the biliary excretion, OATPs, Ki, Km and IC50 dataset can be populated 
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10. Appendix  
 
Appendix I. Percentage of compound’s dose excreted intact through the bile in rats 
and the relevant references 




45.00 Hirom PC, et.al. Biochem J. 1972 Oct; 129(5):1071-7.  
Female Wistar albino rats (180-350g body wt.)  
17-AAG(NSC 330507) 2.00 Musser SM, et.al. Cancer Chemother Pharmacol. 2003 
Aug;52(2):139-46. Male Fischer 344 rats (7-8 weeks of 
age and weighing 220-234g)  
17-DMAG (NSC 707545)  2.38 Egorin MJ, et.al. Cancer Chemother Pharmacol. 2002 
Jan;49(1):7-19. Male Fischer 344 rats (7-8 weeks of 
age). % of Dose (in total): 4.7 ± 1.4. Parent drug 
accounted for 50.7 ± 3.4% of that.  
2-Aminotoluene-5-sulphonic 
acid  
0.27 McMahon KA, et.al. Food Cosmet Toxicol. 1969 
Sep;7(5):497-500. Rats (250-350 g body weight)  
2-Ethylsulphanilic acid  0.29 McMahon KA, et.al. Food Cosmet Toxicol. 1969. 
Sep;7(5):497-500. Rats (250-350 g body weight)  
4-Glucuronosido-4'-
hydroxybiphenyl 
92.00 Millburn P., et al, Biochem. J. 1967; 105, 1275 
Female Wistar albino rats (weighing 200 ± 10g.) 
4-Glucuronosidobiphenyl 59.00 Millburn P., et al, Biochem. J. 1967; 105, 1275 
Female Wistar albino rats (weighing 200 ± 10g.) 
5-fluorouracil (5-FU) 0.40 Young D, et.al. Nuklearmedizin. 1982 Feb;21(1):1-7.  
Male Fischer rats weighing 150 - 200g  




9.10 Zhong DF, et.al. Acta Pharmacol Sin. 2003 
Mar;24(3):256-62. Wistar rats (250 ± 20g)  
acetaminophen(paracetamol)  0.80 Ghanem CI, et.al. J Pharmacol Exp Ther. 2005 
Dec;315(3):987-95.  Male Wistar rats (250-290 g)                                                                                           
Savina PM, et.al. Drug Metab Dispos. 1992 Jul-
Aug;20(4):496-501. Male Sprague-Dawley rats (266-
282 g).  
actinomycin D  31.00 Wosilait WD, et.al. Life Sci I. 1971 Sep 
15;10(18):1051-5  
Male Sprague-Dawley rats, weighing about 300 g.  
adipylsulphathiazole 40.00 Hirom PC, et.al. Biochem J. 1972 Oct;129(5):1071-7.  
Female Wistar albino rats (180-350g body wt.)  
aprepitant 7.00 Huskey SE, et.al. Drug Metab Dispos. 2004 
Feb;32(2):246-58. Male SD rats ( 230-300 g)  
azithromycin 9.60 Sugie M, et.al. Antimicrob Agents Chemother. 2004 
Mar;48(3):809-14. Male Wistar Rats, 260 - 270g. Male 
Sprague-Dawley rats (normal rats) (260 to 280g)  
belotecan 28.29 Namkoong EM, et.al. Arch Pharm Res. 2007 
Nov;30(11):1482-8. Male SD rats (260 - 290g)  
Benzoic acid 0.09 Abou-el-makarem M.M., Millburn P, et al Biochem. 
J.(1967)105, 1269 
beta-methyldigoxin 53.00 Funakoshi S., Murakami T, et al, J Pharm Sci. 
(2005)94(6), 1196-203 
bishydroxycoumarin 1.88 Buttar HS, et.al. Br J Pharmacol. 1973 Jun;48(2):278-
87. Male Albino rats (Wistar, 275 - 355g). % of Dose 
(in total): 12.3 ± 2.7, Parent drug accounted for 15.3 
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Compounds BE% Reference 
(12.5-18.4) % of that.  
BMS-182874 0.90 Chong s, Obermeier M et al. 2003. Arch pharm sci 
26:89-94. 
BMS-187345 4.50 Chong s, Obermeier M et al. 2003. Arch pharm sci 
26:89-94. 
BMS-387032 11.00 Kamath AV chong S et al. 2005. Cancer chemother 
pharmacol 55:110-116. 
BQ-123  52.82 Kato Y, et.al. J Pharmacol Exp Ther. 1999 
Feb;288(2):568-74. Male Sprague-Dawley rats 
weighing approximately 250 to 300g . 
Nakamura T, et.al. J Pharmacol Exp Ther. 1996 
Aug;278(2):564-72. Male Sprague-Dawley rats, 7 to 10 
weeks of age. 
Niinuma K, Kato Y, et al. Am J Physiol. 1999 ;276(5 Pt 
1)1153-1164. 
BQ-485  97.40 Kato Y, et.al. J Pharmacol Exp Ther. 1999 
Feb;288(2):568-74. Male Sprague-Dawley rats 
weighing approximately 250 to 300g  
BQ-518  89.70 Kato Y, et.al. J Pharmacol Exp Ther. 1999 
Feb;288(2):568-74. Male Sprague-Dawley rats 
weighing approximately 250 to 300g  
bretylium 16.00 Kuntzman R, et.al. Clin Pharmacol Ther. 1970 Nov-
Dec;11(6):829-37  
bromochlorophenol blue 89.00 Hirom PC, et.al. Biochem J. 1972 Oct;129(5):1071-7.  
Female Wistar albino rats (180-350g body wt.)  
Bromocresol Green 73.00 Hirom PC, et.al. Biochem J. 1972 Oct;129(5):1071-7.  
Female Wistar albino rats (180-350g body wt.)  
Bromophenol Blue 67.25 Hirom PC, et.al. Biochem J. 1972 Oct;129(5):1071-7.  
Female Wistar albino rats (180-350g body wt.)                                                      
Wills RJ, et.al. J Pharm Sci. 1983 Oct;72(10):1127-31  
Fasted male Sprague-Dawley rats (260 - 470g)  
buprenorphine  1.08 Brewster D, et.al. Xenobiotica. 1981 Mar;11(3):189-96. 
Adult SD rats (200-300g). % of Dose (in total): 92.9 + 
8.0. Parent drug accounted for 1.5 ± 0.8% of that 
(Male)  
% of Dose (in total): 94.5 ± 2.8, Parent drug accounted 
for 0.8 ± 0.4% of that. (female). 
butoprozine 0.00 Overzet F, et.al. Xenobiotica. 1985 Jan;15(1):1-10.  
male Wistar rats (body wt. 300g)  
cadrala 
zine 
3.70 Eur J Drug Metab Pharmacokinet. 1983;8(1):25-33.  
Male and female Sprague Dawley rats with an average 
body weight of 150 to 180 g.  
camptothecin (carboxylate form) 36.40 Scott DO, et.al. Drug Metab Dispos. 1994 May-
Jun;22(3):438-42. Male Sprague-Dawley rats weighing 
between 250-300g. 
Guarino AM, et.al. Cancer Chemother Rep. 1973 
Apr;57(2):125-40. Male Sprague-Dawley rats (240 - 
320g) 
camptothecin (lactone form) 7.50 Scott DO, et.al. Drug Metab Dispos. 1994 May-
Jun;22(3):438-42. Male Sprague-Dawley rats weighing 
between 250-300g.  
carbovir  1.30 Zimmerman CL, et.al. Drug Metab Dispos. 1993 Sep-
Oct;21(5):902-10. Sprague-Dawley rat 
cefamandole 33.00 Wright WE, et.al. Antimicrob Agents Chemother. 1980 
May;17(5):842-6. Male Wistar rats, weighing 350 to 
500g  




Compounds BE% Reference 
Male and female Wistar-WU rats (weight range 175-
320g. 
cefazolin 30.00 Tsuji A, et.al. J Pharm Sci. 1983 Nov;72(11):1239-52.  
Male Wistar rats (240g) 
cefbuperazone (T-1982)  80.00 Saikawa I, et.al. Jpn J Antibiot. 1982 Sep;35(9):2163-
73  
cefixime 40.80 Yasui H, et.al. J Pharm Sci. 1994 Jun;83(6):819-23  
Male Witar rats (177 - 230g).  
cefmenoxime (SCE-1365)  28.50 Tanayama S, et.al. Antimicrob Agents Chemother. 
1980 Oct;18(4):511-8. male or female Sprague-Dawley 
rats weighing 220 to 515g.  
cefmetazole 36.25 Eur J Drug Metab Pharmacinet. 1992 Jul-
Sep;17(3):167-73. Male Wistar: 232-298g.  
cefodizime 28.60 Matsushita H, et.al. J Pharmacol Exp Ther. 1992 
Feb;260(2):499-504. Male Wistar rats weighing 240 to 
280g. 
cefoperazone 85.60 Saikawa I, et.al. Jpn J Antibiot. 1980 Oct;33(10):1084-
96  
cefotetan (YM-09330)  48.00 Komiya M, et.al. Antimicrob Agents Chemother. 1981 
Aug;20(2):176-83. SD rats: 200 - 350g.  
Mizojiri K, et.al. Antimicrob Agents Chemother. 1987 
Aug;31(8):1169-76  
cefpiramide (SM-1652)  59.80 Matsui H, et.al. Antimicrob Agents Chemother. 1982 
Aug;22(2):213-7.  Male Sprague-Dawley rats (200 to 
250 g). 
Imasaki H, et.al. Antimicrob Agents Chemother. 1983 
Jul;24(1):42-7. Sprague-Dawley male rats weighting 
150 to 300g. 
Muraoka I, et.al. Antimicrob Agents Chemother. 1995 
Jan;39(1):70-4. 20-week-old healthy SDR (weight, 494 
to 540 g)                                                     
ceftriaxone 61.80 Matsui H, et.al. Antimicrob Agents Chemother. 1984 
Aug;26(2):204-7. male SD rats (body weight, 200 to 
250 g)  
celiptium (NSC-264137) 6.10 Maftouh M, et.al. Xenobiotica. 1983 May;13(5):303-10  
Male SD rats (300 - 350g).  
Cephalexin 2.50 Wright W.E., Line V.D. Antimicrobial Agents & 
Chemotherapy(1980)17, 842-846. Male Wistar rats 
[HAP(WI)BR], weighing 350 to 500 
Cephradine 27.30 Moriwaki T, Yasui H and Yamamoto A. 2003. J 
Pharmacokinet Phamacodyn 30:119-144. 
chenodeoxycholate (CDC)  0.30 Takikawa H,et.al. Hepatology. 1991. 14(2):352-60. 
Male SDRs weighing about 270g. % of dose (in total): 
~ 3% at steady state. Parent drug accounted for 6 -10% 
of that.  
ciprofloxacin 9.92 Yamaguchi H, et.al. Pharm Res. 2004 Feb;21(2):330-8.  
Male Wistar rats weighing 200-250g  
colchicine  25.36 Hunter AL, et.al. J Pharmacol Exp Ther. 1975 
Mar;192(3):605-17.  
Male Thorp SD rats (350-390g). % of dose (in total): 
52. Parent drug accounted for 53% of that.  
Speeg KV, et.al. Cancer Chemother Pharmacol. 
1994;34(2):133-6. Male Sprague-Dawley rats weighing 
300-400g . 
Speeg KV, et.al. Hepatology. 1992 May;15(5):899-903.  
Male SD rats weighing 300 to 400g. CLsys: 43.05 ± 
2.68 ml/min/kg. CLbiliary: 11.62 ± 0.84 ml/min/                                                                                                             
Kitani K, et.al. Tohu J Exp Med. 1981 Apr;133(4):389-
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Compounds BE% Reference 
97. Male Wistar rats (300g on the average). % of dose 
(in total): 35.19 ± 2.91. Parent drug accounted for 70.82 
± 7.79% of that. 
compound  I  (Merck)  
diastereomer 
13.00 Prueksaritanont T, et.al. Xenobiotica. 2003 
Nov;33(11):1125-37. Male Sprague–Dawley (SD) rats 
(200–320g).  
Prueksaritanont T, et.al. Xenobioticaxenobiotica,2002, 
vol. 32, no. 3, 207±220    Male Sprague–Dawley (SD) 
rats (230–320g).  
compound  II  (Merck) 
diastereomer  
58.00 Prueksaritanont T, et.al. Xenobiotica. 2003 
Nov;33(11):1125-37. Male Sprague–Dawley (SD) rats 
(200–320g).  
Prueksaritanont T, et.al. Xenobioticaxenobiotica,2002, 
vol. 32, no. 3, 207±220    Male Sprague–Dawley (SD) 
rats (230–320g).  
cosalane 1.12 Kuchimanchi KR, et.al. Drug Metab Dispos. 2000 
Apr;28(4):403-8. Male SD rats weighing 200 to 225 g  
CP-671,305  48.33 Kalgutkar AS, et.al. Xenobiotica. 2004 Aug;34(8):755-
70  
Male and female Sprague-Dawley rats (220-250g)                                                    
Kalgutkar AS, et.al. Drug Metab Dispos. 2007 
35(11):2111-8. Male Sprague-Dawley rats (230-250g)  
cromoglycate 71.40 Ashton MJ, et.al. Toxicol Appl Pharmacol. 1973 
Nov;26(3):319-28  
Male Sprague-Dawley rats (200 - 250g)  
DA-5018 (Capsavanil) 3.06 Shim HJ, et.al. J Chromatogr B Biomed Sci Appl. 1997 
Feb 21;689(2):422-6.  
dasatinib 10.40 Christopher LJ, et.al. Drug Metab Dispos. 2008 
Jul;36(7):1341-56.  
male Sprague-Dawley rats weighing approximately 340 
to 380g.  
G.Luo, S.Johnson, et al, Drug Metab Dispos. J. 
(2010)38, 422-430 
daunorubicin  11.76 Yesair DW, et.al. Cancer Res. 1972 Jun;32(6):1177-83  
Male Sprague-Dawley rats (350 to 500 g). Amount 
excreted into bile: ~ 500µg. Dose: 10 mg/kg.  
Decamethonium bromide 1.00 Hughes R.D., Millburn P., et al, Biochem. J. (1973)136, 
979-984 
diazepam 0.00 Inaba T, et.al. Drug Metab Dispos. 1974 Sep-
Oct;2(5):429-32. Male Wistar rats (280-320 g).% of 
Dose (in total): 77; No intact diazepam could be 
detected in bile.  
Dibenzyldimethylammonium 
iodide 
36.00 Hughes RD, Millburn P. et al, Biochem. J. (1973)136, 
967-78 
diclofenac 2.99 Peris-Ribera JE, et.al. J Pharmacinet Biopharm. 1991 
Dec;19(6):647-65. Male Wistar rats (320-380 g). % of 




7.60 Hughes RD, Millburn P. et al, Biochem. J. (1973)136, 
967-78 
digoxin 84.4 Song S, et.al. Drug Metab Dispos. 1999 Jun;27(6):689-
94  
Female Sprague-Dawley (SD) rats weighing 220 to 
270g.                                             S. Funakoshi, T. 
Murakami, et al, J Pharm Sci. (2005)94(6), 1196-203               
H.Fukuda, R.Ohashi, et al,Drug Metab Dispos. 2008 
Jul;36(7):1275-82 
Dimethyltubocurarine iodide 17.00 Hughes RD., Millburn P, et al, Biochem. J. (1973)136, 
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Compounds BE% Reference 
979-984. 
DNP-NAC 42.00 Hinchman CA., Rebbeor JF et. 1998. Am j physiol 
275(4 pt 1): G612-9. 
DNP-SG(2,4-Dinitrophenyl-S-
glutathione) 
100 Niinuma K, Kato Y, et al American journal of 
physiology: Gastrointestinal & liver physiology, 1999 
;276(5 Pt 1)1153-1164. 
doxorubicin 18.26 Vaidyanathan S, et.al. Cancer Chemother Pharmacol. 
2000;46(3):185-92. Female Sprague-Dawley rats 
weighing 225 to 250g. 
 Krishna R, et.al. Clin Cancer Res. 1999 
Oct;5(10):2939-47. Male SD rats, 225-275g.                                                                                                     
Broggini M, et.al. Cancer Treat Rep. 1980. 64(8-
9):897-904. CD-COBS male rats (body weight, 200 ± 
20 g) 
Israel M, et.al. Cancer Res. 1978 Feb;38(2):365-70.  
Male SD rats weighing 320 to 440 g. % of Dose (in 
total): 20; Parent drug accounted for 80% of that. 
DPDPE 80.00 Chen C, et.al. Pharm Res. 1997 Mar;14(3):345-50  
Male Sprague-Dawley rats (250-300g 
drotaverine 0.00 Vargay Z., Simon G., et al. Eur J Drug Metab 
Pharmacokinet. 1980;5(2):69-74  
E3040 glucuronide  90.00 Niinuma K., Kato Y, et al American journal of 
physiology: Gastrointestinal & liver physiology, 1999 
;276(5 Pt 1)1153-1164. 
Takenaka O, Horie T, Suzuki H, Sugiyama Y, J  
Pharmacol Exper Ther. 280(2), 948-958. Male SD rats 
(250–330 g) from Japan Laboratory Animals Inc.  
Hirouchi M et al, Drug Metab Disp. 37 (10)2103-2111; 
OCT 2009, Male Mrp3(- /- ) mice and wild-type FVB 
mice (12–18 weeks). 
edatrexate 43.35 Fanucchi MP, et.al. Cancer Res. 1987 May 
1;47(9):2334-9  
Male CD rats. % of Dose (in total): 51 ± 4; Parent drug 
accounted for 85% of that.  
EDDP 36.00 Baselt RC, et.al. Biochem Pharmacol. 1973 Dec 
1;22(23):3117-20. Sprague-Dawley male rats (200 - 
300 g).  
EMDP 0.20 Baselt RC, et.al. Biochem Pharmacol. 1973 Dec 
1;22(23):3117-20. Sprague-Dawley male rats (200 - 
300 g).  
emepronium (EME) 12.00 Neef C, et.al. Naunyn Schmiedebergs Arch Pharmacol. 
1984 Dec;328(2):103-10. Male Wistar rats 
(approximately 300g). % of Dose (in total): 60; Parent 
drug accounted for < 20% of that  
epirubicin (4'-epiDOX)  20.00 Broggini M, et.al. Cancer Treat Rep. 1980 Aug-
Sep;64(8-9):897-904. CD-COBS male rats (body 
weight, 200 ± 20 g)  
erythromycin 32.20 Akashi M, et.al. Hepatol Res. 2006 Feb 11,193-198  
Male Sprague-Dawley rats weighting approximately 
270g.  
Kageyama M, et.al. Biol Pharm Bull. 2005 
Feb;28(2):316-22. Male Wistar rats (280 to 320g). 
Amount excreted into bile: 200.3 ± 35.6 µg. Dose: 3 
mg/kg.                                                                                                                             
Sato A, et.al. Pharmacology. 1999 Nov;59(5):249-56                                                 
Tachizawa H, et.al. J Gastroenterol Hepatol. 2004 
Sep;19(9):1016-22. Male Sprague-Dawley rats 270g.  
Lam JL, et.al. Drug Metab Dispos. 2006 
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Aug;34(8):1336-44. Male Wistar rats (200 - 350g).  
CLtot: 47.2 ± 12.5 and 42.1 ±  5.7 ml/min/kg. 
CLbiliary: 15.5 ± 2.9 and 11.2 ± 2.0 ml/min/kg.                                                                                                                            
Estradiol-17ß-glucuronide 87.00 Akashi M, et.al. Hepatol Res. 2006 Feb 11,193-198  
Estrone 3-sulphate 18.40 H.Fukuda, R.Ohashi, et al,Drug Metab Dispos. 2008 
Jul;36(7):1275-82. Male Sprague-Dawley rats (Charles 
River Japan, Yokohama. Japan) weighing 200 to 250 g 
felodipine 0.00 Sutfin TA, et.al. Xenobiotica. 1987 Oct;17(10):1203-
14.  
Male SD rats (350g). % of Dose (in total): 74; No 
unchanged felodipine was detected in either bile.  
fexofenadine 55.05 Tahara H, et.al. Drug Metab Dispos. 2005 
Jul;33(7):963-8  
SD rats, 300-350g. CLtot: 28.3 ± 2.1 ml/min/kg; 
CLbiliary: 11.4 ± 1.6 ml/min/kg     
Tian X., Swift B. Drug Metab Dispos. (2008)36(5), 
911-915 
floctafenin 8.90 Pottier J, et.al. Drug Metab Dispos. 1975 May-
Jun;3(3):133-47. Wistar of Sprague-Dawley rats (200 
g).  
flomoxef  17.50 Hishikawa S, et.al. Chronobiol Int. 2003 
May;20(3):463-71. Male Wistar rats weighing 250-300 
g 
fluvastatin  19.50 Lindahl A, et.al. Mol Pharm. 2004 Sep-Oct;1(5):347-56  
Male Sprague-Dawley rats (305 ± 20g 
fosmidomycin  0.10 Murakawa T, et.al. Antimicrob Agents Chemother. 
1982 Feb;21(2):224-30.  
FPL 55712  50.00 Mead B, et.al. J Pharm Pharmacol. 1981 
Oct;33(10):682-4  
Male Wistar rats  
furosemide 1.17 Chen C, et.al. Pharm Res. 2003 Jan;20(1):31-7.  
Male Sprague-Dawley rats, 15 weeks of age (385 - 
550g) 
gemfibrozil 0.10 Dix KJ, et.al. Drug Metab Dispos. 1999 Jan;27(1):138-
46  
Female Sprague-Dawley rats (10-12 weeks old).  
glutarylsulphathiazole 42.00 Hirom PC, et.al. Biochem J. 1972 Oct;129(5):1071-7.  
Female Wistar albino rats (180-350g body wt.)  
grepafloxacin 5.81 Sasabe H, et.al. J Pharmacol Exp Ther. 1998 
Mar;284(3):1033-9. Male Sprague-Dawley rats 
weighing approximately 250 to 300g.                             
Sasabe H,et.al. J Pharmacol Exp Ther. 1998 
Feb;284(2):661-8. Male Sprague-Dawley (SD) 
weighing approximately 250 to 300g. 
Yamaguchi H, et. al. J Pharmacol Exp Ther. 2002 
Mar;300(3):1063-9. Male Wistar rats, 200-240g.                                                                                            
Yamaguchi H, et.al. Pharm Res. 2004 Feb;21(2):330-8.  
Male Wistar rats weighing 200-250g  
hexafluorenium 34.00 Meijer DK, et.al. Eur J Pharmacol. 1971 
May;14(3):280-5  
Male Wistar rats weighing 200-250g 
Hexahydrophthalylsulfathiazole 80.00 Hirom PC, et.al. Biochem J. 1972 Oct;129(5):1071-7.  
Female Wistar albino rats (180-350g body wt.)  
Hippuric acid 0.00 Abou-el-makarem AA, Millburn P, et al Biochem. 
J.(1967)105, 1269 
ID-6105  19.76 Yoo BI, et.al. Biol Pharm Bull. 2005 Apr;28(4):688-93  
Male SD rats (230 - 250 g) .                                                                                                      
Yoo BI, et.a. Arch Pharm Res. 2005 Apr;28(4):476-82  
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Male SD rats (230 - 250 g).                                                                                                                                                                                 
Indocyanine Green 30.00 Jansen PL et.al. Am J Physiol. 1993 Sep;265(3 Pt 
1):G445-52. Male Wistar rats, weighing 250-300g  
Kurisu H, et.al. Life Sci. 1991;49(14):1003-11. 
Sprague-Dawley Rat                                                                                                            
Verkade HJ, et.al. Gastroenterology. 1990 
Nov;99(5):1485-92. Normal Wistar rats weighting 280-
320 g.   
Sathirakul K, et.al. J Pharmacol Exp Ther. 1993 
Jun;265(3):1301-12. Male SD rats weighing 
approximately 280 g.                                                                
Takikawa H, et.al. J Gastroenterol Hepatol. 1998 
Apr;13(4):427-32. Male Sprague-Dawley rats 
weighting approximately 270g. 
Hirom PC, et.al. Biochem J. 1972 Oct;129(5):1071-7.  
Female Wistar albino rats (180-350g body wt.)                                                           
Tachizawa H, et.al. J Gastroenterol Hepatol. 2004 
Sep;19(9):1016-22. Male Spraguc-Dawley rats 270g.                                                                                      
Kimura T, et.al. Biol Pharm Bull. 1993 
Nov;16(11):1140-5. Male Wistar rats weighing 200-
300g                                                                              
Chan PK, et.al. J Toxicol Environ Health. 1981 
Feb;7(2):169-79.  
indomethacin 2.06 Kouzuki H, et.al. Pharm Res. 2000 Apr;17(4):432-8  
SD rats of 302-368 g body weight.  
iododoxorubicin (IODOX)  22.00 Edwards DM, et.al. Drug Metab Dispos. 1991 Sep-
Oct;19(5):938-45. Male SD rats (mean weight 201 ± 
6g). % of Dose (in total): 34; parent drug accounted for 
< 6% of that.  
irinotecan (CPT-11) (lactone 
form)  
7.34 Chu XY, et.al. J Pharmacol Exp Ther. 1997 
Apr;281(1):304-14. Male SD rats weighing 250 to 
300g.                                                                                                                                                                                                                               
Arimori K, et.al. Pharm Res. 2003 Jun;20(6):910-7  
Male Wistar rats from 280 to 340g.                                                                                                                                                                                                                               
Itoh T, et.al. J Pharm Pharm Sci. 2004 Jan 23;7(1):13-8.  
Male Wistar rats, aged 6 to 7 weeks (180-230 g 
J-104132  99.70 Kobayashi N, et.al. Pharm Res. 2003 Jan;20(1):89-95  
Male SDRs (250-470 g).  
lamotrigine 1.40 Maggs JL, et.al. Chem Res Toxicol. 2000 
Nov;13(11):1075-81. Male Wistar rats (180-250g)  
levofloxacin 9.04 Yamaguchi H, et. al. J Pharmacol Exp Ther. 2002 
Mar;300(3):1063-9  
Male Wistar rats, 200-240g.                                                                                                                                                                                                                                            
Yamaguchi H, et.al. Pharm Res. 2004 Feb;21(2):330-8.  
Male Wistar rats weighing 200-250g  
Lissamine Fast Yellow 87.50 Bertagni P, et.al. J Pharm Pharmacol. 1972 
Aug;24(8):620-4. Male and female Wistar albino rats 
(190-350 g).  
Hirom PC, et.al. Biochem J. 1972 Oct;129(5):1071-7.  
Female Wistar albino rats (180-350g body wt). 
lithocholate (LC)  0.98 Takikawa H,et.al. Hepatology. 1991 Aug;14(2):352-60. 
Male SDRs weighing about 270g. % of dose (in total): 
98% ± 1.6%. Parent drug accounted for 1% ± 1% of 
that.  
lomefloxacin 4.26 Sasabe H, et.al. Biopharm Drug Dispos. 1999. 
Apr;20(3):151-8. Male SD rats weighing approximately 
250-300g.  
lopinavir 0.40 Kumar GN, et.al. Pharm Res. 2004 Sep;21(9):1622-30  
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Sprague-Dawley rats 
loteprednol etabonate  4.84 Wu.W, F. Huang; J of pharmacy and pharmacology, 
60(3),2008, 291-297 
LTC4(leukotriene C4) 23.10 K.Niinuma,Y.Kato, et al American journal of 
physiology: Gastrointestinal & liver physiology, 1999 
;276(5 Pt 1)1153-1164 
Denzlinger C, Grimberg M, Kapp A, Haberl C, 
WILMANNS W , British journal of pharmacology; 
1991 102 (4),865-870, male Wistar rats(180-220 g) 
LY110264 34.40 Wright W.E., Line V.D. Antimicrobial Agents & 
Chemotherapy(1980)17, 842-846. Male Wistar rats 
[HAP(WI)BR], weighing 350 to 500 
LY112384 84.70 Wright W.E., Line V.D. Antimicrobial Agents & 
Chemotherapy(1980)17, 842-846. Male Wistar rats 
[HAP(WI)BR], weighing 350 to 500 
LY126351 11.00 Wright W.E., Line V.D. Antimicrobial Agents & 
Chemotherapy(1980)17, 842-846. Male Wistar rats 
[HAP(WI)BR], weighing 350 to 500 
LY78989 74.20 Wright W.E., Line V.D. Antimicrobial Agents & 
Chemotherapy(1980)17, 842-846. Male Wistar rats 
[HAP(WI)BR], weighing 350 to 500 
LY85834 40.30 Wright W.E., Line V.D. Antimicrobial Agents & 
Chemotherapy(1980)17, 842-846. Male Wistar rats 
[HAP(WI)BR], weighing 350 to 500 
LY87780 93.80 Wright W.E., Line V.D. Antimicrobial Agents & 
Chemotherapy(1980)17, 842-846. Male Wistar rats 
[HAP(WI)BR], weighing 350 to 500 
LY88011 49.60 Wright W.E., Line V.D. Antimicrobial Agents & 
Chemotherapy(1980)17, 842-846. Male Wistar rats 
[HAP(WI)BR], weighing 350 to 500 
LY89439 49.60 Wright W.E., Line V.D. Antimicrobial Agents & 
Chemotherapy(1980)17, 842-846. Male Wistar rats 
[HAP(WI)BR], weighing 350 to 500 
merck compound A  30.00 Giuliano C, et.al. Xenobiotica. 2005 Oct-Nov;35(10-
11):1035-54. Male Sprague-Dawley rats weighing 250-
300g.  
Meropenem 80.20 Yl.chan, MH.Chou, J Chromatogr A. 2002 Jun 
28;961(1):119-24. Male specific pathogen-free 
Sprague–Dawley rats. 
methadone  8.80 Baselt RC, et.al. Biochem Pharmacol. 1973 Dec 
1;22(23):3117-20. Sprague-Dawley male rats (200 - 
300 g).  
methasquin (NSC 122870)  29.00 Rader JI, et.al. Cancer Res. 1971 Jul;31(7):964-9  
CD males, 230 to 420 g  
methotrexate 72.00 Masuda M, et.al. Cancer Res. 1997 Aug 
15;57(16):3506-10. Male SDRs (250 - 300g).                                                                                                     
Lutz Fahrig, Helmut Brasch, et al, Cancer Chemother 
Pharmacol(1989)23, 156-160                                                                                                                                          
Sasaki M, et.al. Mol Pharmacol. 2004 Sep;66(3):450-9  
Male SD rats, 240-260g. CLtot: 12.7 ± 1.9 ml/min/kg; 
CLbiliary: 10.7± 1.7 ml/min/kg                                                                                                                              
Chen C, et.al. Pharm Res. 2003 Jan;20(1):31-7.  
Male Sprague-Dawley rats, 15 weeks of age (385 - 
550g)  
Griffin D, et.al. Cancer Chemother Pharmacol. 
1987;19(1):40-1 
Ueda K, et.al. J Pharmacol Exp Ther. 2001 
Jun;297(3):1036-43. Male Sprague-Dawley rats 
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weighing 250 to 300 g. 
Bremnes RM, et.al. Cancer Res. 1989 May 
1;49(9):2460-4  
Male Wistar rats weighing 220-300 g.                                                                             
Steinberg SE, et.al. Cancer Res. 1982 Apr;42(4):1279-
82.  
Female Sprague-Dawley rats weighing 175 to 250 g. 




17.00 Hughes R.D., Millburn P., et al, Biochem. J. (1973)136, 
967-78. 
Mitoxantrone 6.08 Yang XN, Morris ME. J OF PHARM SCI, vol 99 (5) 
Pages: 2502-2510, May 2010. Male Sprague–Dawley 
(SD) rats (300–430 g). 
morphine 9.03 Roerig DL, et.al. Biochem Pharmacol. 1974 Apr 
15;23(8):1331-9. Sprague-Dawley male rats (300 - 
400g). % of dose (in total): 49.3 ± 3.6. 
Peterson RE, et.al. J Pharmacol Exp Ther. 1973 
184(2):409-18. Male SD rats (325-450 g). % of dose (in 
total): 63. Parent drug accounted for 17.0 ± 2.3% of 
that. 
Smith DS, et.al. Biochem Pharmacol. 1973 Feb 
15;22(4):485-92. Male SD rats (350-450 g). % of dose 
(in total): 64 ± 5. Parent drug accounted for 10% of 
that. 
moxalactam (latamoxef)  20.50 Uchida K, et.al. J Pharmacobiodyn. 1985 
Nov;8(11):981-8  
Wistar strain male rats, 8 weeks of age.                                                                                                                                                                                                                      
Mizojiri K, et.al. Antimicrob Agents Chemother. 1987 
Aug;31(8):1169-76. Male Sprague-Dawley rats 
(weight, 250 to 320 g)  
MX-68  84.00 Han YH, et.al. J Pharmacol Exp Ther. 1999 
Oct;291(1):204-12. Male Sprague-Dawley rats (SDRs) 
weighing 250 to 300g.  
N2-methyl-9-
hydroxyolivacinium 
2.20 Maftouh M, et.al. Xenobiotica. 1983 May;13(5):303-10  
Male SD rats (300 - 350g).  
nafenopin 4.00 Jedlitschky G, et.al. Biochem Pharmacol. 1994 Sep 
15;48(6):1113-20. % of Dose (in total): 40; Parent drug 
accounted for 10% of that.  
naftopidil 6.60 Niebch G, et.al. Arzneimittelforschung. 1991 
Oct;41(10):1027-32. Male Sprague-Dawley rats (150-
200g)  
NAPAP 37.90 Hauptmann J, et.al. Biomed Biochim Acta. 
1987;46(6):445-53.Wistar Rats of both sexes, body 
weight 260-340g.  
Hauptmann J, et.al. Pharmazie. 1991 Jan;46(1):57-8                 
napsagatran  61.00 Lavé T, et.al. J Pharm Pharmacol. 1999 Jan;51(1):85-91  
Male rats (230 ± 290 g), SPF, RoRo albino 
nelfinavir 0.05 Kageyama M, et.al. Biol Pharm Bull. 2005 
Feb;28(2):316-22. Male Wistar rats (280-320 g). 
Amount excreted into bile: 0.359 ± 0.027 µg. Dose: 2.5 
mg/kg.  
nitrofurantoin 5.16 Wang X, et.al. Drug Metab Dispos. 2007 
Feb;35(2):268-74. Female SD rats (220g)  
N-Methylpyridinium iodide 0.80 Hughes R.D., Millburn P., et al, Biochem. J. (1973)136, 
967-78 




Compounds BE% Reference 
Male Sprague-Dawley rats weighing approximately 
220g.; Yamada T, et.al. J Pharmacol Exp Ther. 1996 
Dec;279(3):1357-64.; Male SDR (approximately 220g). 
CLtot: 10.53 ± 0.38 ml/minl/kg. CLbiliary: 4.15 ± 0.21 
ml/min/kg.;                                                                          
Yamada T, et.al. Drug Metab Dispos. 1997 
May;25(5):536-43. Male SDRs weighing 220g. CLtot: 
12.63 ± 0.56 ml/minl/kg. CLbiliary: 7.44 ± 0.29 
ml/min/kg.  
Lemaire M, et.al. Drug Metab Dispos. 1989 Nov-
Dec;17(6):699-703. 
Orthanilic acid 0.00 Abou-el-makarem M.M, Millburn P., et al Biochem. 
J.(1967)105, 1269 
paclitaxel (taxol)  11.62 Monsarrat B, et.al. J Natl Cancer Inst Monogr. 
1993;(15):39-46.  Sprague-Dawley rats.                                                                                                         
Monsarrat B, et.al. Drug Metab Dispos. 1990 Nov- 
Dec;18(6):895-901. 
Luo G, Johnson S, et al, Drug Metab Dispos. J. 
(2010)38, 422-430 
PAEB (procaine amid 
ethobromide) - not in other 
tables 
32.20 Watkins JB 3rd, et.al. Drug Metab Dispos. 1987 Mar-
Apr;15(2):177-83. Male Sprague-Dawley rats.                                                                                                       
Alterations in biliary excretory function by 
streptozotocin-induced diabetes 
pancuronium 3.50 Upton RA, et.al. Anesth Analg. 1982 Apr;61(4):313-6  
Male Sprague-Dawley rats, weighting 250-350g.  
Paraquat di-iodide 0.50 Hughes R.D., Millburn P., et al, Biochem. J. (1973)136, 
979-984 
pefloxacin 3.94 Montay G, et.al. Antimicrob Agents Chemother. 1984 
Apr;25(4):463-72. Male Wistar rats (200 to 300g)  
penicillin G (benzylpenicillin)  20.78 Tsuji A, et.al. J Pharm Sci. 1983 Nov;72(11):1239-52.  
Male Wistar rats (240g).                                                                                                             
Ito K, et.al. Am J Physiol Gastrointest Liver Physiol. 
2004 287(1):G42-9. Male SD rats weighing 240-300g. 
% of dose (in total): 31.7; Parent drug accounted for 
50% of that. 
penicillin V 29.50 Tsuji A, et.al. J Pharm Sci. 1983 Nov;72(11):1239-52.  
Male Wistar rats (240g).  
Phenolphthalein 2.00 Millburn P,et al, Biochem. J. 1967; 105, 1275 
Female Wistar albino rats (weighing 200 ± 10g.) 
Phenolphthalein disulphate 74.00 Hirom PC, et.al. Biochem J. 1972 Oct;129(5):1071-7.  
Female Wistar albino rats (180-350g body wt.)  
Phenolphthalein glucuronide 14.10 Itagaki S, et.al. Drug Metab Pharmacinet. 
2003;18(4):238-44. Male SD rats (300 -350g). Amount 
excreted into bile in 1 hr: 311 ± 23.4 nmol/kg. Dose: 
2.2 µmol/kg.  
phenolsulfonephthalein (PSP, 
phenol red) 
14.10 Itagaki S, et.al. Drug Metab Pharmacinet. 
2003;18(4):238-44. Male SD rats (300 -350g). Amount 
excreted into bile in 1 hr: 311 ± 23.4 nmol/kg. Dose: 
2.2 µmol/kg.  
phenytoin (diphenylhydantoin) 0.40 Inaba T, et.al. Drug Metab Dispos. 1975 Mar-
Apr;3(2):69-73.Wistar rats (250-330 g). % of Dose (in 
total): 28 or 54, Parent drug accounted for about 0.3 - 
1.1% of that.  
El-Hawari AM, et.al. J Pharmacol Exp Ther. 1977 
Apr;201(1):14-25. Male SD rats (180-280 g). % of 
Dose (in total) in 2 hr: 32, Parent drug accounted for 
1.9 ± 0.2% of that. 
PhIP 3.09 Dietrich CG, et.al. Carcinogenesis. 2001 
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May;22(5):805-11  
Female wistar rats (200 - 250g).  
pipecuronium 4.48 Bodrogi L, et.al. Arzneimittelforschung. 
1980;30(2a):366-70.Female rats weighing 200 to 320g. 
% of Dose (in total): 6.36; Parent drug accounted for 69 
- 72% of that.  
pitavastatin 76.15 Hirano M, et.al. Mol Pharmacol. 2005 Sep;68(3):800-7  
Male Sprague-Dawley rats weighing approximately 250 
to 300g. 
Fujino H, et.al. Drug Metab Pharmacinet. 
2002;17(5):449-56. Male Sprague-Dawley rats 
weighing approximately 250g  
pravastatin 76.15 Akashi M, et.al. Hepatol Res. 2006 Feb 11,193-198  
Male Sprague-Dawley rats weighting approximately 
270g  
Fukumura S, et.al. Pharm Res. 1998 Jan;15(1):72-6  
Male Sprague-Dawley rats (SDR) approximately 270g                                                
Marumo T, et.al. J Gastroenterol. 2004 Oct;39(10):981-
7.  
Male Sprague-Dawley rats weighting approximately 
270g                                        Sasaki M, et.al. Mol 
Pharmacol. 2004 Sep;66(3):450-9  
male Sprague-Dawley rats weighing approximately 240 
to 260g. 
Takikawa H, et.al. J Gastroenterol Hepatol. 1998 
Apr;13(4):427-32. Male Sprague-Dawley rats 
weighting approximately 270g. 
Ohashi M, et.al. Pharmacology. 2002 Sep;66(1):31-5.                                                 
Ogasawara T, et.al. Hepatol Res. 2001 Jun;20(2):221-
231  
Male Sprague-Dawley rats weighing approximately 
270g                                         Niinuma K, Kato Y, et 
al, Am J Physiol. 1999 ;276(5 Pt 1)1153-1164. 
Fukuda H, Ohashi R, et al,Drug Metab Dispos. 2008 
Jul;36(7):1275-82 
probenecid 13.62 Conway W, et.al. J Pharm Sci. 1974 Oct;63(10):1551-4  
Male SD rats weighting 420- 530g.                                                                                 
Guarino AM, et.al. J Pharmacol Exp Ther. 1968 
Dec;164(2):387-95. Male Sprague-Dawley rats, 
weighing 250 to 320g. % of Dose (in total): 85.5 ± 2.7, 
57.9 ± 4.0, 25.4 ± 3.4. Parent drug accounted for 
16.2%, 37.7% and 34.6% of that.       
prostacyclin (PGI 2) 0.00 Taylor BM, et.al. J Pharmacol Exp Ther. 1980 
Jul;214(1):24-30 Female SD rats (200 - 250g)  
proxicromil 4.40 Smith DA, et.al. Eur J Drug Metab Pharmacokinet. 
1983 8(3):225-32. CRCD rats. Amount excreted into 
bile: 110 µg. Dose: 10 mg/kg. Weight assumed to be 
250 g.  
PSC 833(Valspodar)  0.86 Song S, et.al. Drug Metab Dispos. 1998 
Nov;26(11):1128-33. Female Sprague-Dawley rats (10 
weeks of age, weighing 220-270g)  
QMPB 0.00 Christensen A, et.al. Xenobiotica. 1990 Apr;20(4):417-
34  
female Sprague-Dawley rat, body wt 200g  
ramatroban 16.00 Moriwaki T, et.al. Pharm Res. 2004 Jun;21(6):1055-64  
SDR weighing 200-220g. % of dose (in total): 28.5 ± 
2.6, Parent drug accounted for 56% of that.  
R-benoxaprofen 0.70 Mohri K, et.al. Pharm Res. 2005 Jan;22(1):79-85  
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Male SD rats (250 - 300g)  
R-carprofen 9.84 Kemmerer JM, et.al.J Pharm Sci. 1979 
Oct;68(10):1274-80. Male rats (200-300g) 
remikiren 34.60 Coassolo P, et.al. Xenobiotica. 1996 Mar;26(3):333-45  
Male albino SPF rats (weight 280-320 g)  
reproterol 4.09 Kucharczyk N, et.al. Arzneimittelforschung. 
1981;31(12):2085-8. Male Charles River rats (165-
275g).  
% of Dose (in total): 45.33 ± 4.62; Parent drug 
accounted for 1.7 to 13% of that.  
R-grepafloxacin 4.43 Sasabe H, et.al. Biopharm Drug Dispos. 1999. 
Apr;20(3):151-8. Male SD rats weighing approximately 
250-300g  
Rhodamine 123 3.72 Kageyama M, et.al. Biol Pharm Bull. 2006 
Apr;29(4):779-84.Male Wistar Rats, 300 ± 20g. 
Amount excreted into bile over 2 hr: 2.23 ± 0.06 µg. 
Dose: 0.2 mg/kg.  
Kageyama M, et.al. Biol Pharm Bull. 2005 
Feb;28(2):316-22. Male Wistar rats: 280 -320g. 
Amount excreted into bile: 2.79 ± 0.37 µg. Dose: 0.2 
mg/kg.                                                                                                                              
Yumoto R, et.al. Drug Metab Dispos. 2001 
Feb;29(2):145-51. Male Wistar rats weighing 230 to 
300g.                                                                        
Kageyama M, et.al. Biol Pharm Bull. 2005 
Jan;28(1):130-7. Male Wistar: 300 ± 20g. Amount 
excreted into bile over 2 hr: ~ 2000ng. Dose: 0.2 
mg/kg.  
ritonavir 3.40 Denissen JF, et.al. Drug Metab Dispos. 
1997.Apr;25(4):489-501. SD rats (220-270g). % of 
Dose (in total) in  6 hr: 79.7; Parent drug accounted for 
1.9% of that (Male). % of Dose (in total) in 6 hr: 41.6; 
Parent drug accounted for 12.7% of that (Female).  
Rivaroxaban 48.40 Weinz C, Schwarz T, Kubitza D. et al. (2009). Drug 
Metab Dispos. 2009;37(5):1056-64. 
rosuvastatin 56.90 Kitamura S, et.al. Drug Metab Dispos. 2008 
Oct;36(10):2014-23. Male Sprague-Dawley rats (9 
weeks old) .   
H.Fukuda, R.Ohashi, et al,Drug Metab Dispos. 2008 
Jul;36(7):1275-82. Male Sprague-Dawley rats (Charles 
River Japan, Yokohama, Japan) weighing 200 to 250 g 
Salicylic acid 4.40 H.Fukuda, R.Ohashi, et al,Drug Metab Dispos. 2008 
Jul;36(7):1275-82. Male Sprague-Dawley rats (Charles 
River Japan, Yokohama, Japan) weighing 200 to 250 g 
SB-265123  2.80 WARD K, et.al. Drug Metab Dispos. 1999 
Nov;27(11):1232-41. male Sprague-Dawley rats 
weighing 290 to 350 g 
S-benoxaprofen 3.00 Mohri K, et.al. Pharm Res. 2005 Jan;22(1):79-85  
Male SD rats (250 - 300g)  
S-carprofen 5.70 Kemmerer JM, et.al.J Pharm Sci. 1979 
Oct;68(10):1274-80. Male rats (200-300g) 
s-grepafloxacin 3.66 Sasabe H, et.al. Biopharm Drug Dispos. 1999 
Apr;20(3):151-8. Male SD rats weighing approximately 
250-300g  
sitagliptin 16.39 Beconi MG, et.al. Drug Metab Dispos. 2007 
Apr;35(4):525-32. Male SD rats (360 - 450g). 
SK&F 110679  53.10 Davis CB, et.al. Drug Metab Dispos. 1994 Jan-
Feb;22(1):90-8. Male Sprague-Dawley rats.  
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Compounds BE% Reference 
SN-38 carboxylate 6.72 ltagaki S, Sasaki K, et al, J Pharm Pharm Sci. 
(2004)23;7(1), 8-13. Male Wistar rats, aged 6 to 7 
weeks (180-230 g in weight). 
SN-38 lactone 2.43 ltagaki S, Sasaki K, et al, J Pharm Pharm Sci. 
(2004)23;7(1), 8-13. Male Wistar rats, aged 6 to 7 
weeks (180-230 g in weight). 
SN-38-glucuronide carboxylate 7.00 ltagaki S, Sasaki K, et al, J Pharm Pharm Sci. 
(2004)23;7(1), 8-13. Male Wistar rats, aged 6 to 7 
weeks (180-230 g in weight). 
SN-38-glucuronide lactone 21.90 ltagaki S, Sasaki K, et al, J Pharm Pharm Sci. 
(2004)23;7(1), 8-13. Male Wistar rats, aged 6 to 7 
weeks (180-230 g in weight). 
Stilboestrol 2.92 Millburn P,et al, Biochem. J. 1967; 105, 1275  
Female Wistar albino rats (weighing 200 ± 10g.) % of 
Dose (in total): 94; Parent drug accounted for 3% of 
that. 
stilboestrol glucuronide 89.00 Millburn P,et al, Biochem. J. 1967; 105, 1275 
Female Wistar albino rats (weighing 200 ± 10g.)% of 
Dose (in total): 100; Parent drug accounted for 89% of 
that. 
Succinylsulphathiazole 33.00 Hirom P.C., Millburn P., et al, Biochem. J. (1972)129, 
1071-1077, Female Wistar albino rats (180-350g body 
wt.) 
sulfaethidole 18.50 Kekki M, et.al. J Pharmacokinet Biopharm. 1982 
Feb;10(1):27-51. Male Sprague-Dawley rats weighting 
356 ± 12 g  
sulphanilic acid  0.69 McMahon KA, et.al. Food Cosmet Toxicol. 1969 
Sep;7(5):497-500. Rats (250-350 g body weight 
M.M.Abou-el-makarem, P.millburn, et al Biochem. 
J.(1967)105, 1269 
Tartrazine 19.11 Hirom P.C., Millburn P., et al, Biochem. J. (1972)129, 
1071-1077, Female Wistar albino rats (180-350g body 
wt.)                                                                                  
Gregson RH, et.al. J Pharm Pharmacol. 1972 
Jan;24(1):20-4. Male and female Wistar albino rats, 
190-210g                                                           Bertagni 
P, et.al. J Pharm Pharmacol. 1972. 24(8):620-4 
taurocholate 96.00 Akashi M, et.al. Hepatol Res. 2006 Feb 11,193-198  
Male Sprague-Dawley rats weighting approximately 
270g                                                                                                                                                                                              
Takikawa H, et.al. Hepatology. 1996 Mar;23(3):607-13.  
Male Sprague-Dawley rats (SDR) approximately 270g.                                                                                                                                                                                                     
Fukumura S, et.al. Pharm Res. 1998 Jan;15(1):72-6  
Male Sprague-Dawley rats (SDR) approximately 270g.                                                                                                                                                    
Kuipers F, et.al. J Clin Invest. 1988 May;81(5):1593-9  
Wistar rats                                                                                                                                                                                                                                                                                                  
Jansen PL, et.al. Hepatology. 1987 Jan-Feb;7(1):71-6.  
Homozygous TM rats (200 to 250g)                                                                                                                                                                                                                                                 
Bowmer CJ, et.al. Br J Pharmacol. 1984 
Nov;83(3):773-82  
Male Wistar albino rats (250-350g)                                                                                                                                                                                                                                                     
Bode KA, et.al. Biochem Pharmacol. 2002 Jul 
1;64(1):151-8  
Male Wistar rats weighing about 180 - 220g.                                                                                                                                                                                                                               
Meijer DK, et.al. Drug Metab Dispos. 1976 Jan-
Feb;4(1):1-7. Male Wistar rats weighing about 275g. 
Watkins JB, et.al. Drug Metab Dispos. 1987 Mar-
Apr;15(2):177-83. Male Sprague-Dawley rats. 
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Compounds BE% Reference 
telithromycin 13.80 Yamaguchi S, et.al. Antimicrob Agents Chemother. 
2006 Jan;50(1):80-7. Male SD rats, 270-280g. CLsys: 
6.97 ± 0.22 L/hr/kg. CLbiliary: 4.41 ± 0.21 ml/min.  
temazepam 0.50 Tse FL, et.al. J Pharm Sci. 1983 Mar;72(3):311-2  
Male Wistar strain rats average weight 250g  
temocaprilat 67.16 Takikawa H, et.al. Hepatol Res. 2002 Oct;24(2):136  
Male Sprague-Dawley rats (270 g) .                                                                               
Ishizuka H, et.al. J Pharmacol Exp Ther. 1997 
Mar;280(3):1304-11. Male Sprague-Dawley rats (7 
weeks old). Ishizuka H, et.al. J Pharmacol Exp Ther. 
1999 Sep;290(3):1324-30. Male Sprague-Dawley (SD) 
rats.  
terbutaline  7.88 Eriksson H, et.al. Acta Physiol Scand. 1975 
Sep;95(1):1-5  
Mak SPF Sprague-Dawley mts, wetghing 250 -300g. 
CLtot: 5.2 ml/min/kg; CLbiliary: 0.41 ml/ming/kg 
Tetraethylammonium bromide 0.50 Hughes R.D, Millburn P., et al, Biochem. J. (1973)136, 
967-78 
tetrahydrocannabinol 0.07 Widman M, et.al. Biochem Pharmacol. 1974 Apr 
1;23(7):1163-72. Sprague-Dawley rats. % of Dose (in 
total) in 6 hr: 68, Parent drug accounted for 0.1% of 
that 
thyroxine (T4)  3.46 Wong H, et.al. Toxicol Sci. 2005 Apr;84(2):232-42  
Male Sprague-Dawley rats approximately 8-10 weeks 
old (~ 225-325g).  
tolrestat 54.75 Cayen MN, et.al. Drug Metab Dispos. 1985 Jul- 
Aug;13(4):412-9. Male albino SD rats (200-250 g). % 
of Dose (in total): 73 in 4 hr; Parent drug accounted for 
75% of that.  
TPBE  0.80 Dow J, et.al. Xenobiotica. 1982 Oct;12(10):633-43  
Male Sprague-Dawley rats of approx. 150g  
TR-14035  29.40 Tsuda-Tsukimoto N, et.al. Pharm Res. 2006 
Nov;23(11):2646-56. Male Sprague-Dawley rats 
weighing 250 to 320 g.  
triamterene 5.50 Kau ST, et.al. Drug Metab Dispos. 1975 Sep-
Oct;3(5):345-51. Male SD rats (200 - 250g 
tributylmethylammonium 
(TBuMA) 
33.30 Hong SS, et.al. Pharm Res. 2000 Jul;17(7):833-8.  
Male Sprague-Dawley rats, 7 to 8 weeks of age.  
Han YH, et.al. Drug Metab Dispos. 1999 
Aug;27(8):872-9  
Male Wistar rats (250-300g).                                                                                              
Hong SS, et.al. Arch Pharm Res. 2005 Mar;28(3):330-4  
Male Sprague-Dawley rats, 7 to 8 weeks of age.                                                           
Neef C, et.al. Naunyn Schmiedebergs Arch Pharmacol. 
1984 Dec;328(2):103-10.Male Wistar rats, weighing 
approximately 300g. Lee IK, et.al. Arch Pharm Res. 
2002 Dec;25(6):969-72.Male Sprague-Dawiey rats 
(250-270g).                                                                           
Jansen PL, et.al. Hepatology. 1987 Jan-Feb;7(1):71-6.  
Wistar rats: 200-250g.  
triethylmethylammonium(TEM
A) 
0.39 Hong SS, et.al. Pharm Res. 2000 Jul;17(7):833-8.  
Male Sprague-Dawley rats, 7 to 8 weeks of age.                                                           
Neef C, et.al. Naunyn Schmiedebergs Arch Pharmacol. 
1984 Dec;328(2):103-10.Male Wistar rats, weighing 
approximately 300g. Han YH, et.al. Drug Metab 
Dispos. 1999 Aug;27(8):872-9. Male Wistar rats (250-
300g).  
trifluoperazine 0.30 Schmalzing G, et.al. Xenobiotica. 1978 Jan;8(1):45-54  
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Compounds BE% Reference 
Male Wistar rats. 200-250g.  
triiodothyroacetic acid  1.05 Rutgers M, et.al. Endocrinology. 1989 Jul;125(1):433-
43. Male Wistar rats (approximately 200 g). % of Dose 
(in total): 42 ± 4; Parent drug accounted for less than 
2.5% of that.  
Trimethylphenylammonium 
iodide 
0.70 Hughes RD, Millburn P. et al, Biochem. J. (1973)136, 
967-78 
trimetrexate 0.80 Wong BK, et.al. Drug Metab Dispos. 1990 Nov-
Dec;18(6):980-6  
Male SD rats (333 to 382g).  
UK-224,671  28.90 Beaumont K, et.al. Eur J Pharm Sci. 2000 
Nov;12(1):41-50 Male Sprague-Dawley rats 
UK-240,455  23.20 Webster R, et.al. Xenobiotica. 2003 May;33(5):541-60  
Male Sprague-Dawley rats (300-350g).  
UK-427,857  40.00 Walker DK, et.al. Drug Metab Dispos. 2005 
Apr;33(4):587-95  Male Sprague-Dawley rats ( 250g).  
ulifloxacin (UFX) 9.10 Yagi Y, et.al. Drug Metab Pharmacokinet. 
2003;18(6):381-9  Male SD rats aged 7 weeks.  
valsartan 42.75 Yamashiro W, et.al. Drug Metab Dispos. 2006 
Jul;34(7):1247-54  Male Sprague-Dawley (SD) rats (7-
8 weeks old).  H.Fukuda, R.Ohashi, et al,Drug Metab 
Dispos. 2008 Jul;36(7):1275-82  Male Sprague-Dawley 
rats (Charles River Japan, Yokohama, Japan) weighing 
200 to 250 g 
vecuronium 46.00 Upton RA, et.al. Anesth Analg. 1982 Apr;61(4):313-6  
Male Sprague-Dawley rats, weighting 250-350g.  
verlukast(MK-571) 17.75 Nicoll-Griffith DA, et.al. Drug Metab Dispos. 1995 
Oct;23(10):1085-93 male SD rats (~ 350g)  
Vinblastine 30.00 Kurihara H, Sano N and Takikawa H. 2005. 20:1069-
1074. 
vincristine (VCR)  42.60 Song S, et.al. Drug Metab Dispos. 1999 Jun;27(6):689-
94  
Female Sprague-Dawley (SD) rats weighing 220 to 
270g.                                                                                                                                                                                     
Castle MC, et.al. Cancer Res. 1976 Oct;36(10):3684-9. 
Male and female SD rats (200 to 250g).  
Voreloxin 35.20 Evanchik MJ, et al. Drug Metab Dispos. 2009 
Mar;37(3):594-601. male Sprague-Dawley rats, 
weighing 225 to 275 g 
xamoterol 0.00 Mulder GJ, et.al. Xenobiotica. 1987 Jan;17(1):85-92  
Male Wistar rats (body wt approx. 200g). % of Dose (in 
total): 40; No unchanged drug existed.  
YM-13115 72.20 Matsui H, et.al. Antimicrob Agents Chemother. 1984 
Aug;26(2):204-7 male SD rats (body weight, 200 to 





Appendix II. Binding data for P-gp inhibitors 










LY335979 Digoxin Caco-2 0.02 177 0.023 5 Choo et al, 2000 
Elacridar  Prazosin MDCK II-
MDR1 
   0.05 1 Rautio et al 2006 
LY335979  Abacavir MDCK II-
MDR1 
0.07  0.05  Shaik et al 2007 
Loperamide  quinidine MDCK II-
MDR1 
   0.1 3 Lumen et al 2010 
Reserpine Daunomycin P388 
lymphoma 
   0.14 0.002 Lan et al, 1996 
Verapamil vincristine K562-MDR 0.2 1.7 0.179 0.2 Richter et al 2009 
Elacridar calcein MDCK II-
MDR1 
0.3 10 0.273 1 Matsson P et al 
2009 
Elacridar Irinotecan  MDCK II-
MDR1 
0.38 46 0.312 10 Luo et al, 2002 
Elacridar Digoxin Caco-2    0.39 0.011 Tang et al 2002 
Mefloquine Daunomycin P388 
lymphoma 
   0.43 0.002 Lan et al, 1996 
Dipyridamole Daunomycin P388 
lymphoma 
   0.52 0.002 Lan et al, 1996 
Itraconazole calcein MDCK-
MDR1 
0.6 3.1 0.581 0.1 Cook et al, 2009 
Terfenadine Daunomycin P388 
lymphoma 
   0.63 0.002 Lan et al, 1996 
CP147478 Digoxin Caco-2 0.14  0.75 5 Wandal et al, 1999 
Reserpine vinblastine LLC-
PK1/MDR1 
   0.97 2 Ekins et al, 2002 
Cyclosporine Prazosin MDCK II-
MDR1 
   0.98 1 Rautio et al 2006 
Verapamil Prazosin MDCK II-
MDR1 
   1.18 1 Rautio et al 2006 
Gallopamil vinblastine Caco-2 1.63 4.1 1.308 1 Neuhoff et al, 
2000 
Nelfinavir Digoxin Caco-2 1.4 177 1.362 5 Choo et al, 2000 
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Tamoxifen Daunomycin P388 
lymphoma 
   1.39 0.002 Lan et al, 1996 
D-703 Digoxin Caco-2 1.6 177 1.556 5 Pauli-Magnus et 
al, 2000 
pumafentrine calcein K562-MDR 3.12 0.3 1.56 0.25 Richter et al 2009 
CP99542 Digoxin Caco-2 3.8  1.6 5 Wandal et al, 1999 
Erlotinib vincristine K562-MDR 2 1.7 1.787 0.2 Richter et al 2009 
Cyclosporin Digoxin Caco-2    0.46 0.011 Noguchi et al, 
2009 
CP114769 Digoxin Caco-2 0.3  2 5 Wandal et al, 1999 
Quinidine Daunomycin P388 
lymphoma 
   2.05 0.002 Lan et al, 1996 
Ketoconazole Prazosin MDCK II-
MDR1 





   2.41 0.002 Lan et al, 1996 
Bromocriptine calcein LLC-
PK1/MDR1 
   2.81  Ekins et al, 2002 
Ketoconazole Digoxin Caco-2 1.2 177 1.167 5 Cook et al, 2009 
CP117227 Digoxin Caco-2 0.07  3 5 Wandal et al, 1999 
Norverapamil vinblastine Caco-2 4.24 4.1 3.402 1 Neuhoff et al, 
2000 
Promethazine Daunomycin P388 
lymphoma 
   3.45 0.002 Lan et al, 1996 
Itraconazole Digoxin Caco-2 2 385 1.974 5 Cook et al, 2009 
Carvedilol Digoxin Caco-2 4 385 3.949 5 Cook et al, 2009 
Bromocriptine vinblastine LLC-
PK1/MDR1 
   3.96 2 Ekins et al, 2002 
Nicardipine calcein MDCK-
MDR1 
4.2 3.1 4.069 0.1 Cook et al, 2009 
Spironolactone Daunomycin P388 
lymphoma 
   4.14 0.002 Lan et al, 1996 














Mibefradil Digoxin Caco-2 1.2 177 1.167 5 Ekins et al, 2002 
Progesterone Daunomycin P388 
lymphoma 
   4.6 0.002 Lan et al, 1996 
tolafentrine calcein K562-MDR 9.46 0.3 4.73 0.25 Richter et al 2009 
Telmisartan  Digoxin Caco-2 5 385 4.936 5 Cook et al, 2009 
Amprenavir quinidine MDCK II-
MDR1 
   5 3 Lumen et al 2010 
Fluphenazine Daunomycin P388 
lymphoma 
   5.52 0.002 Lan et al, 1996 
Mibefradil calcein MDCK-
MDR1 
6 3.1 5.813 0.1 Cook et al, 2009 
CP101556 Digoxin Caco-2 0.6  5.9 5 Wandal et al, 1999 
Ritonavir Digoxin Caco-2 3.8 177 3.696 5 Choo et al, 2000 
Fentanyl Digoxin Caco-2 6.5 177 6.321 5 Ekins et al, 2002 
ergocryptine vinblastine LLC-
PK1/MDR1 
   6.43 2 Ekins et al, 2002 
Amitriptyline Daunomycin P388 
lymphoma 
   7.53 0.002 Lan et al, 1996 
Saquinavir Digoxin Caco-2 6.5 177 6.321 5 Choo et al, 2000 
Montelukast  Digoxin Caco-2 8 385 7.897 5 Cook et al, 2009 
Nicardipine  Digoxin Caco-2 8 385 7.897 5 Cook et al, 2009 
Verapamil fexofenadine Caco-2 8.44 150 7.913 10 Petri et al, 2004 
Amiodarone calcein LLC-
PK1/MDR1 
   5.78 1 Ekins et al, 2002 
Tiapamil vinblastine Caco-2 12 4.1 9.645 1 Neuhoff et al, 
2000 
Ivermectin Digoxin Caco-2 10 177 9.725 5 Ekins et al, 2002 
Lovastatin Digoxin Caco-2 10 177 9.725 5 Ekins et al, 2002 
Mitomycin C Digoxin Caco-2 10 177 9.725 5 Ekins et al, 2002 
Procainamide Digoxin Caco-2 10 177 9.725 5 Ekins et al, 2002 


















11.8 24 11.783 0.035 Katoh et al, 2000 
ergocryptine calcein LLC-
PK1/MDR1 
   12.2 1 Ekins et al, 2002 
CP100356 Digoxin Caco-2 0.11  13 5 Wandal et al, 1999 





25.2 11 25.143 0.025 Katoh et al, 2000 
ergocristine vinblastine LLC-
PK1/MDR1 
   13.33 2 Ekins et al, 2002 
Nitrendipine  Digoxin Caco-2 14 385 13.821 5 Cook et al, 2009 
ergotamine vinblastine LLC-
PK1/MDR1 
   14.25 2 Ekins et al, 2002 
Gemcabene calcein MDCK-
MDR1 
15 3.1 14.531 0.1 Cook et al, 2009 
Isradipine  Digoxin Caco-2 15 385 14.808 5 Cook et al, 2009 
Verapamil calcein MDCK-
MDR1 





15.4 24 15.378 0.035 Katoh et al, 2000 
Felodipine calcein MDCK-
MDR1 
16 3.1 15.5 0.1 Cook et al, 2009 
quinidine Digoxin MDCK II-
MDR1 
   0.1 0.03 Lumen et al 2010 
Ketoconazole calcein LLC-
PK1/MDR1 
   24.9 1 Ekins et al, 2002 
Azelastine Daunomycin LLC-
PK1/MDR1 
16 24 15.977 0.035 Katoh et al, 2000 
PSC-833 
(Valsopodar) 
Digoxin Caco-2 0.11  16  Wandal et al, 1999 
Carvedilol calcein MDCK-
MDR1 
17 3.1 16.469 0.1 Cook et al, 2009 
Repaglinide  Digoxin Caco-2 17 385 16.782 5 Cook et al, 2009 
Troglitazone calcein MDCK-
MDR1 
19 3.1 18.406 0.1 Cook et al, 2009 
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5.48 11 5.431 0.1 Katoh et al, 2000 
Azithromycin Digoxin Caco-2 21.8 177 21.201 5 Ebrel et al, 2007 
Conivaptan calcein MDCK-
MDR1 
22 3.1 21.313 0.1 Cook et al, 2009 
vinblastine Prazosin MDCK II-
MDR1 
   21.9 1 Rautio et al 2006 
Amiodarone Daunomycin LLC-
PK1/MDR1 
22.5 24 22.467 0.035 Katoh et al, 2000 
CP69042 Digoxin Caco-2 2.3  23 5 Wandal et al, 1999 
Loperamide  calcein MDCK II-
MDR1 
26 10 23.636 1 Matsson P et al 
2009 
MK571 calcein MDCK II-
MDR1 




   26.36 2 Ekins et al, 2002 
Felodipine  Digoxin Caco-2 29 385 28.628 5 Cook et al, 2009 
Diltiazem calcein MDCK-
MDR1 
30 3.1 29.063 0.1 Cook et al, 2009 
clotrimazole vinblastine LLC-
PK1/MDR1 
   29.92 2 Ekins et al, 2002 
Isradipine calcein MDCK-
MDR1 
31 3.1 30.031 0.1 Cook et al, 2009 
Troglitazone  Digoxin Caco-2 31 385 30.603 5 Cook et al, 2009 
Dipyridamole Digoxin LLC-
PK1/MDR1 
40 11 40  Kakumoto 2002 
Ranolazine calcein MDCK-
MDR1 
34 3.1 32.938 0.1 Cook et al, 2009 
Clarithromycin Digoxin Caco-2 4.1 177 3.987 5 Ebrel et al,2007 
Ritonavir calcein MDCK-
MDR1 
36 3.1 34.875 0.1 Cook et al, 2009 
Diltiazem Digoxin Caco-2 36 385 35.538 5 Cook et al, 2009 
Midazolam calcein K562-MDR 73.9 0.3 36.95 0.25 Richter et al 2009 
Erythromycin vinblastine LLC-
PK1/MDR1 
   37.79 2 Ekins et al, 2002 
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Conivaptan  Digoxin Caco-2 39 385 38.5 5 Cook et al, 2009 
Thioridazine calcein MDCK II-
MDR1 






41.8 11 41.705 0.025 Katoh et al, 2000 
ergocristine calcein LLC-
PK1/MDR1 
   42.8 1 Ekins et al, 2002 
Lansoprazole calcein K562-MDR 86.9 0.3 43.45 0.25 Richter et al 2009 
clotrimazole calcein LLC-
PK1/MDR1 
   44  Ekins et al, 2002 
Saquinavir calcein MDCK-
MDR1 
46 3.1 44.563 0.1 Cook et al, 2009 
Nifedipine calcein MDCK-
MDR1 
47 3.1 45.531 0.1 Cook et al, 2009 
Omeprazole calcein MDCK-
MDR1 
54 3.1 52.313 0.1 Cook et al, 2009 
Talinolol calcein MDCK-
MDR1 
48 3.1 46.5 0.1 Cook et al, 2009 
Ranolazine  Digoxin Caco-2 49 385 48.372 5 Cook et al, 2009 
Indinavir Prazosin MDCK II-
MDR1 
   50 1 Rautio et al 2006 
Nifedipine  Digoxin Caco-2 53 385 52.321 5 Cook et al, 2009 
vinblastine Digoxin Caco-2    8.92 0.011 Tang et al 2002 
Cortisol Digoxin Caco-2 55 177 53.489 5 Ekins et al, 2002 
Tamoxifen Digoxin Caco-2 55 177 53.489 5 Ekins et al, 2002 
Pantoprazole calcein K562-MDR 108 0.3 54 0.25 Richter et al 2009 
Clarithromycin calcein MDCK-
MDR1 
57 3.1 55.219 0.1 Cook et al, 2009 
Miconazole calcein LLC-
PK1/MDR1 
   55.5 1 Ekins et al, 2002 
Paroxetine calcein MDCK-
MDR1 
61 3.1 59.094 0.1 Cook et al, 2009 
Pantoprazole  Digoxin Caco-2 69 385 68.115 5 Cook et al, 2009 
Omeprazole vinblastine Caco-2 89 4.1 71.411 1 Neuhoff et al, 
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fluvastatin calcein K562-MDR 151 0.3 75.5 0.25 Richter et al 2009 
Desmethylcarv
edilol 
vinblastine Caco-2 97.6 4.1 78.311 1 Neuhoff et al, 
2000 





   87.64 2 Ekins et al, 2002 
imipramine calcein K562-MDR 180 0.3 90 0.25 Richter et al 2009 
Alprenolol calcein K562-MDR 181 0.3 90.5 0.25 Richter et al 2009 
digoxin calcein K562-MDR 189 0.3 94.5 0.25 Richter et al 2009 
Captopril calcein MDCK-
MDR1 
100 3.1 96.875 0.1 Cook et al, 2009 
Cimetidine  calcein MDCK-
MDR1 
100 3.1 96.875 0.1 Cook et al, 2009 
Losartan calcein MDCK-
MDR1 
100 3.1 96.875 0.1 Cook et al, 2009 
Milameline  calcein MDCK-
MDR1 
100 3.1 96.875 0.1 Cook et al, 2009 
Chlorzoxazone Digoxin Caco-2 100 177 97.253 5 Ekins et al, 2002 
colchicine Digoxin Caco-2 100 177 97.253 5 Ekins et al, 2002 
Debrisoquine Digoxin Caco-2 100 177 97.253 5 Ekins et al, 2002 
fexofenadine Digoxin Caco-2 100 177 97.253 5 Ekins et al, 2002 
Paclitaxel Digoxin Caco-2 100 177 97.253 5 Ekins et al, 2002 
S-
Mephenytoin 
Digoxin Caco-2 100 177 97.253 5 Ekins et al, 2002 
Tolbutamide Digoxin Caco-2 100 177 97.253 5 Ekins et al, 2002 
ergotamine calcein LLC-
PK1/MDR1 
   98.9 1 Ekins et al, 2002 
ergometrine vinblastine LLC-
PK1/MDR1 




vinblastine Caco-2 128 4.1 102.59
1 
















   105.2 1 Ekins et al, 2002 
desipramine calcein K562-MDR 221 0.3 110.5 0.25 Richter et al 2009 
ergometrine calcein LLC-
PK1/MDR1 







1 Matsson & par 
2009 
guanabenz calcein K562-MDR 250 0.3 125 0.25 Richter et al 2009 
Losartan  Digoxin Caco-2 144 385 142.15
4 
5 Cook et al, 2009 




10 Luo et al, 2002 
Avasimibe  Digoxin Caco-2 200 385 197.43
6 
5 Cook et al, 2009 
Talinolol Digoxin Caco-2 294 385 290.23
1 
5 Cook et al, 2009 
Sitagliptin  Digoxin Caco-2 300 385 296.15
4 
5 Cook et al, 2009 
Sparfloxacin  Digoxin Caco-2 300 385 296.15
4 





   360.5 1 Ekins et al, 2002 
Fluconazole vinblastine LLC-
PK1/MDR1 
   400 2 Ekins et al, 2002 
Levofloxacin  Digoxin Caco-2 500 385 493.59 5 Cook et al, 2009 
Meloxicam  Digoxin Caco-2 500 385 493.59 5 Cook et al, 2009 





   511 1 Ekins et al, 2002 
Etoposide Digoxin Caco-2    294 0.011 Tang et al 2002 




10 Luo et al, 2002 
Dilevalol vinblastine Caco-2 1185 4.1 950.81 1 Neuhoff et al, 
2000 
Captopril  Digoxin Caco-2 1000 385 987.17 5 Cook et al, 2009 
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Cimetidine  Digoxin Caco-2 1000 385 987.17
9 
5 Cook et al, 2009 
Milameline  Digoxin Caco-2 1000 385 987.17
9 
5 Cook et al, 2009 
Paroxetine  Digoxin Caco-2 1000 385 987.17
9 





   1000 1 Ekins et al, 2002 
Fluconazole calcein LLC-
PK1/MDR1 
   1000 1 Ekins et al, 2002 
Diacetolol vinblastine Caco-2 3520 4.1 2824.3
48 
1 Neuhoff et al, 
2000 
Cyclosporin Daunomycin P388 
lymphoma 
   0.038 0.002 Lan et al, 1996 
quinidine quinidine MDCK II-
MDR1 
   0.1 3 Lumen et al 2010 
Norverapamil Digoxin Caco-2 0.3 177 0.292 5 Pauli-Magnus et 
al, 2000 
Propafenone Daunomycin P388 
lymphoma 
   0.44 0.002 Lan et al, 1996 
Verapamil Daunomycin P388 
lymphoma 
   0.69 0.002 Lan et al, 1996 
Verapamil Digoxin Caco-2 1.1 177 1.07 5 Pauli-Magnus et 
al, 2000 
Verapamil vinblastine Caco-2 1.48 4.1 1.188 1 Neuhoff et al, 
2000 
Reserpine Digoxin Caco-2    1.38 0.011 Tang et al 2002 
Telithromycin Digoxin Caco-2 1.8 177 1.751 5 Ebrel et al, 2007 





   3.8 0.002 Lan et al, 1996 
Sufentanil Digoxin Caco-2 4.2 177 4.085 5 Ekins et al, 2002 
Cyclosporine calcein LLC-
PK1/MDR1 
   4.66 1 Ekins et al, 2002 
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Diltiazem Daunomycin P388 
lymphoma 
   5.41 0.002 Lan et al, 1996 
Telmisartan calcein MDCK-
MDR1 
6 3.1 5.813 0.1 Cook et al, 2009 
Fluoxetine Digoxin Caco-2 10 177 9.725 5 Ekins et al, 2002 
Terfenadine Digoxin Caco-2 10 177 9.725 5 Ekins et al, 2002 
Quinidine calcein MDCK-
MDR1 
11 3.1 10.656 0.1 Cook et al, 2009 
Reserpine calcein LLC-
PK1/MDR1 
   12.2 1 Ekins et al, 2002 
Quinidine Prazosin MDCK II-
MDR1 
   14 1 Rautio et al 2006 










   19.82 2 Ekins et al, 2002 
Erythromycin  Digoxin Caco-2 22.7 177 22.076 5 Eberl et al, 2007 
ergocornine  vinblastine LLC-
PK1/MDR1 
   24.5 2 Ekins et al, 2002 
testosterone calcein K562-MDR 56.4 0.3 28.2 0.25 Richter et al 2009 
Azelastine  Digoxin LLC-
PK1/MDR1 
30 11 29.932 0.025 Katoh et al, 2000 
Haloperidol calcein MDCK II-
MDR1 




41 3.1 39.719 0.1 Cook et al, 2009 
Indinavir Digoxin Caco-2 44 177 42.791 5 Choo et al, 2000 
Midazolam Digoxin Caco-2 55 177 53.489 5 Ekins et al, 2002 
Citalopram  Digoxin Caco-2 58 385 57.256 5 Cook et al, 2009 
vincristine  Digoxin Caco-2    71.1 0.011 Tang et al 2002 
Omeprazole Digoxin Caco-2 85 385 83.91 5 Cook et al, 2009 
Avasimibe calcein MDCK-
MDR1 
100 3.1 96.875 0.1 Cook et al, 2009 
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caffeine Digoxin Caco-2 100 177 97.253 5 Ekins et al, 2002 
Morphine Digoxin Caco-2 100 177 97.253 5 Ekins et al, 2002 
Amprenavir Prazosin MDCK II-
MDR1 
   100 1 Rautio et al 2006 
Alfentanil Digoxin Caco-2 112 177 108.92
3 









vinblastine Caco-2 188 4.1 151.08
7 






1 Ekins et al, 2002 
Troleandomyci
n 
calcein Caco-2    483.3 1 Ekins et al, 2002 
Gemcabene  Digoxin Caco-2 1000 385 987.17
9 
5 Cook et al, 2009 
Labetalol vinblastine Caco-2 2194 4.1 1760.4
03 








11. List of Conference Attended 
 
1. PPI-NET Young Researchers Symposium. 7th April 2014. (Abstract, 
Poster). Imperial College London. 
2. Exchange Fellowship Drug Discovery Workshop. 9-10th December 2013. 
Milton Keynes, UK. 
3. Marie Curie Initial Training Network (ITN) conference “Environmental 
ChemOinformatics” (ECO). (Abstract, Poster). 15-18
th
 September 2013. 
Hosted by Helmholtz-Zentrum München. Chiemsee, Germany. 
4. UK-QSAR Meeting (Awarded best poster prize - short talk). 23th April 
2013. Hosted by Unilever. UK.  
5. AAPS student conference (Poster). University of Greenwich. 25th March 
2013. London. 
6. 4th RSC/SCI International Symposium on Ion Channels as Therapeutic 




 March 2012. Abington Hall, 
Cambridge, UK.  
7. Protein-Protein Interactions International Conference: Emerging science and 





 January 2013. Royal Society of Chemistry, London. 
8. NSCCS meeting 2012. Poster (student bursary). 12th December 2012. 
Imperial College London. 
9. MOE training course ("hands-on" applications training by CCG). 10th -11th 
December 2012. University of Manchester. UK. 
10. Medway School of Pharmacy Postgraduate Poster Day (Poster). 5th 
December, University of Kent. UK. 
11. MGMS Young Modellers' Forum. (Abstract, Poster, Short talk). 30th 
November 2012. London. 
  
12. UK-QSAR (Autumn Meeting). Poster. 8th November 2012. Cambridge, UK. 
Hosted by Takeda. 
  
13. Cutting edge approaches to drug design symposium (Abstract, Poster) – 26th 




14. UK-QSAR Meeting (Poster). 25th April 2012. Horsham, UK. Hosted by 
Novartis. 
 
15. 15th International workshop on Quantitative Structure-Activity 
Relationships in environmental and health science (Abstract, Poster) 18-22 
June 2012, Estonia. 
  
16. Postgraduate Teaching and Learning Course and Delivery strategies. 
Educational Development Unit by University of Greenwich, UK. (15 
hours), Jan-Feb 2012 – Certificate. 
  
17. RSC/ChemSoc Meeting. 17th Novermber 2011. University of Greenwich. 
UK. 
  
18. DMDG open meeting (DMDG full student bursary) 14-16th September 
2011. University of Cambridge (Poster). 
  
19. Forth SFB – Symposium (Grant). September 8-9th 2011 – University of 
Vienna, Austria. Paper published in the Symposium journal (Abstract, 
Poster). 
  
20. Experiences of applying system biology. BBSRC Funded seminar. 19th 
October 2011 – Kings College London. Poster presentation. 
  
21. Chemoinformatics practical training course (winner of full-bursary). 21–
24
th
 June 2011 University of Sheffield. UK. 
  
22. UK-QSAR Meeting (Abstract, Poster). 26th May 2011. University of 
Manchester. UK. 
 













 of November 
2011. 
24. Postgraduate poster presentation day. University of Greenwich. (poster) 
presentation. 17
th
 June 2011. 
  





 October 2010.  
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12. List of Publications 
 
Estimation of Biliary Excretion of Foreign Compounds Using Properties of 
Molecular Structure. 2014. Sharifi M., Ghafourian T. AAPS J. 16 (1) 65-78. 
 
Karanjin interferes with ABCB1, ABCC1, and ABCG2. Michaelis M, Rothweiler 
F, Nerreter T, Sharifi M, Ghafourian T, Cinatl J. 2014. Journal of Pharmacy & 
Pharmaceutical Sciences (US). 17(1) 92-105. 
 
Testing of SNS-032 in a panel of human neuroblastoma cell lines with acquired 
resistance to a broad range of drugs. Dec 2013. Löschmann N, Michaelis M, Sharifi 
M. et al. Translational Oncology. 6 (6) 685-696. 
 
Prediction of P-glycoprotein inhibition constant using QSAR. Sharifi M., 
Ghafourian T. Eur Med Chem. Submitted on 05 March - 2014. 
 
Differential effects of the oncogenic BRAF Inhibitor PLX4032 (vemurafenib) 
andits progenitor PLX4720 on ABCB1 function. Michaelis M, Rothweiler F, 
NerreterT, van Rikxoort M, Sharifi M, Wiese M, Ghafourian T, Cinatl J. Journal of 
Pharmacy & Pharmaceutical Sciences (US). Accepted on 11 March - 2014.  
 
Physiologically based pharmacokinetic modeling to predict biliary excretion using 
OATPs. Sharifi M. Ghafourian T. 2014. In progress.  
 
 
